<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10767794</article-id>
    <article-id pub-id-type="pmid">37889038</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkad888</article-id>
    <article-id pub-id-type="publisher-id">gkad888</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>CDS-DB, an omnibus for patient-derived gene expression signatures induced by cancer treatment</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3371-2392</contrib-id>
        <name>
          <surname>Liu</surname>
          <given-names>Zhongyang</given-names>
        </name>
        <!--liuzy1984@163.com-->
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>College of Chemistry and Materials Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis (Hebei University), Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>College of Life Sciences, Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Ruzhen</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Lele</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>College of Chemistry and Materials Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis (Hebei University), Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-1810-6260</contrib-id>
        <name>
          <surname>Jiang</surname>
          <given-names>Jianzhou</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>College of Life Sciences, Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ma</surname>
          <given-names>Shurui</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>School of Basic Medicine, Anhui Medical University</institution>, <addr-line>Hefei 230032</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Lanhui</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>He</surname>
          <given-names>Mengqi</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Mao</surname>
          <given-names>Yichao</given-names>
        </name>
        <aff><institution>College of Life Sciences, Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Guo</surname>
          <given-names>Congcong</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Kong</surname>
          <given-names>Xiangya</given-names>
        </name>
        <aff><institution>Beijing Cloudna Technology Company</institution>, Limited, <addr-line>Beijing 100029</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Xinlei</given-names>
        </name>
        <aff><institution>Beijing Cloudna Technology Company</institution>, Limited, <addr-line>Beijing 100029</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Qi</surname>
          <given-names>Yaning</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>College of Chemistry and Materials Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis (Hebei University), Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Fengsong</given-names>
        </name>
        <aff><institution>College of Life Sciences, Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>He</surname>
          <given-names>Fuchu</given-names>
        </name>
        <!--hefc@nic.bmi.ac.cn-->
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR3" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8680-0468</contrib-id>
        <name>
          <surname>Li</surname>
          <given-names>Dong</given-names>
        </name>
        <!--lidong.bprc@foxmail.com-->
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR2" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +861061777056; Fax: +861061777004; Email: <email>liuzy1984@163.com</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Dong Li. Tel: +861061777057; Fax: +861061777004; Email: <email>lidong.bprc@foxmail.com</email></corresp>
      <corresp id="COR3">Correspondence may also be addressed to Fuchu He. Tel: +861061771001; Fax: +861061777004; Email: <email>hefc@nic.bmi.ac.cn</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first four authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-10-27">
      <day>27</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>27</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <volume>52</volume>
    <issue>D1</issue>
    <fpage>D1163</fpage>
    <lpage>D1179</lpage>
    <history>
      <date date-type="accepted">
        <day>05</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>25</day>
        <month>9</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>15</day>
        <month>8</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkad888.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Patient-derived gene expression signatures induced by cancer treatment, obtained from paired pre- and post-treatment clinical transcriptomes, can help reveal drug mechanisms of action (MOAs) in cancer patients and understand the molecular response mechanism of tumor sensitivity or resistance. Their integration and reuse may bring new insights. Paired pre- and post-treatment clinical transcriptomic data are rapidly accumulating. However, a lack of systematic collection makes data access, integration, and reuse challenging. We therefore present the Cancer Drug-induced gene expression Signature DataBase (CDS-DB). CDS-DB has collected 78 patient-derived, paired pre- and post-treatment transcriptomic source datasets with uniformly reprocessed expression profiles and manually curated metadata such as drug administration dosage, sampling time and location, and intrinsic drug response status. From these source datasets, 2012 patient-level gene perturbation signatures were obtained, covering 85 therapeutic regimens, 39 cancer subtypes and 3628 patient samples. Besides data browsing, download and search, CDS-DB also supports single signature analysis (including differential gene expression, functional enrichment, tumor microenvironment and correlation analyses), signature comparative analysis and signature connectivity analysis. This provides insights into drug MOA and its heterogeneity in patients, drug resistance mechanisms, drug repositioning and drug (combination) discovery, etc. CDS-DB is available at <ext-link xlink:href="http://cdsdb.ncpsb.org.cn/" ext-link-type="uri">http://cdsdb.ncpsb.org.cn/</ext-link>.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="gkad888figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>32088101</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Key Research and Development Program of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100012166</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2021YFA1301603</award-id>
        <award-id>2020YFE0202200</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="17"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p>In cancer drug development, it is well known that drugs which demonstrate efficacy in preclinical models do not always achieve the expected curative effects in patients (<xref rid="B1" ref-type="bibr">1</xref>), where many such examples have been reported (e.g. (<xref rid="B2" ref-type="bibr">2</xref>)). Meanwhile, both for cancer chemotherapy and targeted therapy, the response rate of a so-called clinically effective drug is often far below 100% (i.e. intrinsic drug resistance) (<xref rid="B3" ref-type="bibr">3</xref>), and even for responders, a significant proportion of them progress after an initial treatment response (i.e. acquired drug resistance) (<xref rid="B4" ref-type="bibr">4</xref>). These problems are mainly due to the inevitable difference between preclinical models and patients (such as the lack of a native tumor microenvironment (TME) in preclinical models) (<xref rid="B5" ref-type="bibr">5</xref>) and the nature of tumor heterogeneity in patients (<xref rid="B6" ref-type="bibr">6</xref>). The key to addressing these problems is understanding the molecular changes (including TME dynamics) in patients in response to clinical treatment.</p>
    <p>Patient-derived gene perturbation signatures induced by cancer treatment, obtained from paired (i.e. from the same patient) pre- and post-treatment clinical transcriptomes, can help solve the above problems. Numerous studies have indicated that patient-derived treatment-induced gene perturbation signatures can help fill the knowledge gap on drug mechanisms of action (MOAs) (especially TME-related MOAs) in patients and reveal the molecular response mechanism that results in treatment sensitivity (<xref rid="B7" ref-type="bibr">7</xref>) or resistance (<xref rid="B8" ref-type="bibr">8</xref>), and even discover predictive biomarkers of treatment response (<xref rid="B9" ref-type="bibr">9</xref>) and potential combinational drug B to overcome resistance to drug A (<xref rid="B10" ref-type="bibr">10</xref>). More importantly, the integration and reuse of these data may provide unprecedented new insights, such as exploring the heterogeneity of molecular response of patients to treatment and drug repositioning by connectivity analysis with disease signatures.</p>
    <p>In the era of precision medicine, paired pre- and post-treatment clinical transcriptomic data derived from patients with cancer are rapidly accumulated. However, these data are scattered and often mixed with various other types of data, and often have inconsistent data formats, use non-uniform data processing pipelines and have poor machine-readable metadata, which brings challenges to data access, integration and reuse.</p>
    <p>Many great resources related to drug-induced molecular perturbation signatures have been developed. The most famous are the Connectivity Map (CMAP) (<xref rid="B11" ref-type="bibr">11</xref>) and its extended version LINCS L1000 (<xref rid="B12" ref-type="bibr">12</xref>), together with their numerous derivative resources/tools designed to search, visualize or reuse the CMAP/LINCS L1000 data as reviewed by Keenan <italic toggle="yes">et al.</italic> (<xref rid="B13" ref-type="bibr">13</xref>). Currently, CMAP and LINCS L1000 contain approximately one million gene perturbation signatures at the cell line level, induced by tens of thousands of small molecules (<ext-link xlink:href="https://clue.io/" ext-link-type="uri">https://clue.io/</ext-link>), which are highly valuable for drug discovery and drug repurposing. At the cell line level, there are also several other drug-induced molecular perturbation signature resources. For example, Zhao <italic toggle="yes">et al.</italic>’s study generated perturbed expression profiles of hundreds of clinically relevant proteins in response to ∼170 drug compounds (<xref rid="B14" ref-type="bibr">14</xref>), Mitchell <italic toggle="yes">et al.</italic> characterized proteome-wide perturbation signatures of 875 compounds (<xref rid="B15" ref-type="bibr">15</xref>), and Tian <italic toggle="yes">et al.</italic> developed the largest-to-date data repository of gene perturbation signatures for active ingredients of traditional Chinese medicine (including 496 active ingredients) (<xref rid="B16" ref-type="bibr">16</xref>). In addition, in ICBatlas (a comprehensive resource for collecting and reusing transcriptomic data from patients receiving immune checkpoint blockade therapy), besides the dominant pre-treatment samples, 7 of the 25 source datasets collected by them also contain post-treatment patient samples (154 post-treatment samples in total) (<xref rid="B17" ref-type="bibr">17</xref>). All of these resources have greatly contributed to (cancer) drug development and use. However, to the best of our knowledge, there is still no data resource focusing on patient-derived gene expression signatures induced by cancer treatment (obtained from a comprehensive collection of patient-derived paired pre- and post-treatment transcriptomic data).</p>
    <p>Here, we present the Cancer Drug-induced gene expression Signature DataBase (CDS-DB) (<ext-link xlink:href="http://cdsdb.ncpsb.org.cn/" ext-link-type="uri">http://cdsdb.ncpsb.org.cn/</ext-link>), a comprehensive database, designed to specifically collect patient-derived paired pre- and post-treatment clinical transcriptomic data in cancer and provide abundant analysis functions facilitating data integration and reuse.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <sec id="SEC2-1">
      <title>Data collection and curation</title>
      <p>Paired pre- and post-treatment transcriptomes derived from patients with cancer were manually mined from GEO (<xref rid="B18" ref-type="bibr">18</xref>) and ArrayExpress (<xref rid="B19" ref-type="bibr">19</xref>) (until July 2022). First, we obtained potentially related datasets by retrieving GEO/ArrayExpress with ‘cancer-related keywords AND drug-related keywords AND patient-related keywords AND <italic toggle="yes">Homo sapiens</italic>’ (see <xref rid="sup1" ref-type="supplementary-material">Supplementary methods</xref> for the detailed keyword lists). Then, we manually picked those that met the inclusion criteria described below. For the eligible source datasets, we downloaded raw-formatted microarray gene expression data directly from the GEO/ArrayExpress website and downloaded RNA-seq SRA files from NCBI using the ‘prefetch’ function in the sra-tools (version: 2.11.0) (<ext-link xlink:href="https://github.com/ncbi/sra-tools" ext-link-type="uri">https://github.com/ncbi/sra-tools</ext-link>), and then extracted FASTQ files from the SRA files with the ‘fastq-dump’ function. In CDS-DB, the raw SRA files cannot be obtained for only two RNA-seq source datasets (GSE136114 and GSE191127), and their count data were directly downloaded from GEO. Metadata were manually curated from the corresponding source references, including sample identifier (ID), patient ID, therapeutic regimen and administration dosage, the most fine-grained cancer subtype, drug response status and the response status definition given by the original authors (if available), sampling time and location, pediatric tumor or not, data production platform, source dataset and source publication. Intrinsic drug response status information was available for 45% of patients in CDS-DB. Based on the drug response status, we further classified patients into response and non-response groups (see <xref rid="sup1" ref-type="supplementary-material">Supplementary methods</xref> for the detailed response grouping criteria).</p>
      <p>Source dataset inclusion/exclusion criteria include the following: (i) paired (i.e. from the same patient) pre- and post-treatment patient samples were required; (ii) for microarray data, only datasets from Affymetrix, Agilent and Illumina platforms were collected; (iii) bulk transcriptomes were collected; (iv) datasets, in which drug therapy is combined with other physical therapies, were excluded (to ensure that the perturbation is induced only by drug therapy).</p>
    </sec>
    <sec id="SEC2-2">
      <title>Unified transcriptomic data processing</title>
      <sec id="SEC2-2-1">
        <title>Microarray data processing pipeline</title>
        <p>We only collected microarray datasets from Affymetrix, Illumina and Agilent platforms. Raw CEL files from Affymetrix chips were processed using the ‘rma’ function of the ‘affy’ R package (version: 1.70.0) (<xref rid="B20" ref-type="bibr">20</xref>). Summary-level files from Illumina BeadArrays were processed using the ‘neqc’ and ‘normalizeBetweenArrays’ functions of the ‘limma’ R package (version: 3.48.3) (<xref rid="B21" ref-type="bibr">21</xref>), and probes with detection <italic toggle="yes">P</italic>-values &gt;0.05 in at least three samples were removed. Image analysis output files from Agilent one-color chips were processed using the ‘backgroundCorrect’ and ‘normalizeBetweenArrays’ functions of the ‘limma’ R package. After processing, the expression values were log<sub>2</sub> transformed. Then, according to the platform-specific probe annotation files, probes were converted into gene symbols. Further, based on the gene information file from NCBI Entrez Gene (version: 20230411) (<xref rid="B22" ref-type="bibr">22</xref>), the gene symbols were converted into gene IDs. The maximum expression value was used for ‘many to one’ mapping during the conversion process.</p>
      </sec>
      <sec id="SEC2-2-2">
        <title>RNA-seq data processing pipeline</title>
        <p>Starting from FASTQ files, Trim Galore (version: 0.6.7) was first used to filter adaptor sequences and low-quality bases and remove reads with sequence lengths shorter than 20 bp (<ext-link xlink:href="https://github.com/FelixKrueger/TrimGalore" ext-link-type="uri">https://github.com/FelixKrueger/TrimGalore</ext-link>). Next, STAR (version: 2.7.10a) (2-pass mode) was used to map reads to the <italic toggle="yes">Homo sapiens</italic> genome (assembly hg38 and annotation v22) (<xref rid="B23" ref-type="bibr">23</xref>). HTSeq (version: 2.0.2) was used to count the reads mapped to each gene (<xref rid="B24" ref-type="bibr">24</xref>). Finally, Ensembl gene IDs were converted to the Entrez Gene IDs and gene symbols based on the gene information file from the NCBI Entrez Gene (version: 20230411), and the maximum count value was used for ‘many to one’ mapping. For the source dataset ‘GSE168204’, because its data were produced by two RNA-seq platforms, batch effect removal was also performed using the ‘ComBat_seq’ function of the ‘sva’ R package (<xref rid="B25" ref-type="bibr">25</xref>). The FPKM (Fragments Per Kilobase of transcript per million mapped reads) method was used to normalize read counts.</p>
      </sec>
    </sec>
    <sec id="SEC2-3">
      <title>Terminology standardization</title>
      <p>Drugs were standardized with DrugBank IDs and names (if they can be mapped to DrugBank drugs) (version: 5.1.9) (<xref rid="B26" ref-type="bibr">26</xref>), cancer subtypes with Disease Ontology (DO) IDs and names (version: August 2022) (<xref rid="B27" ref-type="bibr">27</xref>), and genes with Entrez Gene IDs (<xref rid="B22" ref-type="bibr">22</xref>) and HGNC gene symbols (<xref rid="B28" ref-type="bibr">28</xref>).</p>
    </sec>
    <sec id="SEC2-4">
      <title>External annotation integration</title>
      <p>We also integrated drug, cancer and gene annotations from external databases in CDS-DB. For drugs, target annotations were from DrugBank (version: 5.1.10) (<xref rid="B26" ref-type="bibr">26</xref>), MOA annotations were from Drug Repurposing Hub (version: 20200324) (<xref rid="B29" ref-type="bibr">29</xref>), and drug type (chemotherapy, targeted therapy, hormone therapy or immunotherapy) and FDA approval annotations were obtained by manual curation. For cancers, the annotations and classification were from the DO database (version: March 2023) (<xref rid="B27" ref-type="bibr">27</xref>). For genes, their protein − protein interaction (PPI) partners were parsed from BioGRID (version: 4.4.219) (<xref rid="B30" ref-type="bibr">30</xref>); gene sets (a gene belongs to) were from the Molecular Signatures Database (MSigDB, v7.4) (<xref rid="B31" ref-type="bibr">31</xref>), including Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway (<xref rid="B32" ref-type="bibr">32</xref>), Reactome pathway (<xref rid="B33" ref-type="bibr">33</xref>), WikiPathways (<xref rid="B34" ref-type="bibr">34</xref>), hallmark gene set, microRNA target and transcription factor target; immune checkpoint-related information was from CKTTD (version: 2020-September) (<xref rid="B35" ref-type="bibr">35</xref>), mainly including whether a gene is a known immune checkpoint together with its confidence score and the primary reference, and its corresponding drug (if it has) together with the primary reference; cancer type-specific fitness genes together with corresponding cancer types were from Behan <italic toggle="yes">et al.</italic>’s study (<xref rid="B36" ref-type="bibr">36</xref>), and are defined as those required for cancer cell growth or viability.</p>
    </sec>
    <sec id="SEC2-5">
      <title>CDS-DB dataset definition</title>
      <p>A source dataset (from GEO/ArrayExpress) was further divided into ‘CDS-DB datasets’. A CDS-DB dataset was composed of paired pre- and post-treatment patient samples with the same therapeutic regimen and administration dosage, with the same cancer subtype of the finest particle size, with similar post-treatment sampling time and the same sampling location category (tissue, blood, bone marrow or ascites), with the same drug response grouping (response or non-response) if available, from the same source dataset. The CDS-DB dataset partitioning principle, especially the involved several factors such as administration dosage, sampling time and sampling location, is mainly based on original references.</p>
    </sec>
    <sec id="SEC2-6">
      <title>CDS-DB dataset- and patient-level signature definitions</title>
      <p>A gene perturbation signature was composed of all genes in the transcriptome with log<sub>2</sub> fold changes (logFCs). The logFCs were derived from differential gene expression analysis between paired post- and pre-treatment transcriptomes, assuming the pre-treatment samples as the control group (see more in ‘Differential gene expression analysis’). A dataset-level gene perturbation signature was obtained based on paired patient samples in a CDS-DB dataset, while a patient-level gene signature based on a pair of post- and pre-treatment samples of a patient.</p>
      <p>Analogous to the gene perturbation signature, a cell perturbation signature was composed of all cell populations in TME with logFCs. The logFCs were obtained by differential analysis of abundances of TME cell populations between paired post- and pre-treatment samples (see more in ‘Tumor microenvironment analysis’). In the later text of this paper, a ‘CDS-DB signature’ is usually equivalent to a gene perturbation signature unless the signature is specially described as a cell perturbation signature (mainly used in the signature connectivity analysis-related paragraphs).</p>
      <p>A CDS-DB dataset-level signature must correspond to a CDS-DB dataset, but a CDS-DB dataset does not necessarily correspond to a CDS-DB dataset-level signature. Only the CDS-DB datasets with ≥2 patients (i.e. 4 samples) have corresponding dataset-level signatures. Because for those datasets only having 1 patient (i.e. 2 samples), statistical test for differential gene expression analysis (see more in ‘Differential gene expression analysis’) cannot be performed, they don’t have dataset-level signatures.</p>
    </sec>
    <sec id="SEC2-7">
      <title>Differential gene expression analysis</title>
      <p>To obtain a CDS-DB dataset-level gene perturbation signature, the ‘limma’ (version: 3.48.3) (<xref rid="B21" ref-type="bibr">21</xref>) and ‘DESeq2’ (version: 1.32.0) (<xref rid="B37" ref-type="bibr">37</xref>) R packages were used to obtain the logFC together with <italic toggle="yes">P</italic>-value and adjusted <italic toggle="yes">P</italic>-value separately for microarray and RNA-seq data. To obtain a CDS-DB patient-level gene signature, the logFC of each gene was computed based on the log<sub>2</sub> expression value for microarray data and the FPKM for RNA-seq data.</p>
    </sec>
    <sec id="SEC2-8">
      <title>Tumor microenvironment analysis</title>
      <p>The abundances of various cell populations in TME were first predicted based on the bulk gene expression profile of a patient sample. Differential analysis of cell abundances between paired post- and pre-treatment samples was then performed to obtain a dataset- or patient-level cell perturbation signature. For a CDS-DB dataset-level signature, differential analysis for a TME cell type was implemented using the two-sided Student's <italic toggle="yes">t</italic>-test, the adjusted <italic toggle="yes">P</italic>-value was computed by Benjamini-Hochberg (BH) multiple testing correction (<xref rid="B38" ref-type="bibr">38</xref>), and the logFC was computed based on the mean value of abundances of the cell type in post-/pre-treatment samples. For a CDS-DB patient-level signature, this was done by directly computing the logFC. Here, we used two methods, MCP-counter and xCell, to predict cell type abundances, implemented by their respective R packages (version 1.2.0 for the former and version 1.1.0 for the latter) (<xref rid="B39" ref-type="bibr">39</xref>,<xref rid="B40" ref-type="bibr">40</xref>). These two methods support 10 (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>) and 64 cell types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>), respectively. Therefore, a cell perturbation signature from MCP-counter consists of 10 cell types, while a signature from xCell 64 cell types.</p>
    </sec>
    <sec id="SEC2-9">
      <title>Functional enrichment analysis</title>
      <sec id="SEC2-9-1">
        <title>Functional enrichment analysis for the single signature analysis workflow</title>
        <p>Over-representation analysis (ORA) and gene set enrichment analysis (GSEA) (<xref rid="B41" ref-type="bibr">41</xref>) two methods are supported. ORA was conducted based on significantly differentially expressed genes (DEGs) (satisfying the |logFC| and adjusted <italic toggle="yes">P</italic>-value cutoffs), and GSEA based on all genes ranked by descending logFCs. Both ORA and GSEA were implemented using the ‘clusterProfiler’ R package (version: 4.0.5) (<xref rid="B42" ref-type="bibr">42</xref>), where <italic toggle="yes">P</italic>-values were adjusted by BH method. In ORA, the enrichment ratio (ER) was used to measure the enrichment degree of a functional gene set, calculated as the ratio of the proportion of gene set member genes among significant DEGs to that among the whole genome. In GSEA, the normalized enrichment score (NES) was computed to measure the degree to which a gene set is over-represented at the top (NES &gt;0) or bottom (NES &lt;0) of the ranked genes, i.e. the degree to which a gene set is up- or down-regulated.</p>
      </sec>
      <sec id="SEC2-9-2">
        <title>Cancer subtype and therapeutic regimen enrichment analyses for the search workflow</title>
        <p>For a given item (gene, cell type or pathway), CDS-DB signatures were first ranked in descending order of the item's logFCs or NESs in these signatures. ‘GSEA’ was then conducted, where CDS-DB signatures with a certain cancer subtype/therapeutic regimen constituted a ‘signature set’ (equivalent to a ‘gene set’ in the standard GSEA).</p>
      </sec>
      <sec id="SEC2-9-3">
        <title>Drug target and MOA enrichment analyses for the signature connectivity analysis workflow</title>
        <p>‘GSEA’ was performed based on signatures ranked in descending order of connectivity score, where signatures with a certain target or MOA constituted a ‘signature set’ (equivalent to a ‘gene set’ in the standard GSEA).</p>
      </sec>
    </sec>
    <sec id="SEC2-10">
      <title>Correlation analysis</title>
      <p>For a pair of items (gene, gene set or cell type), the correlation was measured by Spearman's rank correlation coefficient between their perturbation extents across all patients in a CDS-DB dataset using the ‘cor.test’ function of the ‘stats’ R package (version: 4.1.1). The perturbation extent of an item in a patient was measured by logFC for a gene/cell type and by NES for a pathway, which was from the analysis results of the patient-level signature.</p>
    </sec>
    <sec id="SEC2-11">
      <title>Meta-analysis</title>
      <p>The variable coefficient for an item (gene, cell type or pathway) was computed as the standard deviation divided by the mean of its perturbation extents across different CDS-DB signatures, where the perturbation extent was measured by logFC for a gene/cell type and NES for a pathway. For the comparison of multiple CDS-DB dataset-level signatures, a meta-<italic toggle="yes">P</italic>-value was further computed by integrating the <italic toggle="yes">P</italic>-values of individual signatures using the sumz method in the ‘metap’ R package (version: 1.8) (<ext-link xlink:href="https://CRAN.R-project.org/package=metap" ext-link-type="uri">https://CRAN.R-project.org/package=metap</ext-link>), and the adjusted meta-<italic toggle="yes">P</italic>-value was obtained using the BH method.</p>
    </sec>
    <sec id="SEC2-12">
      <title>Signature connectivity analysis</title>
      <p>When a gene signature with logFCs is submitted, its connectivity score with a CDS-DB gene perturbation signature is computed as the cosine similarity of the two logFC vectors. When up- and down-regulated gene sets or cell type sets are submitted, we use the Connectivity Map (CMAP) score (<xref rid="B11" ref-type="bibr">11</xref>) (see Supplementary methods).</p>
    </sec>
    <sec id="SEC2-13">
      <title>Database implementation</title>
      <p>Node.js (<ext-link xlink:href="https://nodejs.org/" ext-link-type="uri">https://nodejs.org/</ext-link>) and Vue.js (<ext-link xlink:href="https://vuejs.org/" ext-link-type="uri">https://vuejs.org/</ext-link>) were used as back- and front-end frameworks, respectively. Nginx was used as a reverse proxy (<ext-link xlink:href="https://www.nginx.com/" ext-link-type="uri">https://www.nginx.com/</ext-link>). Back-end data were stored and managed using MongoDB (<ext-link xlink:href="https://docs.mongodb.com/" ext-link-type="uri">https://docs.mongodb.com/</ext-link>). The data analysis workflows were written in R, where the volcano plot, barplot and slope plot were implemented using the ‘ggplot2’ R package (version: 3.4.2) (<xref rid="B43" ref-type="bibr">43</xref>). The interactive heatmap on the analysis result page of ‘Analyze’ was implemented using D3.js (<ext-link xlink:href="https://d3js.org/" ext-link-type="uri">https://d3js.org/</ext-link>) and other heatmaps using the ‘ComplexHeatmap’ R package (version: 2.10.0) (<xref rid="B44" ref-type="bibr">44</xref>). The interactive doughnut chart on the homepage was drawn using Apache ECharts (<ext-link xlink:href="https://echarts.apache.org/en/index.html" ext-link-type="uri">https://echarts.apache.org/en/index.html</ext-link>).</p>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>Results</title>
    <sec id="SEC3-1">
      <title>Overview</title>
      <p>CDS-DB is designed to be a comprehensive data resource for basic and clinical researchers to access, integrate and (re-)use patient-derived drug-induced gene expression signatures obtained from paired pre- and post-treatment clinical transcriptomic data derived from patients with cancer (Figure <xref rid="F1" ref-type="fig">1</xref>).</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Overview of the CDS-DB.</p>
        </caption>
        <graphic xlink:href="gkad888fig1" position="float"/>
      </fig>
      <p>The patient-derived paired pre- and post-treatment transcriptomes were manually collected from GEO and ArrayExpress under strict inclusion criteria. The related clinical annotations were manually curated from the corresponding source references, and terminologies were standardized. All transcriptomic data were reprocessed using the uniform data preprocessing pipeline. The processed and standardized source datasets were partitioned into CDS-DB datasets, and further, CDS-DB dataset- and patient-level gene perturbation signatures were obtained (see Methods). Cancer/drug/ gene-related annotations from external databases were also integrated (Figure <xref rid="F1" ref-type="fig">1</xref>).</p>
      <p>To facilitate the access, integration and (re-)use of the CDS-DB data, besides basic data browsing, retrieval and download using the ‘Browse’ function of the website, CDS-DB also supports multiple data analysis workflows (Figure <xref rid="F1" ref-type="fig">1</xref>). The single signature analysis workflow, including perturbation signature analysis, tumor microenvironment analysis and correlation analysis, is used to analyze a CDS-DB dataset- or patient-level signature, and the pre-analysis results are presented on the detailed annotation page of a CDS-DB dataset- or patient-level signature. The signature comparative analysis workflow (accessed using the ‘Compare’ function) supports comparison of the single signature analysis results of multiple user-selected signatures for meta-analysis. The ‘Search’ workflow allows users to check the perturbed extents of the gene, pathway or TME cell type of interest across different CDS-DB signatures and to further analyze the cancer subtype or drug preference of the perturbations. Finally, the signature connectivity analysis workflow (‘Analyze’) is designed to search CDS-DB signatures that mimic or reverse the user-uploaded signature and further analyze enriched targets or MOAs of the returned signatures. All website functions ‘interact with’ each other. Analysis results are returned as heatmaps, volcano plots, slope plots, bar graphs and various result tables (Figure <xref rid="F1" ref-type="fig">1</xref>), and all results can be downloaded.</p>
    </sec>
    <sec id="SEC3-2">
      <title>Data statistics</title>
      <p>The current version of the CDS-DB houses 2012 CDS-DB patient-level gene perturbation signatures and 181 CDS-DB dataset-level gene perturbation signatures obtained from 3628 patient samples of 219 CDS-DB datasets. These CDS-DB datasets were obtained by dividing 78 patient-derived paired pre- and post-treatment transcriptomic source datasets. These signatures involve 39 cancer subtypes of the finest particle size belonging to 19 cancer histological types, with breast cancer, kidney cancer, leukemia, melanoma and ovarian cancer having the most dataset-/patient-level signatures (Figure <xref rid="F2" ref-type="fig">2A</xref> and <xref rid="F2" ref-type="fig">B</xref>). There are 85 therapeutic regimens (Figure <xref rid="F2" ref-type="fig">2C</xref>), 71 drugs covering targeted therapy, chemotherapy, immunotherapy and hormone therapy (ordered from high to low) (Figure <xref rid="F2" ref-type="fig">2D</xref>). The post-treatment sampling time of 94% of dataset-level signatures is within 3 months, 78% within 2 months, 66% within 4 weeks and 36% within 2 weeks (Figure <xref rid="F2" ref-type="fig">2E</xref>). The proportions are 82%, 64%, 53% and 31% for patient-level signatures, respectively (Figure <xref rid="F2" ref-type="fig">2F</xref>). Sampling locations include tissue, blood, bone marrow and ascites (Figure <xref rid="F2" ref-type="fig">2A</xref> and <xref rid="F2" ref-type="fig">B</xref>). 70% of the CDS-DB datasets have samples not smaller than 6, and 56% not smaller than 10 (Figure <xref rid="F2" ref-type="fig">2G</xref>). Intrinsic drug response information is available for 57% of the CDS-DB dataset-level signatures.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Data statistics of the CDS-DB. (<bold>A, B</bold>) CDS-DB dataset-level (A) and patient-level (B) signature distributions across data types, therapeutic regimen types, sampling location categories and cancer histological types (from the inner to the outer ring). (<bold>C</bold>) Therapeutic regimen type distribution. (<bold>D</bold>) Drug type distribution. (<bold>E, F</bold>) Post-treatment sampling time distributions of CDS-DB dataset-level (E) and patient-level (F) signatures. Only 146 dataset-level signatures and 1799 patient-level signatures with specific and single sampling times were included in the analyses. (<bold>G</bold>) Patient sample number distribution of CDS-DB datasets. (<bold>H, I</bold>) Dataset-level (H) and patient-level (I) signature number distributions of therapeutic regimens. (<bold>J</bold>) Cancer subtype number distribution of the therapeutic regimens in CDS-DB. (<bold>K</bold>) Therapeutic regimen number distribution of cancer subtypes in CDS-DB. (<bold>L</bold>) Numbers of therapeutic regimens/drugs with different cancer types in CDS-DB. (<bold>M</bold>) Publication year distribution of CDS-DB source datasets (from 2006 to July 2022).</p>
        </caption>
        <graphic xlink:href="gkad888fig2" position="float"/>
      </fig>
      <p>The medians of CDS-DB dataset- and patient-level perturbation signatures that a therapeutic regimen has are 2 and 9, respectively. 91% and 74% of therapeutic regimens have dataset-level signatures not larger than 3 and patient-level signatures not larger than 20, respectively (Figure <xref rid="F2" ref-type="fig">2H</xref> and <xref rid="F2" ref-type="fig">I</xref>). Nivolumab and Letrozole have received the most attention and have the most perturbation signatures. In CDS-DB data, in most cases, a therapeutic regimen is only used for the treatment of a cancer subtype, indicating the cancer specificity of treatment (Figure <xref rid="F2" ref-type="fig">2J</xref>). Also, most cancer subtypes have ≤2 therapeutic regimens (Figure <xref rid="F2" ref-type="fig">2K</xref>). In CDS-DB, the cancer types with the most therapeutic regimens are breast cancer, leukemia, melanoma and ovarian cancer (Figure <xref rid="F2" ref-type="fig">2L</xref>). Finally, publication years for source datasets collected by CDS-DB show increasing attention to patient-derived paired pre- and post-treatment transcriptomic data, as 34% of the collected source datasets (spanning the 17 years from 2006 to July 2022) are from the last 3 years and 47% from the last 5 years (Figure <xref rid="F2" ref-type="fig">2M</xref>).</p>
    </sec>
    <sec id="SEC3-3">
      <title>Browse and download</title>
      <p>Using ‘Browse’ function of the website, CDS-DB dataset-level signatures, patient-level signatures, drugs and cancers can be browsed and retrieved, and signature-related data can be downloaded.</p>
      <p>On the ‘Dataset’/‘Patient’ tab (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1A</xref>), CDS-DB dataset-/patient-level signatures and their corresponding key clinical annotations are listed. These signatures can be filtered/retrieved by drug type (chemotherapy, immunotherapy, hormone therapy and targeted therapy), drug name, cancer (sub-)type, sampling location category (ascites, bone marrow, blood and tumor tissue), sample size, data type (RNA-seq and Microarray), response grouping (non-response and response), pediatric oncology, source dataset (GEO or ArrayExpress dataset ID) and CDS-DB signature ID. Gene expression matrix, sample clinical information, and gene perturbation signature files of user-selected or all signatures can also be downloaded here. Clicking on the CDS-DB signature ID in the data browsing table leads to a detailed annotation page, where the more detailed annotations of the signature and the interactive single signature analysis results are displayed.</p>
      <p>On the ‘Drug’ tab, all drugs related to CDS-DB signatures are listed in four categories (chemotherapy, immunotherapy, hormone therapy and targeted therapy) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1B</xref>). On the ‘Cancer’ tab, cancer subtypes and their parent cancer types can be browsed as a six-level hierarchy (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1C</xref>). The search box enables search of a drug or cancer (sub-)type by name. Once a drug or cancer (sub-)type is selected, the right side of the page shows its detailed annotations. ‘CDS-DB dataset signature number’ gives the number of CDS-DB dataset-level signatures related to the selected drug/cancer (sub-)type, and ‘CDS-DB patient signature number’ gives the number of the related CDS-DB patient-level signatures. Clicking on the number leads to the corresponding signature browsing page.</p>
      <p>In addition, CDS-DB dataset- or patient-level signatures can also be browsed using the doughnut of data statistics on the homepage (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1D and E</xref>). Clicking on a sector (data type, sampling location category, drug type or cancer type) on the doughnut leads to the browsing page for the sector-related signatures.</p>
    </sec>
    <sec id="SEC3-4">
      <title>Single signature analysis</title>
      <p>Each CDS-DB dataset- or patient-level signature has been pre-analyzed using the single signature analysis workflow, which includes perturbation signature analysis and tumor microenvironment analysis. Interactive correlation analysis is also supported for a dataset-level signature. This workflow is designed to reveal the drug MOAs in patients with cancer. The pre-analysis results and the correlation analysis function are presented on the detailed annotation page of the CDS-DB signature.</p>
      <sec id="SEC3-4-1">
        <title>Perturbation signature analysis</title>
        <p>The results of this function include three tabs: DEG, ORA and GSEA, aiming at revealing molecular and functional changes induced by the cancer treatment and understanding the molecular mechanisms of drug response/non-response for signatures with drug response grouping information.</p>
        <p>The DEG tab gives the differential gene expression analysis results between paired post- and pre-treatment patient samples of the signature (i.e. gene perturbation signature itself) (Figure <xref rid="F3" ref-type="fig">3A</xref>). For a dataset-level signature, significant DEGs (with the absolute values of logFCs larger than a certain cutoff and the adjusted <italic toggle="yes">P</italic>-values smaller than a certain cutoff) are potentially important molecules related to drug MOAs in patients. The ‘Significant DEGs’ mode of the result table, the volcano plot and the heatmap emphasize these significant DEGs. To further help users focus on drug MOA-related key genes, in the result table, for each gene, we also provide the following fields: whether the gene is the known target of the therapeutic regimen of the signature or the target's interactors (‘Target or target's interactor’ field), whether an ‘Immune checkpoint’ or a ‘Cancer type-specific fitness gene’ (required for cancer cell growth or viability) together with the cancer types. The table headers support gene filtering and re-ranking. For patient-level signatures, the DEG tab only gives the result table presenting the differential analysis results of all genes (i.e. patient-level gene perturbation signature itself), without the heatmap and volcano plot.</p>
        <fig position="float" id="F3">
          <label>Figure 3.</label>
          <caption>
            <p>Result pages of the single signature analysis. Here the dataset-level signature CDS_dataset_Microarray_81 is used as an example. (<bold>A</bold>) The perturbation signature analysis result page and the DEG tab page. Users can change logFC and adjusted <italic toggle="yes">P</italic>-value cutoffs to redefine significant DEGs and update the DEG and ORA results. DEG tab displays the differential gene expression analysis results of the dataset-level signature, including a volcano plot, a heatmap and a detailed result table. Clicking on the gene symbol in the result table leads to the ‘Search’ result page for the gene. Clicking on the ‘&gt;’ front of the gene symbol will lead to a slope plot presenting the gene's expression changes in the paired pre- and post-treatment samples in the dataset (shown in the embedded figure). (<bold>B</bold>) The ORA tab. Here presents the ORA results of KEGG pathways. Clicking on the pathway name in the result table leads to the ‘Search’ result page for the pathway. (<bold>C</bold>) The GSEA tab. Here shows the GSEA results of KEGG pathways. Clicking on the pathway name in the result table leads to the ‘Search’ result page for the pathway. (<bold>D</bold>) Tumor microenvironment analysis result page. Here shows the results obtained based on MCP-counter. Clicking on the ‘&gt;’ front of the cell type leads to a slope plot displaying the cell type's abundance changes in the paired pre- and post-treatment samples in the dataset (shown in the embedded figure). Clicking on the name itself leads to the ‘Search’ result page for the cell type. (<bold>E</bold>) Correlation analysis result page.</p>
          </caption>
          <graphic xlink:href="gkad888fig3" position="float"/>
        </fig>
        <p>The ORA tab gives the functional gene sets significantly perturbed by the treatment (Figure <xref rid="F3" ref-type="fig">3B</xref>), and the GSEA tab displays the gene sets significantly up-/down-regulated by the treatment (Figure <xref rid="F3" ref-type="fig">3C</xref>). Six types of gene sets are supported, including hallmark gene sets, KEGG pathways, Reactome pathways, WikiPathways, target gene sets of transcriptional factors and target gene sets of microRNAs. For a patient-level signature, there is no ORA tab.</p>
        <p>Users can change logFC and adjusted <italic toggle="yes">P</italic>-value cutoffs to redefine significant DEGs and update results in the DEG and ORA tabs (GSEA results are unaffected by parameter changes) (Figure <xref rid="F3" ref-type="fig">3A</xref>). Parameter change is not supported for a patient-level signature.</p>
      </sec>
      <sec id="SEC3-4-2">
        <title>Tumor microenvironment analysis</title>
        <p>Tumors contain a complex mixture of noncancerous cell types and matrix components, referred to as the tumor microenvironment (TME) (<xref rid="B45" ref-type="bibr">45</xref>). Compared with pre-clinical models such as cell lines, one advantage of patient samples is that they can reflect TME responses to treatment. In addition to immunotherapy targeting TME, accumulating evidence has shown that chemotherapy, targeted therapy and even hormone therapy also influence immune and non-immune components in the TME, which plays an important role in activity and efficacy of treatments (<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B47" ref-type="bibr">47</xref>). This function is designed to reveal drug-induced TME changes, providing more clues for understanding drug MOAs in patients and optimizing the combination of immunotherapy and other types of therapy. The TME analysis page gives differential analysis results of the predicted cell population abundances in TME between paired post- and pre-treatment samples (Figure <xref rid="F3" ref-type="fig">3D</xref>). We used two methods (MCP-counter and xCell) to predict cell type abundances (see Methods), and analysis results are given, respectively.</p>
      </sec>
      <sec id="SEC3-4-3">
        <title>Correlation analysis</title>
        <p>If a pair of items has consistent or opposite changes after treatment in all patients in a CDS-DB dataset, they are likely to be functionally related. This analysis is designed to reveal such functional relevance based on the correlation analysis of two items’ respective drug-induced changes across all patients in a CDS-DB dataset, in order to provide more clues for uncovering drug MOAs in patients. This analysis is only suitable for CDS-DB dataset-level signatures with patients not smaller than three. Three classes of items are supported, including genes, gene sets and TME cell types. The result table and heatmap (visually) give the correlation analysis results between items (Figure <xref rid="F3" ref-type="fig">3E</xref>).</p>
      </sec>
    </sec>
    <sec id="SEC3-5">
      <title>Signature comparative analysis</title>
      <p>This workflow can be accessed using the ‘Compare’ function, to implement the comparison of pre-analysis results (including DEG, GSEA and TME) of the user-selected multiple CDS-DB dataset- or patient-level signatures and their meta-analysis. This workflow is designed to explore the heterogeneity and homogeneity of treatment-induced gene, pathway and TME cell population perturbations across different patients or patient cohorts (e.g. those using the same drug, but with different cancer subtypes, administration dosages, post-treatment sampling times, sampling locations or treatment response states), and discover interesting shared/inconsistent drug MOA-related molecules, pathways or TME cell types. The signature filtering function on the left side of the submission page facilitates the signature selection. In particular, comparing a pair of CDS-DB dataset-level signatures with the same key metadata but with opposite drug response groupings (i.e. they are from the same source dataset, and were divided into two different CDS-DB datasets only because they have opposite response groupings) can help reveal intrinsic drug resistance mechanisms and discover predictive biomarkers of drug response from the perspective of drug perturbation. On the detailed annotation page of a CDS-DB dataset-level signature, the signature with drug response grouping opposite to it is given if available. In total, there are 43 pairs of such CDS-DB dataset-level signatures having opposite response groupings.</p>
      <p>The analysis results include seven tabs: DEG, TME-MCP-counter, TME-xCell, Hallmark gene set GSEA, KEGG pathway GSEA, Reactome pathway GSEA and WikiPathways GSEA. Each tab contains two heatmaps (except TME-MCP-counter) and a result table (Figure <xref rid="F4" ref-type="fig">4</xref>). The result table gives the meta-analysis results, where a large/small absolute value of variable coefficient indicates inconsistent/consistent perturbations of an item (gene, cell type or pathway) across different CDS-DB signatures. For the dataset-level signature comparison, meta-<italic toggle="yes">P</italic>-value is also computed, and a small meta-<italic toggle="yes">P</italic>-value means that the item has strong relevance with drug perturbations across multiple signatures. The heatmaps present the perturbations of the most consistent and inconsistent items across signatures.</p>
      <fig position="float" id="F4">
        <label>Figure 4.</label>
        <caption>
          <p>The signature comparative analysis result page. Here we use the comparison of 5 Imatinib-induced dataset-level signatures as the example and present the comparative analysis results for KEGG pathways. For dataset-level signature comparison, the heatmaps show the top 10 significantly inconsistent/consistent items across different CDS-DB signatures, where the statistical significance is measured by the adjusted meta-<italic toggle="yes">P</italic>-value. Users can change the adjusted meta-<italic toggle="yes">P</italic>-value cutoff to re-define statistical significance and update the heatmaps. Clicking on the item name in the table leads to its ‘Search’ result page.</p>
        </caption>
        <graphic xlink:href="gkad888fig4" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-6">
      <title>Search</title>
      <p>This workflow can be accessed using ‘Search’ function of the website. It supports the search for a gene, biological pathway or TME cell type. The result page includes two sections: ‘Basic information’ and ‘Analysis results’. The ‘Basic information’ gives the item-related detailed annotations. The ‘Analysis results’ gives the item's perturbed extents across all CDS-DB dataset- or patient-level perturbation signatures (Figure <xref rid="F5" ref-type="fig">5A</xref>) and drug and cancer subtype enrichment analysis results (see Methods), in order to explore by which drugs or in which cancer subtypes the item is significantly up-/down-regulated (Figure <xref rid="F5" ref-type="fig">5B</xref> and <xref rid="F5" ref-type="fig">C</xref>). The primary objective of this workflow is to elucidate the functions of the gene/biological pathway/cell type of interest and contribute to new target and drug discovery.</p>
      <fig position="float" id="F5">
        <label>Figure 5.</label>
        <caption>
          <p>The search result page. Here we use <italic toggle="yes">SKP2</italic> gene as the example and show the results for dataset-level signatures. (<bold>A</bold>) The results presenting the perturbation extents of the gene across CDS-DB dataset-level signatures. The two bar plots display the top and down 10 signatures, according to the perturbation extent. (<bold>B</bold>) Cancer subtype enrichment analysis result table. (<bold>C</bold>) Drug enrichment analysis result table.</p>
        </caption>
        <graphic xlink:href="gkad888fig5" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-7">
      <title>Signature connectivity analysis</title>
      <p>The signature connectivity analysis workflow can be accessed using ‘Analyze’ function of the website. This workflow is used to prioritize CDS-DB dataset-/patient-level signatures mimicking (‘mimic’ mode) or reversing (‘reverse’ mode) a user-uploaded signature and to further analyze MOA and target preference of the returned ranked signatures. Depending on the user's submission, this workflow can be used in many biomedical settings. For example, when a (patient-derived) disease signature is submitted, potential drugs and targets/MOAs for the disease can be recommended by searching CDS-DB signatures reversing the input (i.e. drug discovery/repositioning or target/MOA discovery); when a (patient-derived) drug resistance signature is submitted, the analysis results can suggest a combinational drug B that may be able to overcome resistance to drug A via the ‘reverse’ mode. This workflow aims at providing clues for such biomedical settings from a new dimension (i.e. patient-derived perturbation signature).</p>
      <p>Three input types are supported (Figure <xref rid="F6" ref-type="fig">6A</xref>): (i) ‘Gene set’, up- and down-regulated gene lists are required; (ii) ‘Signature’, a gene list with logFCs is required; (iii) ‘Cell type’, up- and down-regulated cell type lists are required. For the first two input types, the input signature is connected with CDS-DB gene perturbation signatures, while for the last one, with the cell perturbation signature (see Methods). We used MCP-counter and xCell two methods to obtain the cell perturbation signatures, and thus here, users need to select the method. MCP-counter supports 10 cell types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>), and xCell supports 64 cell types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>). Users can only use the supported cell types as the input. In addition, users can also select a patient-derived drug intrinsic resistance signature from CTR-DB as the input of the ‘Signature’ type by clicking the ‘CTR-DB patient-derived intrinsic drug resistance signatures’ button. CTR-DB, previously developed by our group, is a database designed to comprehensively collect patient-derived baseline transcriptomes with intrinsic cancer drug response (<xref rid="B48" ref-type="bibr">48</xref>), where an intrinsic drug resistance signature was obtained from differential gene expression analysis of baseline (i.e. pre-treatment) transcriptomes between non-responsive and responsive patients. In signature connectivity analysis, the optional parameters include signature level (CDS-DB dataset- or patient-level signature) and direction (mimic or reverse).</p>
      <fig position="float" id="F6">
        <label>Figure 6.</label>
        <caption>
          <p>User submission page (A) and result pages (B, C, D and E) of the signature connectivity analysis workflow. An acute lymphoblastic leukemia (ALL) disease signature is used as the input example (see Supplementary methods), and ‘dataset-level signature’ and ‘reverse’ mode are selected. (<bold>A</bold>) User submission page. (<bold>B</bold>) The interactive heatmap which presents top 20 returned CDS-DB dataset-level signatures. Users can modify the logFC cutoff to recolor the heatmap and also switch the column label name of the heatmap among cancer subtype, therapeutic regimen and signature ID. (<bold>C</bold>) The detailed result table presents the returned ranked CDS-DB signatures. Users can select ≥2 CDS-DB signatures in the table, and check their signature comparative analysis results by clicking the ‘Compare’ button under the table. Users can also select signatures of interest in the table and use the ‘Refresh’ button to repeat the MOA and target enrichment analyses based on the selected signatures. (<bold>D</bold>) The MOA enrichment analysis result table. (<bold>E</bold>) The target enrichment analysis result table.</p>
        </caption>
        <graphic xlink:href="gkad888fig6" position="float"/>
      </fig>
      <p>The analysis results include an interactive heatmap (Figure <xref rid="F6" ref-type="fig">6B</xref>) and three result tables (Figure <xref rid="F6" ref-type="fig">6C</xref>–<xref rid="F6" ref-type="fig">E</xref>). The heatmap visualizes the perturbation extents (logFCs) of the input genes/cell types in the top 20 returned CDS-DB gene/cell signatures, emphasizing the reversal or simulation of the CDS-DB signatures to the input signature (Figure <xref rid="F6" ref-type="fig">6B</xref>). Below the heatmap is the detailed result table of the returned CDS-DB signatures, ranked according to descending/ascending connectivity scores for the ‘mimic’/‘reverse’ mode (see Methods) (Figure <xref rid="F6" ref-type="fig">6C</xref>). In order to help users better check consistent or inconsistent parts of the returned signatures, users can select ≥2 CDS-DB signatures in the table and click the ‘Compare’ button under the table (Figure <xref rid="F6" ref-type="fig">6C</xref>) to obtain the comparative analysis results of the selected signatures. The last two tables give targets and MOAs significantly enriched at the top of the returned ranked signature list in the first table (Figure <xref rid="F6" ref-type="fig">6D</xref> and <xref rid="F6" ref-type="fig">E</xref>). Users can filter the returned signatures based on various data fields in the first table, and then click ‘Refresh’ button under the first table to update the target and MOA enrichment analysis results (Figure <xref rid="F6" ref-type="fig">6C</xref>). For example, users can require that the length of the intersection between the input and the CDS-DB signature (‘Overlap_num’) is not smaller than a certain cutoff, the sampling location category is tumor tissue, the response grouping is ‘response’, and childhood cancer is excluded.</p>
    </sec>
    <sec id="SEC3-8">
      <title>Use cases</title>
      <p>Here, we use several examples to demonstrate the use and potential of key CDS-DB workflows used to reveal drug MOAs (including TME-related MOAs) and their homogeneity/heterogeneity in patients and for drug (combination) discovery.</p>
      <sec id="SEC3-8-1">
        <title>Single signature analysis</title>
        <p>We used the dataset-level signature CDS_dataset_Microarray_81 as an example. In this dataset, nine patients with chronic myeloid leukemia (CML) received Imatinib, and paired bone marrow samples were obtained before and four weeks after treatment. The original reference did not report the drug response status information. It has been known that CML is caused mainly by the fusion oncogene BCR-ABL1, whose protein product has constitutive tyrosine kinase activity, and Imatinib, a BCR-ABL1 tyrosine kinase inhibitor, is the standard therapy for CML (<xref rid="B49" ref-type="bibr">49</xref>).</p>
        <p>The ‘Perturbation signature analysis’ results show that after four weeks of treatment, the most significantly down-regulated hallmark gene set is E2F targets (NES = −2.35, <italic toggle="yes">P</italic>-value = 1.00E−10) and DNA replication is also significantly down-regulated in KEGG GSEA analysis (NES = −2.09, <italic toggle="yes">P</italic>-value = 3.11E−08). Upstream, we find that the transcriptional factor E2F1 is significantly down-regulated (logFC = −0.22, <italic toggle="yes">P</italic>-value = 4.32E−02), several cyclin-dependent kinases (CDKs) such as CDK4 (logFC = −0.87, <italic toggle="yes">P</italic>-value = 3.56E−02) and CDK2 (logFC = −0.48, <italic toggle="yes">P</italic>-value = 7.27E−02) are down-regulated, as is SKP2 (logFC = −0.94, <italic toggle="yes">P</italic>-value = 3.82E−05). SKP2 is a ubiquitin ligase subunit that specifically recognizes the CDK inhibitor CDKN1B (i.e. P27) and promotes its degradation (<xref rid="B50" ref-type="bibr">50</xref>). Indeed, in our analysis results we find that, consistent with the down-regulation of SKP2, ‘REACTOME_SCF_SKP2_MEDIATED_DEGRADATION_OF_ P27_P21’ is significantly down-regulated (NES = −1.65, <italic toggle="yes">P</italic>-value = 2.44E−03). Further, CDKs are known to promote the release of E2F transcriptional factors, drive cell-cycle progression from G1 to S, and launch DNA replication (<xref rid="B51" ref-type="bibr">51</xref>). Integrating the prior knowledge and our results, we speculate that in these patients with CML, Imatinib caused cell cycle arrest at G1-S transition via the upstream SKP2-P27-CDK-E2F axis (Figure <xref rid="F7" ref-type="fig">7</xref>). This finding is consistent with previous cell line level studies that BCR-ABL up-regulates SKP2 expression via PI3K pathway, and Imatinib can induce cell cycle arrest by reducing SKP2 expression and accumulating P27 in BCR-ABL-positive cells (<xref rid="B52" ref-type="bibr">52</xref>).</p>
        <fig position="float" id="F7">
          <label>Figure 7.</label>
          <caption>
            <p>Schematic diagram of Imatinib MOAs in the treatment of chronic myeloid leukemia. The MOAs are speculated based on the single signature analysis results of CDS_dataset_Microarray_81, presented in the figure. The results suggest that on the one hand, Imatinib down-regulates SKP2 and further reduces ubiquitination-mediated degradation of P27 protein, then accumulating P27 inhibits the activities of CDKs and downstream E2F1, and eventually Imatinib induces cell cycle arrest. On the other hand, Imatinib exerts anti-tumor effects also by CD8+ T cell- and NK-cell-mediated cytotoxicity. These findings are consistent with previous studies (<xref rid="B52" ref-type="bibr">52</xref>,<xref rid="B53" ref-type="bibr">53</xref>). The red crosses in the figure represent the action of Imatinib, and the red arrows show its regulatory direction (up- or down-regulation).</p>
          </caption>
          <graphic xlink:href="gkad888fig7" position="float"/>
        </fig>
        <p>Further, from the ‘Tumor microenvironment analysis’ results of MCP-counter, we find that after treatment, the abundances of CD8+ T cells (logFC = 0.16, <italic toggle="yes">P</italic>-value = 7.08E−04) and NK cells (logFC = 0.16, <italic toggle="yes">P</italic>-value = 2.85E−03) are significantly up-regulated. Meanwhile, the related ‘T cell receptor signature pathway’ (NES = 2.11, <italic toggle="yes">P</italic>-value = 2.32E−07), ‘antigen processing and presentation’ (NES = 2.00, <italic toggle="yes">P</italic>-value = 5.91E−06), and ‘natural killer cell mediated cytotoxicity’ (NES = 2.48, <italic toggle="yes">P</italic>-value = 1.00E−10) KEGG pathways are also significantly up-regulated. These results suggest that in these patients, in addition to stopping the cell cycle, Imatinib exerted therapeutic effects via CD8+ T cell- and NK cell-mediated cell cytotoxicity (Figure <xref rid="F7" ref-type="fig">7</xref>). These findings are consistent with previous studies (<xref rid="B53" ref-type="bibr">53</xref>).</p>
      </sec>
      <sec id="SEC3-8-2">
        <title>Signature comparative analysis</title>
        <p>In addition to CDS_dataset_Microarray_81, CDS-DB contains four other dataset-level signatures induced by Imatinib, including CDS_dataset_Microarray_91 and CDS_dataset_Microarray_92 for CML, CDS_dataset_Microarray_71 for gastrointestinal stromal tumor and CDS_dataset_RNAseq_41 for colorectal cancer. None have drug response information, and CDS_dataset_Microarray_91 and CDS_dataset_Microarray_92 are derived from the same source dataset with different administration dosages (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S3</xref>). According to the comparative analysis results across different dataset-level signatures of CML, we find that Imatinib MOAs (both cell cycle arrest induced by SKP2-CDK-E2F axis and CD8+ T cell- and NK cell-mediated cell cytotoxicity) identified in the single signature analysis above are further validated in the other two dataset-level signatures (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref>), showing the homogeneity of Imatinib MOAs in CML. The comparative results also suggest strong heterogeneity in treating different cancer types. For example, in colorectal cancer (CDS_dataset_RNAseq_41), the perturbation of the SKP2-CDK-E2F axis has almost the exact opposite trend with CML (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref>), and Imatinib hardly induces significant changes on SKP2-CDK-E2F axis, CD8+ T cells, and NK cells in gastrointestinal stromal tumor (CDS_dataset_Microarray_71) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref>). Indeed, previous studies have indicated that instead of targeting BCR-ABL fusion oncoprotein in CML, the therapeutic effects of Imatinib depend on inhibiting the tyrosine kinase activities of c-kit and PDGF in gastrointestinal stromal tumor (<xref rid="B54" ref-type="bibr">54</xref>) and perhaps c-kit and PDGF in colorectal cancer (<xref rid="B55" ref-type="bibr">55</xref>,<xref rid="B56" ref-type="bibr">56</xref>).</p>
      </sec>
      <sec id="SEC3-8-3">
        <title>Signature connectivity analysis</title>
        <p>Using the patient-derived acute lymphoblastic leukemia (ALL) disease signature (see <xref rid="sup1" ref-type="supplementary-material">Supplementary methods</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S5</xref>) as the input, we searched CDS-DB signatures reversing it. We find that, in both dataset- and patient-level signature connectivity analyses, the most significantly enriched MOA at the top of the returned signatures is ‘glucocorticoid receptor agonist’ such as prednisone, prednisolone and dexamethasone (NES = −1.74, <italic toggle="yes">P</italic>-value = 1.85E−03 for dataset-level; NES = −2.14, <italic toggle="yes">P</italic>-value = 2.65E−10 for patient-level), and the target in the first place is NR3C1 (i.e. glucocorticoid receptor) (NES = −1.73, <italic toggle="yes">P</italic>-value = 1.61E−03 for dataset-level; NES = −2.11, <italic toggle="yes">P</italic>-value = 3.69E−10 for patient-level) (Figure <xref rid="F6" ref-type="fig">6D</xref> and <xref rid="F6" ref-type="fig">E</xref>). It is known that in clinical ALL treatment glucocorticoids are essential chemotherapy components (<xref rid="B57" ref-type="bibr">57</xref>), demonstrating this workflow's potential in cancer drug discovery.</p>
        <p>To further demonstrate the workflow's potential in drug combination discovery, using the ‘CTR-DB patient-derived intrinsic drug resistance signatures’ function, we selected the patient-derived intrinsic drug resistance signature ‘CTR_RNAseq_342″ from the CTR-DB database as the input. CTR_RNAseq_342 has 38 patients with oligodendroglioma receiving Temozolomide, of which 10 are responders, and 28 are resistant. The resistance signature was obtained by differential gene expression analysis between non-responders and responders. Using ‘Analyze’, we looked for combinational drug B able to overcome the Temozolomide resistance by searching CDS-DB signatures that reverse the intrinsic resistance signature. We find that, at the dataset-level, three of the top 10 returned signatures are Letrozole-related, and one is Tamoxifen-related. In the patient-level results, these two drugs are also ranked near the top. We know that Letrozole is an aromatase inhibitor, where aromatase is also called estrogen synthetase. Tamoxifen is an estrogen receptor antagonist. The results suggest that estrogen and estrogen receptor may be important targets combined with Temozolomide. Recent preclinical studies indeed found that Letrozole (<xref rid="B58" ref-type="bibr">58</xref>) and Tamoxifen (<xref rid="B59" ref-type="bibr">59</xref>) may have an important role in the treatment of gliomas, and Letrozole/Tamoxifen and Temozolomide have synergistic effects in glioblastoma cell lines (<xref rid="B60" ref-type="bibr">60</xref>,<xref rid="B61" ref-type="bibr">61</xref>). A Phase I clinical trial has been conducted to test the combination of Tamoxifen and Temozolomide in gliomas (<xref rid="B62" ref-type="bibr">62</xref>), and Cristofori <italic toggle="yes">et al.</italic> suggested that Tamoxifen potentially increases the efficacy of Temozolomide in patients with recurrent glioblastoma (<xref rid="B63" ref-type="bibr">63</xref>).</p>
      </sec>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>Discussion</title>
    <p>Patient-derived gene expression signatures induced by cancer treatment, obtained from paired pre- and post-treatment clinical transcriptomes, can help understand molecular changes in patients in response to treatment and reveal the molecular response mechanisms resulting in tumor sensitivity or resistance. Moreover, their integration and reuse may provide new insights. In the era of precision medicine, increasing amounts of paired pre- and post-treatment clinical transcriptomic data are being generated. However, to date, there is no database comprehensively collecting these data and facilitating their integration and (re-)use. Therefore, we developed CDS-DB.</p>
    <p>In current CDS-DB, we have used two methods (MCP-counter and xCell) to predict abundances of cell populations in TME. As many other scholars have argued, each method has strengths and weaknesses, and it is advisable to compare results of several methods (e.g. (<xref rid="B64" ref-type="bibr">64</xref>)). Actually there are several other options. For example, the advantage of ImmuCellAI is comprehensive T-cell subset abundance prediction (<xref rid="B65" ref-type="bibr">65</xref>). In the future version, we plan to support more methods, facilitating users to compare results from different methods and gain more comprehensive and robust results.</p>
    <p>As the first database of patient-derived cancer drug-induced gene expression signatures, CDS-DB can help answer questions that existing related resources cannot answer. To be specific, CDS-DB will have irreplaceable advantages for (i) validating drug MOA knowledge obtained from laboratory settings in patients, (ii) filling the knowledge gap (especially TME-related) on drug MOAs in patients, (iii) exploring molecular response mechanism heterogeneity of patients to treatment and (iv) understanding drug sensitivity/resistance mechanisms in patients from the perspective of drug perturbation. (v) Furthermore, when used for drug discovery, drug repositioning, etc., connectivity analysis based on CDS-DB signatures can provide clues from a new dimension (i.e. the patient level). These clues can validate and complement analyses based on currently commonly used cell line-level drug perturbation signatures (e.g. CMAP(11) or LINCS L1000 (<xref rid="B12" ref-type="bibr">12</xref>)). Moreover, when users input a patient-derived signature, analysis based on CDS-DB drug perturbation signatures also from patient samples may have potentially better performance. (vi) Finally, because the CDS-DB data come from clinical patients, there are many perturbation signatures induced by drug combination regimens in clinical use (e.g. chemotherapy regimens or combined chemotherapy and immunotherapy) as well as antibody drugs such as Trastuzumab, Rituximab, Cetuximab, Figitumumab, Pidilizumab, etc., which generally are not covered by existing resources. Understanding the molecular response of patients to them will contribute to the understanding of their MOAs, leading to more precise clinical use, as well as the exact combination with other drugs.</p>
    <p>In summary, CDS-DB, with unique patient-derived treatment-induced transcriptomic signatures, and abundant and useful data analysis functions, can benefit numerous basic and clinical researchers focusing on (cancer) drug development and clinical precise use of cancer drugs.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkad888_Supplemental_Files</label>
      <media xlink:href="gkad888_supplemental_files.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>We would like to thank Qiaosheng Xie from China-Japan Friendship Hospital (Beijing, China) for the fruitful discussion, Pengfei Gao, Honglei Li, Xiaohua Luo, Xun Wang, Zhonghua Yan, Jiachen Guo and He Chen for the technical support.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>CDS-DB can be accessed at <ext-link xlink:href="http://cdsdb.ncpsb.org.cn/" ext-link-type="uri">http://cdsdb.ncpsb.org.cn/</ext-link>.</p>
  </sec>
  <sec id="SEC6">
    <title>Supplementary data</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkad888#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC7">
    <title>Funding</title>
    <p>National Natural Science Foundation of China [32088101]; National Key Research and Development Program of China [2021YFA1301603, 2020YFE0202200]. Funding for open access charge: National Natural Science Foundation of China [32088101].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. The human body image in the graphical abstract and Figure <xref rid="F1" ref-type="fig">1</xref> is from Figdraw and Figure <xref rid="F7" ref-type="fig">7</xref> was created with BioRender.com.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname><given-names>J.</given-names></string-name>, <string-name><surname>Fong</surname><given-names>S.H.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Bakkenist</surname><given-names>C.J.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Mourragui</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wessels</surname><given-names>L.F.A.</given-names></string-name>, <string-name><surname>Hafner</surname><given-names>M.</given-names></string-name>, <string-name><surname>Sharan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Peng</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients</article-title>. <source>Nat. Cancer</source>. <year>2021</year>; <volume>2</volume>:<fpage>233</fpage>–<lpage>244</lpage>.<pub-id pub-id-type="pmid">34223192</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Engel</surname><given-names>R.H.</given-names></string-name>, <string-name><surname>Brown</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Von Roenn</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>O’Regan</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Bergan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Badve</surname><given-names>S.</given-names></string-name>, <string-name><surname>Rademaker</surname><given-names>A.</given-names></string-name>, <string-name><surname>Gradishar</surname><given-names>W.J.</given-names></string-name></person-group><article-title>A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience</article-title>. <source>Cancer Invest.</source><year>2007</year>; <volume>25</volume>:<fpage>733</fpage>–<lpage>737</lpage>.<pub-id pub-id-type="pmid">17952740</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schwaederle</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>M.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Eggermont</surname><given-names>A.M.</given-names></string-name>, <string-name><surname>Schilsky</surname><given-names>R.L.</given-names></string-name>, <string-name><surname>Mendelsohn</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lazar</surname><given-names>V.</given-names></string-name>, <string-name><surname>Kurzrock</surname><given-names>R.</given-names></string-name></person-group><article-title>Impact of Precision Medicine in Diverse Cancers: a Meta-Analysis of Phase II Clinical Trials</article-title>. <source>J. Clin. Oncol.</source><year>2015</year>; <volume>33</volume>:<fpage>3817</fpage>–<lpage>3825</lpage>.<pub-id pub-id-type="pmid">26304871</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X.</given-names></string-name></person-group><article-title>Drug resistance and combating drug resistance in cancer</article-title>. <source>Cancer Drug Resist.</source><year>2019</year>; <volume>2</volume>:<fpage>141</fpage>–<lpage>160</lpage>.<pub-id pub-id-type="pmid">34322663</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meng</surname><given-names>F.</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>C.M.</given-names></string-name>, <string-name><surname>Joung</surname><given-names>D.</given-names></string-name>, <string-name><surname>Vallera</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>McAlpine</surname><given-names>M.C.</given-names></string-name>, <string-name><surname>Panoskaltsis-Mortari</surname><given-names>A.</given-names></string-name></person-group><article-title>3D Bioprinted In Vitro Metastatic Models via Reconstruction of Tumor Microenvironments</article-title>. <source>Adv. Mater.</source><year>2019</year>; <volume>31</volume>:<fpage>e1806899</fpage>.<pub-id pub-id-type="pmid">30663123</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Palmer</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Sorger</surname><given-names>P.K.</given-names></string-name></person-group><article-title>Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy</article-title>. <source>Cell</source>. <year>2017</year>; <volume>171</volume>:<fpage>1678</fpage>–<lpage>1691</lpage>.<pub-id pub-id-type="pmid">29245013</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schmidt</surname><given-names>S.</given-names></string-name>, <string-name><surname>Rainer</surname><given-names>J.</given-names></string-name>, <string-name><surname>Riml</surname><given-names>S.</given-names></string-name>, <string-name><surname>Ploner</surname><given-names>C.</given-names></string-name>, <string-name><surname>Jesacher</surname><given-names>S.</given-names></string-name>, <string-name><surname>Achmüller</surname><given-names>C.</given-names></string-name>, <string-name><surname>Presul</surname><given-names>E.</given-names></string-name>, <string-name><surname>Skvortsov</surname><given-names>S.</given-names></string-name>, <string-name><surname>Crazzolara</surname><given-names>R.</given-names></string-name>, <string-name><surname>Fiegl</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia</article-title>. <source>Blood</source>. <year>2006</year>; <volume>107</volume>:<fpage>2061</fpage>–<lpage>2069</lpage>.<pub-id pub-id-type="pmid">16293608</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ward</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Pettaway</surname><given-names>C.A.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>L.Z.</given-names></string-name>, <string-name><surname>Subudhi</surname><given-names>S.K.</given-names></string-name>, <string-name><surname>Vence</surname><given-names>L.M.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>H.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>H.</given-names></string-name>, <string-name><surname>Efstathiou</surname><given-names>E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer</article-title>. <source>Nat. Med.</source><year>2017</year>; <volume>23</volume>:<fpage>551</fpage>–<lpage>555</lpage>.<pub-id pub-id-type="pmid">28346412</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Triulzi</surname><given-names>T.</given-names></string-name>, <string-name><surname>Regondi</surname><given-names>V.</given-names></string-name>, <string-name><surname>De Cecco</surname><given-names>L.</given-names></string-name>, <string-name><surname>Cappelletti</surname><given-names>M.R.</given-names></string-name>, <string-name><surname>Di Modica</surname><given-names>M.</given-names></string-name>, <string-name><surname>Paolini</surname><given-names>B.</given-names></string-name>, <string-name><surname>Lollini</surname><given-names>P.L.</given-names></string-name>, <string-name><surname>Di Cosimo</surname><given-names>S.</given-names></string-name>, <string-name><surname>Sfondrini</surname><given-names>L.</given-names></string-name>, <string-name><surname>Generali</surname><given-names>D.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit</article-title>. <source>Br. J. Cancer</source>. <year>2018</year>; <volume>119</volume>:<fpage>1487</fpage>–<lpage>1494</lpage>.<pub-id pub-id-type="pmid">30478407</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Odunsi</surname><given-names>K.</given-names></string-name>, <string-name><surname>Qian</surname><given-names>F.</given-names></string-name>, <string-name><surname>Lugade</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Geller</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Fling</surname><given-names>S.P.</given-names></string-name>, <string-name><surname>Kaiser</surname><given-names>J.C.</given-names></string-name>, <string-name><surname>Lacroix</surname><given-names>A.M.</given-names></string-name>, <string-name><surname>D’Amico</surname><given-names>L.</given-names></string-name>, <string-name><surname>Ramchurren</surname><given-names>N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses</article-title>. <source>Sci. Transl. Med.</source><year>2022</year>; <volume>14</volume>:<fpage>eabg8402</fpage>.<pub-id pub-id-type="pmid">35294258</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lamb</surname><given-names>J.</given-names></string-name>, <string-name><surname>Crawford</surname><given-names>E.D.</given-names></string-name>, <string-name><surname>Peck</surname><given-names>D.</given-names></string-name>, <string-name><surname>Modell</surname><given-names>J.W.</given-names></string-name>, <string-name><surname>Blat</surname><given-names>I.C.</given-names></string-name>, <string-name><surname>Wrobel</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Lerner</surname><given-names>J.</given-names></string-name>, <string-name><surname>Brunet</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ross</surname><given-names>K.N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease</article-title>. <source>Science</source>. <year>2006</year>; <volume>313</volume>:<fpage>1929</fpage>–<lpage>1935</lpage>.<pub-id pub-id-type="pmid">17008526</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Narayan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Corsello</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Peck</surname><given-names>D.D.</given-names></string-name>, <string-name><surname>Natoli</surname><given-names>T.E.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Gould</surname><given-names>J.</given-names></string-name>, <string-name><surname>Davis</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Tubelli</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Asiedu</surname><given-names>J.K.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A next generation connectivity map: L1000 platform and the first 1,000,000 profiles</article-title>. <source>Cell</source>. <year>2017</year>; <volume>171</volume>:<fpage>1437</fpage>–<lpage>1452</lpage>.<pub-id pub-id-type="pmid">29195078</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keenan</surname><given-names>A.B.</given-names></string-name>, <string-name><surname>Wojciechowicz</surname><given-names>M.L.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Jagodnik</surname><given-names>K.M.</given-names></string-name>, <string-name><surname>Jenkins</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Lachmann</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ma’ayan</surname><given-names>A.</given-names></string-name></person-group><article-title>Connectivity mapping: methods and applications</article-title>. <source>Annu. Rev. Biomed. Data Sci.</source><year>2019</year>; <volume>2</volume>:<fpage>69</fpage>–<lpage>92</lpage>.</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>W.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>M.M.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ju</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Nesser</surname><given-names>N.K.</given-names></string-name>, <string-name><surname>Johnson-Camacho</surname><given-names>K.</given-names></string-name>, <string-name><surname>Boniface</surname><given-names>C.T.</given-names></string-name>, <string-name><surname>Lawrence</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Pande</surname><given-names>N.T.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Large-scale characterization of drug responses of clinically relevant proteins in cancer cell lines</article-title>. <source>Cancer Cell</source>. <year>2020</year>; <volume>38</volume>:<fpage>829</fpage>–<lpage>843</lpage>.<pub-id pub-id-type="pmid">33157050</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mitchell</surname><given-names>D.C.</given-names></string-name>, <string-name><surname>Kuljanin</surname><given-names>M.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Van Vranken</surname><given-names>J.G.</given-names></string-name>, <string-name><surname>Bulloch</surname><given-names>N.</given-names></string-name>, <string-name><surname>Schweppe</surname><given-names>D.K.</given-names></string-name>, <string-name><surname>Huttlin</surname><given-names>E.L.</given-names></string-name>, <string-name><surname>Gygi</surname><given-names>S.P.</given-names></string-name></person-group><article-title>A proteome-wide atlas of drug mechanism of action</article-title>. <source>Nat. Biotechnol.</source><year>2023</year>; <volume>41</volume>:<fpage>845</fpage>–<lpage>857</lpage>.<pub-id pub-id-type="pmid">36593396</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tian</surname><given-names>S.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Lv</surname><given-names>C.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Fang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>L.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zu</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Exploring pharmacological active ingredients of traditional Chinese medicine by pharmacotranscriptomic map in ITCM</article-title>. <source>Brief. Bioinform.</source><year>2023</year>; <volume>24</volume>:<fpage>bbad027</fpage>.<pub-id pub-id-type="pmid">36719094</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>M.</given-names></string-name>, <string-name><surname>Miao</surname><given-names>Y.R.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>G.Y.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Kwok</surname><given-names>H.F.</given-names></string-name>, <string-name><surname>Feng</surname><given-names>J.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.Y.</given-names></string-name></person-group><article-title>ICBatlas: a comprehensive resource for depicting immune checkpoint blockade therapy characteristics from transcriptome profiles</article-title>. <source>Cancer Immunol. Res.</source><year>2022</year>; <volume>10</volume>:<fpage>1398</fpage>–<lpage>1406</lpage>.<pub-id pub-id-type="pmid">36095221</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clough</surname><given-names>E.</given-names></string-name>, <string-name><surname>Barrett</surname><given-names>T.</given-names></string-name></person-group><article-title>The Gene Expression Omnibus Database</article-title>. <source>Methods Mol. Biol.</source><year>2016</year>; <volume>1418</volume>:<fpage>93</fpage>–<lpage>110</lpage>.<pub-id pub-id-type="pmid">27008011</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sarkans</surname><given-names>U.</given-names></string-name>, <string-name><surname>Füllgrabe</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ali</surname><given-names>A.</given-names></string-name>, <string-name><surname>Athar</surname><given-names>A.</given-names></string-name>, <string-name><surname>Behrangi</surname><given-names>E.</given-names></string-name>, <string-name><surname>Diaz</surname><given-names>N.</given-names></string-name>, <string-name><surname>Fexova</surname><given-names>S.</given-names></string-name>, <string-name><surname>George</surname><given-names>N.</given-names></string-name>, <string-name><surname>Iqbal</surname><given-names>H.</given-names></string-name>, <string-name><surname>Kurri</surname><given-names>S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>From ArrayExpress to BioStudies</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D1502</fpage>–<lpage>D1506</lpage>.<pub-id pub-id-type="pmid">33211879</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gautier</surname><given-names>L.</given-names></string-name>, <string-name><surname>Cope</surname><given-names>L.</given-names></string-name>, <string-name><surname>Bolstad</surname><given-names>B.M.</given-names></string-name>, <string-name><surname>Irizarry</surname><given-names>R.A.</given-names></string-name></person-group><article-title>affy–analysis of Affymetrix GeneChip data at the probe level</article-title>. <source>Bioinformatics</source>. <year>2004</year>; <volume>20</volume>:<fpage>307</fpage>–<lpage>315</lpage>.<pub-id pub-id-type="pmid">14960456</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ritchie</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Phipson</surname><given-names>B.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>D.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Law</surname><given-names>C.W.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>W.</given-names></string-name>, <string-name><surname>Smyth</surname><given-names>G.K.</given-names></string-name></person-group><article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>. <source>Nucleic Acids Res.</source><year>2015</year>; <volume>43</volume>:<fpage>e47</fpage>.<pub-id pub-id-type="pmid">25605792</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maglott</surname><given-names>D.</given-names></string-name>, <string-name><surname>Ostell</surname><given-names>J.</given-names></string-name>, <string-name><surname>Pruitt</surname><given-names>K.D.</given-names></string-name>, <string-name><surname>Tatusova</surname><given-names>T.</given-names></string-name></person-group><article-title>Entrez Gene: gene-centered information at NCBI</article-title>. <source>Nucleic Acids Res.</source><year>2011</year>; <volume>39</volume>:<fpage>D52</fpage>–<lpage>D57</lpage>.<pub-id pub-id-type="pmid">21115458</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dobin</surname><given-names>A.</given-names></string-name>, <string-name><surname>Davis</surname><given-names>C.A.</given-names></string-name>, <string-name><surname>Schlesinger</surname><given-names>F.</given-names></string-name>, <string-name><surname>Drenkow</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zaleski</surname><given-names>C.</given-names></string-name>, <string-name><surname>Jha</surname><given-names>S.</given-names></string-name>, <string-name><surname>Batut</surname><given-names>P.</given-names></string-name>, <string-name><surname>Chaisson</surname><given-names>M.</given-names></string-name>, <string-name><surname>Gingeras</surname><given-names>T.R.</given-names></string-name></person-group><article-title>STAR: ultrafast universal RNA-seq aligner</article-title>. <source>Bioinformatics</source>. <year>2013</year>; <volume>29</volume>:<fpage>15</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">23104886</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anders</surname><given-names>S.</given-names></string-name>, <string-name><surname>Pyl</surname><given-names>P.T.</given-names></string-name>, <string-name><surname>Huber</surname><given-names>W.</given-names></string-name></person-group><article-title>HTSeq–a Python framework to work with high-throughput sequencing data</article-title>. <source>Bioinformatics</source>. <year>2015</year>; <volume>31</volume>:<fpage>166</fpage>–<lpage>169</lpage>.<pub-id pub-id-type="pmid">25260700</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leek</surname><given-names>J.T.</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>W.E.</given-names></string-name>, <string-name><surname>Parker</surname><given-names>H.S.</given-names></string-name>, <string-name><surname>Jaffe</surname><given-names>A.E.</given-names></string-name>, <string-name><surname>Storey</surname><given-names>J.D.</given-names></string-name></person-group><article-title>The sva package for removing batch effects and other unwanted variation in high-throughput experiments</article-title>. <source>Bioinformatics</source>. <year>2012</year>; <volume>28</volume>:<fpage>882</fpage>–<lpage>883</lpage>.<pub-id pub-id-type="pmid">22257669</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Feunang</surname><given-names>Y.D.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Lo</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Marcu</surname><given-names>A.</given-names></string-name>, <string-name><surname>Grant</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Sajed</surname><given-names>T.</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>D.</given-names></string-name>, <string-name><surname>Li</surname><given-names>C.</given-names></string-name>, <string-name><surname>Sayeeda</surname><given-names>Z.</given-names></string-name><etal>et al</etal>.</person-group><article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schriml</surname><given-names>L.M.</given-names></string-name>, <string-name><surname>Munro</surname><given-names>J.B.</given-names></string-name>, <string-name><surname>Schor</surname><given-names>M.</given-names></string-name>, <string-name><surname>Olley</surname><given-names>D.</given-names></string-name>, <string-name><surname>McCracken</surname><given-names>C.</given-names></string-name>, <string-name><surname>Felix</surname><given-names>V.</given-names></string-name>, <string-name><surname>Baron</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>R.</given-names></string-name>, <string-name><surname>Bello</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Bearer</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The Human Disease Ontology 2022 update</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D1255</fpage>–<lpage>D1261</lpage>.<pub-id pub-id-type="pmid">34755882</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seal</surname><given-names>R.L.</given-names></string-name>, <string-name><surname>Braschi</surname><given-names>B.</given-names></string-name>, <string-name><surname>Gray</surname><given-names>K.</given-names></string-name>, <string-name><surname>Jones</surname><given-names>T.E.M.</given-names></string-name>, <string-name><surname>Tweedie</surname><given-names>S.</given-names></string-name>, <string-name><surname>Haim-Vilmovsky</surname><given-names>L.</given-names></string-name>, <string-name><surname>Bruford</surname><given-names>E.A.</given-names></string-name></person-group><article-title>Genenames.org: the HGNC resources in 2023</article-title>. <source>Nucleic Acids Res.</source><year>2023</year>; <volume>51</volume>:<fpage>D1003</fpage>–<lpage>D1009</lpage>.<pub-id pub-id-type="pmid">36243972</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Corsello</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Bittker</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Gould</surname><given-names>J.</given-names></string-name>, <string-name><surname>McCarren</surname><given-names>P.</given-names></string-name>, <string-name><surname>Hirschman</surname><given-names>J.E.</given-names></string-name>, <string-name><surname>Johnston</surname><given-names>S.E.</given-names></string-name>, <string-name><surname>Vrcic</surname><given-names>A.</given-names></string-name>, <string-name><surname>Wong</surname><given-names>B.</given-names></string-name>, <string-name><surname>Khan</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The Drug Repurposing Hub: a next-generation drug library and information resource</article-title>. <source>Nat. Med.</source><year>2017</year>; <volume>23</volume>:<fpage>405</fpage>–<lpage>408</lpage>.<pub-id pub-id-type="pmid">28388612</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Oughtred</surname><given-names>R.</given-names></string-name>, <string-name><surname>Rust</surname><given-names>J.</given-names></string-name>, <string-name><surname>Chang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Breitkreutz</surname><given-names>B.J.</given-names></string-name>, <string-name><surname>Stark</surname><given-names>C.</given-names></string-name>, <string-name><surname>Willems</surname><given-names>A.</given-names></string-name>, <string-name><surname>Boucher</surname><given-names>L.</given-names></string-name>, <string-name><surname>Leung</surname><given-names>G.</given-names></string-name>, <string-name><surname>Kolas</surname><given-names>N.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The BioGRID database: a comprehensive biomedical resource of curated protein, genetic, and chemical interactions</article-title>. <source>Protein Sci.</source><year>2021</year>; <volume>30</volume>:<fpage>187</fpage>–<lpage>200</lpage>.<pub-id pub-id-type="pmid">33070389</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liberzon</surname><given-names>A.</given-names></string-name>, <string-name><surname>Birger</surname><given-names>C.</given-names></string-name>, <string-name><surname>Thorvaldsdóttir</surname><given-names>H.</given-names></string-name>, <string-name><surname>Ghandi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Mesirov</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Tamayo</surname><given-names>P.</given-names></string-name></person-group><article-title>The Molecular Signatures Database (MSigDB) hallmark gene set collection</article-title>. <source>Cell Syst.</source><year>2015</year>; <volume>1</volume>:<fpage>417</fpage>–<lpage>425</lpage>.<pub-id pub-id-type="pmid">26771021</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kanehisa</surname><given-names>M.</given-names></string-name>, <string-name><surname>Furumichi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Sato</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Kawashima</surname><given-names>M.</given-names></string-name>, <string-name><surname>Ishiguro-Watanabe</surname><given-names>M.</given-names></string-name></person-group><article-title>KEGG for taxonomy-based analysis of pathways and genomes</article-title>. <source>Nucleic Acids Res.</source><year>2023</year>; <volume>51</volume>:<fpage>D587</fpage>–<lpage>D592</lpage>.<pub-id pub-id-type="pmid">36300620</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gillespie</surname><given-names>M.</given-names></string-name>, <string-name><surname>Jassal</surname><given-names>B.</given-names></string-name>, <string-name><surname>Stephan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Milacic</surname><given-names>M.</given-names></string-name>, <string-name><surname>Rothfels</surname><given-names>K.</given-names></string-name>, <string-name><surname>Senff-Ribeiro</surname><given-names>A.</given-names></string-name>, <string-name><surname>Griss</surname><given-names>J.</given-names></string-name>, <string-name><surname>Sevilla</surname><given-names>C.</given-names></string-name>, <string-name><surname>Matthews</surname><given-names>L.</given-names></string-name>, <string-name><surname>Gong</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The reactome pathway knowledgebase 2022</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D687</fpage>–<lpage>D692</lpage>.<pub-id pub-id-type="pmid">34788843</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Martens</surname><given-names>M.</given-names></string-name>, <string-name><surname>Ammar</surname><given-names>A.</given-names></string-name>, <string-name><surname>Riutta</surname><given-names>A.</given-names></string-name>, <string-name><surname>Waagmeester</surname><given-names>A.</given-names></string-name>, <string-name><surname>Slenter</surname><given-names>D.N.</given-names></string-name>, <string-name><surname>Hanspers</surname><given-names>K.</given-names></string-name>, <string-name><surname>Miller</surname><given-names>R.A.</given-names></string-name>, <string-name><surname>Digles</surname><given-names>D.</given-names></string-name>, <string-name><surname>Lopes</surname><given-names>E.N.</given-names></string-name>, <string-name><surname>Ehrhart</surname><given-names>F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>WikiPathways: connecting communities</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D613</fpage>–<lpage>D621</lpage>.<pub-id pub-id-type="pmid">33211851</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Yao</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>P.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Tian</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy</article-title>. <source>J. Immunother. Cancer</source>. <year>2020</year>; <volume>8</volume>:<fpage>e001247</fpage>.<pub-id pub-id-type="pmid">33109630</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Behan</surname><given-names>F.M.</given-names></string-name>, <string-name><surname>Iorio</surname><given-names>F.</given-names></string-name>, <string-name><surname>Picco</surname><given-names>G.</given-names></string-name>, <string-name><surname>Gonçalves</surname><given-names>E.</given-names></string-name>, <string-name><surname>Beaver</surname><given-names>C.M.</given-names></string-name>, <string-name><surname>Migliardi</surname><given-names>G.</given-names></string-name>, <string-name><surname>Santos</surname><given-names>R.</given-names></string-name>, <string-name><surname>Rao</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Sassi</surname><given-names>F.</given-names></string-name>, <string-name><surname>Pinnelli</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens</article-title>. <source>Nature</source>. <year>2019</year>; <volume>568</volume>:<fpage>511</fpage>–<lpage>516</lpage>.<pub-id pub-id-type="pmid">30971826</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Love</surname><given-names>M.I.</given-names></string-name>, <string-name><surname>Huber</surname><given-names>W.</given-names></string-name>, <string-name><surname>Anders</surname><given-names>S.</given-names></string-name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biol.</source><year>2014</year>; <volume>15</volume>:<fpage>550</fpage>.<pub-id pub-id-type="pmid">25516281</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Benjamini</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hochberg</surname><given-names>Y.</given-names></string-name></person-group><article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source>J. R. Stat. Soc.</source><year>1995</year>; <volume>57</volume>:<fpage>289</fpage>–<lpage>300</lpage>.</mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Becht</surname><given-names>E.</given-names></string-name>, <string-name><surname>Giraldo</surname><given-names>N.A.</given-names></string-name>, <string-name><surname>Lacroix</surname><given-names>L.</given-names></string-name>, <string-name><surname>Buttard</surname><given-names>B.</given-names></string-name>, <string-name><surname>Elarouci</surname><given-names>N.</given-names></string-name>, <string-name><surname>Petitprez</surname><given-names>F.</given-names></string-name>, <string-name><surname>Selves</surname><given-names>J.</given-names></string-name>, <string-name><surname>Laurent-Puig</surname><given-names>P.</given-names></string-name>, <string-name><surname>Sautès-Fridman</surname><given-names>C.</given-names></string-name>, <string-name><surname>Fridman</surname><given-names>W.H.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression</article-title>. <source>Genome Biol.</source><year>2016</year>; <volume>17</volume>:<fpage>218</fpage>.<pub-id pub-id-type="pmid">27765066</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aran</surname><given-names>D.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Butte</surname><given-names>A.J.</given-names></string-name></person-group><article-title>xCell: digitally portraying the tissue cellular heterogeneity landscape</article-title>. <source>Genome Biol.</source><year>2017</year>; <volume>18</volume>:<fpage>220</fpage>.<pub-id pub-id-type="pmid">29141660</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Tamayo</surname><given-names>P.</given-names></string-name>, <string-name><surname>Mootha</surname><given-names>V.K.</given-names></string-name>, <string-name><surname>Mukherjee</surname><given-names>S.</given-names></string-name>, <string-name><surname>Ebert</surname><given-names>B.L.</given-names></string-name>, <string-name><surname>Gillette</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Paulovich</surname><given-names>A.</given-names></string-name>, <string-name><surname>Pomeroy</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Golub</surname><given-names>T.R.</given-names></string-name>, <string-name><surname>Lander</surname><given-names>E.S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2005</year>; <volume>102</volume>:<fpage>15545</fpage>–<lpage>15550</lpage>.<pub-id pub-id-type="pmid">16199517</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>T.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>E.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>M.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>P.</given-names></string-name>, <string-name><surname>Dai</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Feng</surname><given-names>T.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>L.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Zhan</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>clusterProfiler 4.0: a universal enrichment tool for interpreting omics data</article-title>. <source>Innovation</source>. <year>2021</year>; <volume>2</volume>:<fpage>100141</fpage>.<pub-id pub-id-type="pmid">34557778</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Wickham</surname><given-names>H.</given-names></string-name></person-group><source>ggplot<italic toggle="yes">2: Elegant Graphics for Data Analysis</italic></source>. <year>2016</year>; <publisher-loc>NY</publisher-loc><publisher-name>Springer-Verlag</publisher-name>.</mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Eils</surname><given-names>R.</given-names></string-name>, <string-name><surname>Schlesner</surname><given-names>M.</given-names></string-name></person-group><article-title>Complex heatmaps reveal patterns and correlations in multidimensional genomic data</article-title>. <source>Bioinformatics</source>. <year>2016</year>; <volume>32</volume>:<fpage>2847</fpage>–<lpage>2849</lpage>.<pub-id pub-id-type="pmid">27207943</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hirata</surname><given-names>E.</given-names></string-name>, <string-name><surname>Sahai</surname><given-names>E.</given-names></string-name></person-group><article-title>Tumor microenvironment and differential responses to therapy</article-title>. <source>Cold Spring Harb. Perspect. Med.</source><year>2017</year>; <volume>7</volume>:<fpage>a026781</fpage>.<pub-id pub-id-type="pmid">28213438</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>J.Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.P.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.Q.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>N.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>J.</given-names></string-name></person-group><article-title>Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades</article-title>. <source>Mol. Cancer</source>. <year>2021</year>; <volume>20</volume>:<fpage>27</fpage>.<pub-id pub-id-type="pmid">33541368</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Li</surname><given-names>N.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>J.</given-names></string-name>, <string-name><surname>Pan</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>B.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>B.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>G.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>B.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer</article-title>. <source>Cancer Cell</source>. <year>2023</year>; <volume>41</volume>:<fpage>1345</fpage>–<lpage>1362</lpage>.<pub-id pub-id-type="pmid">37352863</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Kong</surname><given-names>X.</given-names></string-name>, <string-name><surname>He</surname><given-names>M.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Deng</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>CTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D1184</fpage>–<lpage>D1199</lpage>.<pub-id pub-id-type="pmid">34570230</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mojtahedi</surname><given-names>H.</given-names></string-name>, <string-name><surname>Yazdanpanah</surname><given-names>N.</given-names></string-name>, <string-name><surname>Rezaei</surname><given-names>N.</given-names></string-name></person-group><article-title>Chronic myeloid leukemia stem cells: targeting therapeutic implications</article-title>. <source>Stem Cell Res. Ther.</source><year>2021</year>; <volume>12</volume>:<fpage>603</fpage>.<pub-id pub-id-type="pmid">34922630</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carrano</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Eytan</surname><given-names>E.</given-names></string-name>, <string-name><surname>Hershko</surname><given-names>A.</given-names></string-name>, <string-name><surname>Pagano</surname><given-names>M.</given-names></string-name></person-group><article-title>SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27</article-title>. <source>Nat. Cell Biol.</source><year>1999</year>; <volume>1</volume>:<fpage>193</fpage>–<lpage>199</lpage>.<pub-id pub-id-type="pmid">10559916</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Otto</surname><given-names>T.</given-names></string-name>, <string-name><surname>Sicinski</surname><given-names>P.</given-names></string-name></person-group><article-title>Cell cycle proteins as promising targets in cancer therapy</article-title>. <source>Nat. Rev. Cancer</source>. <year>2017</year>; <volume>17</volume>:<fpage>93</fpage>–<lpage>115</lpage>.<pub-id pub-id-type="pmid">28127048</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andreu</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Lledó</surname><given-names>E.</given-names></string-name>, <string-name><surname>Poch</surname><given-names>E.</given-names></string-name>, <string-name><surname>Ivorra</surname><given-names>C.</given-names></string-name>, <string-name><surname>Albero</surname><given-names>M.P.</given-names></string-name>, <string-name><surname>Martínez-Climent</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Montiel-Duarte</surname><given-names>C.</given-names></string-name>, <string-name><surname>Rifón</surname><given-names>J.</given-names></string-name>, <string-name><surname>Pérez-Calvo</surname><given-names>J.</given-names></string-name>, <string-name><surname>Arbona</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells</article-title>. <source>Cancer Res.</source><year>2005</year>; <volume>65</volume>:<fpage>3264</fpage>–<lpage>3272</lpage>.<pub-id pub-id-type="pmid">15833859</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zitvogel</surname><given-names>L.</given-names></string-name>, <string-name><surname>Rusakiewicz</surname><given-names>S.</given-names></string-name>, <string-name><surname>Routy</surname><given-names>B.</given-names></string-name>, <string-name><surname>Ayyoub</surname><given-names>M.</given-names></string-name>, <string-name><surname>Kroemer</surname><given-names>G.</given-names></string-name></person-group><article-title>Immunological off-target effects of imatinib</article-title>. <source>Nat. Rev. Clin. Oncol.</source><year>2016</year>; <volume>13</volume>:<fpage>431</fpage>–<lpage>446</lpage>.<pub-id pub-id-type="pmid">27030078</pub-id></mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Pang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>H.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Tu</surname><given-names>L.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Jia</surname><given-names>X.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J.C.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.</given-names></string-name></person-group><article-title>Integrated screens identify CDK1 as a therapeutic target in advanced gastrointestinal stromal tumors</article-title>. <source>Cancer Res.</source><year>2021</year>; <volume>81</volume>:<fpage>2481</fpage>–<lpage>2494</lpage>.<pub-id pub-id-type="pmid">33727226</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Attoub</surname><given-names>S.</given-names></string-name>, <string-name><surname>Rivat</surname><given-names>C.</given-names></string-name>, <string-name><surname>Rodrigues</surname><given-names>S.</given-names></string-name>, <string-name><surname>Van Bocxlaer</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bedin</surname><given-names>M.</given-names></string-name>, <string-name><surname>Bruyneel</surname><given-names>E.</given-names></string-name>, <string-name><surname>Louvet</surname><given-names>C.</given-names></string-name>, <string-name><surname>Kornprobst</surname><given-names>M.</given-names></string-name>, <string-name><surname>André</surname><given-names>T.</given-names></string-name>, <string-name><surname>Mareel</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy</article-title>. <source>Cancer Res.</source><year>2002</year>; <volume>62</volume>:<fpage>4879</fpage>–<lpage>4883</lpage>.<pub-id pub-id-type="pmid">12208734</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <label>56.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Olsen</surname><given-names>R.S.</given-names></string-name>, <string-name><surname>Dimberg</surname><given-names>J.</given-names></string-name>, <string-name><surname>Geffers</surname><given-names>R.</given-names></string-name>, <string-name><surname>Wågsäter</surname><given-names>D</given-names></string-name></person-group><article-title>Possible role and therapeutic target of PDGF-D signalling in colorectal cancer</article-title>. <source>Cancer Invest.</source><year>2019</year>; <volume>37</volume>:<fpage>99</fpage>–<lpage>112</lpage>.<pub-id pub-id-type="pmid">30836770</pub-id></mixed-citation>
    </ref>
    <ref id="B57">
      <label>57.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kośmider</surname><given-names>K.</given-names></string-name>, <string-name><surname>Karska</surname><given-names>K.</given-names></string-name>, <string-name><surname>Kozakiewicz</surname><given-names>A.</given-names></string-name>, <string-name><surname>Lejman</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zawitkowska</surname><given-names>J.</given-names></string-name></person-group><article-title>Overcoming steroid resistance in pediatric acute lymphoblastic leukemia - the state-of-the-art knowledge and future prospects</article-title>. <source>Int. J. Mol. Sci.</source><year>2022</year>; <volume>23</volume>:<fpage>3795</fpage>.<pub-id pub-id-type="pmid">35409154</pub-id></mixed-citation>
    </ref>
    <ref id="B58">
      <label>58.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arora</surname><given-names>P.</given-names></string-name>, <string-name><surname>Adams</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Gudelsky</surname><given-names>G.</given-names></string-name>, <string-name><surname>DasGupta</surname><given-names>B.</given-names></string-name>, <string-name><surname>Desai</surname><given-names>P.B.</given-names></string-name></person-group><article-title>Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats</article-title>. <source>Cancer Chemother. Pharmacol.</source><year>2019</year>; <volume>83</volume>:<fpage>81</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="pmid">30357450</pub-id></mixed-citation>
    </ref>
    <ref id="B59">
      <label>59.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>He</surname><given-names>W.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>R.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>S.H.</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>F.</given-names></string-name></person-group><article-title>Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas</article-title>. <source>Anticancer Drugs</source>. <year>2015</year>; <volume>26</volume>:<fpage>293</fpage>–<lpage>300</lpage>.<pub-id pub-id-type="pmid">25535979</pub-id></mixed-citation>
    </ref>
    <ref id="B60">
      <label>60.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Karve</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Desai</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Dave</surname><given-names>N.</given-names></string-name>, <string-name><surname>Wise-Draper</surname><given-names>T.M.</given-names></string-name>, <string-name><surname>Gudelsky</surname><given-names>G.A.</given-names></string-name>, <string-name><surname>Phoenix</surname><given-names>T.N.</given-names></string-name>, <string-name><surname>DasGupta</surname><given-names>B.</given-names></string-name>, <string-name><surname>Sengupta</surname><given-names>S.</given-names></string-name>, <string-name><surname>Plas</surname><given-names>D.R.</given-names></string-name>, <string-name><surname>Desai</surname><given-names>P.B.</given-names></string-name></person-group><article-title>Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole</article-title>. <source>Cancer Chemother. Pharmacol.</source><year>2022</year>; <volume>90</volume>:<fpage>345</fpage>–<lpage>356</lpage>.<pub-id pub-id-type="pmid">36050497</pub-id></mixed-citation>
    </ref>
    <ref id="B61">
      <label>61.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Balça-Silva</surname><given-names>J.</given-names></string-name>, <string-name><surname>Matias</surname><given-names>D.</given-names></string-name>, <string-name><surname>do Carmo</surname><given-names>A.</given-names></string-name>, <string-name><surname>Girão</surname><given-names>H.</given-names></string-name>, <string-name><surname>Moura-Neto</surname><given-names>V.</given-names></string-name>, <string-name><surname>Sarmento-Ribeiro</surname><given-names>A.B.</given-names></string-name>, <string-name><surname>Lopes</surname><given-names>M.C.</given-names></string-name></person-group><article-title>Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines</article-title>. <source>Biochim. Biophys. Acta.</source><year>2015</year>; <volume>1850</volume>:<fpage>722</fpage>–<lpage>732</lpage>.<pub-id pub-id-type="pmid">25554223</pub-id></mixed-citation>
    </ref>
    <ref id="B62">
      <label>62.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Patel</surname><given-names>S.</given-names></string-name>, <string-name><surname>DiBiase</surname><given-names>S.</given-names></string-name>, <string-name><surname>Meisenberg</surname><given-names>B.</given-names></string-name>, <string-name><surname>Flannery</surname><given-names>T.</given-names></string-name>, <string-name><surname>Patel</surname><given-names>A.</given-names></string-name>, <string-name><surname>Dhople</surname><given-names>A.</given-names></string-name>, <string-name><surname>Cheston</surname><given-names>S.</given-names></string-name>, <string-name><surname>Amin</surname><given-names>P.</given-names></string-name></person-group><article-title>Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma</article-title>. <source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2012</year>; <volume>82</volume>:<fpage>739</fpage>–<lpage>742</lpage>.<pub-id pub-id-type="pmid">21353747</pub-id></mixed-citation>
    </ref>
    <ref id="B63">
      <label>63.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DI Cristofori</surname><given-names>A.</given-names></string-name>, <string-name><surname>Carrabba</surname><given-names>G.</given-names></string-name>, <string-name><surname>Lanfranchi</surname><given-names>G.</given-names></string-name>, <string-name><surname>Menghetti</surname><given-names>C.</given-names></string-name>, <string-name><surname>Rampini</surname><given-names>P.</given-names></string-name>, <string-name><surname>Caroli</surname><given-names>M.</given-names></string-name></person-group><article-title>Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma</article-title>. <source>Anticancer Res.</source><year>2013</year>; <volume>33</volume>:<fpage>3383</fpage>–<lpage>3389</lpage>.<pub-id pub-id-type="pmid">23898108</pub-id></mixed-citation>
    </ref>
    <ref id="B64">
      <label>64.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>T.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>D.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Li</surname><given-names>B.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.S.</given-names></string-name></person-group><article-title>TIMER2.0 for analysis of tumor-infiltrating immune cells</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>W509</fpage>–<lpage>W514</lpage>.<pub-id pub-id-type="pmid">32442275</pub-id></mixed-citation>
    </ref>
    <ref id="B65">
      <label>65.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miao</surname><given-names>Y.R.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Lei</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>G.Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.Y.</given-names></string-name></person-group><article-title>ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy</article-title>. <source>Adv. Sci.</source><year>2020</year>; <volume>7</volume>:<fpage>1902880</fpage>.</mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10767794</article-id>
    <article-id pub-id-type="pmid">37889038</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkad888</article-id>
    <article-id pub-id-type="publisher-id">gkad888</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>CDS-DB, an omnibus for patient-derived gene expression signatures induced by cancer treatment</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3371-2392</contrib-id>
        <name>
          <surname>Liu</surname>
          <given-names>Zhongyang</given-names>
        </name>
        <!--liuzy1984@163.com-->
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>College of Chemistry and Materials Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis (Hebei University), Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>College of Life Sciences, Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Ruzhen</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Lele</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>College of Chemistry and Materials Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis (Hebei University), Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-1810-6260</contrib-id>
        <name>
          <surname>Jiang</surname>
          <given-names>Jianzhou</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>College of Life Sciences, Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ma</surname>
          <given-names>Shurui</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>School of Basic Medicine, Anhui Medical University</institution>, <addr-line>Hefei 230032</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Lanhui</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>He</surname>
          <given-names>Mengqi</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Mao</surname>
          <given-names>Yichao</given-names>
        </name>
        <aff><institution>College of Life Sciences, Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Guo</surname>
          <given-names>Congcong</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Kong</surname>
          <given-names>Xiangya</given-names>
        </name>
        <aff><institution>Beijing Cloudna Technology Company</institution>, Limited, <addr-line>Beijing 100029</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Xinlei</given-names>
        </name>
        <aff><institution>Beijing Cloudna Technology Company</institution>, Limited, <addr-line>Beijing 100029</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Qi</surname>
          <given-names>Yaning</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>College of Chemistry and Materials Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis (Hebei University), Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Fengsong</given-names>
        </name>
        <aff><institution>College of Life Sciences, Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>He</surname>
          <given-names>Fuchu</given-names>
        </name>
        <!--hefc@nic.bmi.ac.cn-->
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR3" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8680-0468</contrib-id>
        <name>
          <surname>Li</surname>
          <given-names>Dong</given-names>
        </name>
        <!--lidong.bprc@foxmail.com-->
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR2" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +861061777056; Fax: +861061777004; Email: <email>liuzy1984@163.com</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Dong Li. Tel: +861061777057; Fax: +861061777004; Email: <email>lidong.bprc@foxmail.com</email></corresp>
      <corresp id="COR3">Correspondence may also be addressed to Fuchu He. Tel: +861061771001; Fax: +861061777004; Email: <email>hefc@nic.bmi.ac.cn</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first four authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-10-27">
      <day>27</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>27</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <volume>52</volume>
    <issue>D1</issue>
    <fpage>D1163</fpage>
    <lpage>D1179</lpage>
    <history>
      <date date-type="accepted">
        <day>05</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>25</day>
        <month>9</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>15</day>
        <month>8</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkad888.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Patient-derived gene expression signatures induced by cancer treatment, obtained from paired pre- and post-treatment clinical transcriptomes, can help reveal drug mechanisms of action (MOAs) in cancer patients and understand the molecular response mechanism of tumor sensitivity or resistance. Their integration and reuse may bring new insights. Paired pre- and post-treatment clinical transcriptomic data are rapidly accumulating. However, a lack of systematic collection makes data access, integration, and reuse challenging. We therefore present the Cancer Drug-induced gene expression Signature DataBase (CDS-DB). CDS-DB has collected 78 patient-derived, paired pre- and post-treatment transcriptomic source datasets with uniformly reprocessed expression profiles and manually curated metadata such as drug administration dosage, sampling time and location, and intrinsic drug response status. From these source datasets, 2012 patient-level gene perturbation signatures were obtained, covering 85 therapeutic regimens, 39 cancer subtypes and 3628 patient samples. Besides data browsing, download and search, CDS-DB also supports single signature analysis (including differential gene expression, functional enrichment, tumor microenvironment and correlation analyses), signature comparative analysis and signature connectivity analysis. This provides insights into drug MOA and its heterogeneity in patients, drug resistance mechanisms, drug repositioning and drug (combination) discovery, etc. CDS-DB is available at <ext-link xlink:href="http://cdsdb.ncpsb.org.cn/" ext-link-type="uri">http://cdsdb.ncpsb.org.cn/</ext-link>.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="gkad888figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>32088101</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Key Research and Development Program of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100012166</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2021YFA1301603</award-id>
        <award-id>2020YFE0202200</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="17"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p>In cancer drug development, it is well known that drugs which demonstrate efficacy in preclinical models do not always achieve the expected curative effects in patients (<xref rid="B1" ref-type="bibr">1</xref>), where many such examples have been reported (e.g. (<xref rid="B2" ref-type="bibr">2</xref>)). Meanwhile, both for cancer chemotherapy and targeted therapy, the response rate of a so-called clinically effective drug is often far below 100% (i.e. intrinsic drug resistance) (<xref rid="B3" ref-type="bibr">3</xref>), and even for responders, a significant proportion of them progress after an initial treatment response (i.e. acquired drug resistance) (<xref rid="B4" ref-type="bibr">4</xref>). These problems are mainly due to the inevitable difference between preclinical models and patients (such as the lack of a native tumor microenvironment (TME) in preclinical models) (<xref rid="B5" ref-type="bibr">5</xref>) and the nature of tumor heterogeneity in patients (<xref rid="B6" ref-type="bibr">6</xref>). The key to addressing these problems is understanding the molecular changes (including TME dynamics) in patients in response to clinical treatment.</p>
    <p>Patient-derived gene perturbation signatures induced by cancer treatment, obtained from paired (i.e. from the same patient) pre- and post-treatment clinical transcriptomes, can help solve the above problems. Numerous studies have indicated that patient-derived treatment-induced gene perturbation signatures can help fill the knowledge gap on drug mechanisms of action (MOAs) (especially TME-related MOAs) in patients and reveal the molecular response mechanism that results in treatment sensitivity (<xref rid="B7" ref-type="bibr">7</xref>) or resistance (<xref rid="B8" ref-type="bibr">8</xref>), and even discover predictive biomarkers of treatment response (<xref rid="B9" ref-type="bibr">9</xref>) and potential combinational drug B to overcome resistance to drug A (<xref rid="B10" ref-type="bibr">10</xref>). More importantly, the integration and reuse of these data may provide unprecedented new insights, such as exploring the heterogeneity of molecular response of patients to treatment and drug repositioning by connectivity analysis with disease signatures.</p>
    <p>In the era of precision medicine, paired pre- and post-treatment clinical transcriptomic data derived from patients with cancer are rapidly accumulated. However, these data are scattered and often mixed with various other types of data, and often have inconsistent data formats, use non-uniform data processing pipelines and have poor machine-readable metadata, which brings challenges to data access, integration and reuse.</p>
    <p>Many great resources related to drug-induced molecular perturbation signatures have been developed. The most famous are the Connectivity Map (CMAP) (<xref rid="B11" ref-type="bibr">11</xref>) and its extended version LINCS L1000 (<xref rid="B12" ref-type="bibr">12</xref>), together with their numerous derivative resources/tools designed to search, visualize or reuse the CMAP/LINCS L1000 data as reviewed by Keenan <italic toggle="yes">et al.</italic> (<xref rid="B13" ref-type="bibr">13</xref>). Currently, CMAP and LINCS L1000 contain approximately one million gene perturbation signatures at the cell line level, induced by tens of thousands of small molecules (<ext-link xlink:href="https://clue.io/" ext-link-type="uri">https://clue.io/</ext-link>), which are highly valuable for drug discovery and drug repurposing. At the cell line level, there are also several other drug-induced molecular perturbation signature resources. For example, Zhao <italic toggle="yes">et al.</italic>’s study generated perturbed expression profiles of hundreds of clinically relevant proteins in response to ∼170 drug compounds (<xref rid="B14" ref-type="bibr">14</xref>), Mitchell <italic toggle="yes">et al.</italic> characterized proteome-wide perturbation signatures of 875 compounds (<xref rid="B15" ref-type="bibr">15</xref>), and Tian <italic toggle="yes">et al.</italic> developed the largest-to-date data repository of gene perturbation signatures for active ingredients of traditional Chinese medicine (including 496 active ingredients) (<xref rid="B16" ref-type="bibr">16</xref>). In addition, in ICBatlas (a comprehensive resource for collecting and reusing transcriptomic data from patients receiving immune checkpoint blockade therapy), besides the dominant pre-treatment samples, 7 of the 25 source datasets collected by them also contain post-treatment patient samples (154 post-treatment samples in total) (<xref rid="B17" ref-type="bibr">17</xref>). All of these resources have greatly contributed to (cancer) drug development and use. However, to the best of our knowledge, there is still no data resource focusing on patient-derived gene expression signatures induced by cancer treatment (obtained from a comprehensive collection of patient-derived paired pre- and post-treatment transcriptomic data).</p>
    <p>Here, we present the Cancer Drug-induced gene expression Signature DataBase (CDS-DB) (<ext-link xlink:href="http://cdsdb.ncpsb.org.cn/" ext-link-type="uri">http://cdsdb.ncpsb.org.cn/</ext-link>), a comprehensive database, designed to specifically collect patient-derived paired pre- and post-treatment clinical transcriptomic data in cancer and provide abundant analysis functions facilitating data integration and reuse.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <sec id="SEC2-1">
      <title>Data collection and curation</title>
      <p>Paired pre- and post-treatment transcriptomes derived from patients with cancer were manually mined from GEO (<xref rid="B18" ref-type="bibr">18</xref>) and ArrayExpress (<xref rid="B19" ref-type="bibr">19</xref>) (until July 2022). First, we obtained potentially related datasets by retrieving GEO/ArrayExpress with ‘cancer-related keywords AND drug-related keywords AND patient-related keywords AND <italic toggle="yes">Homo sapiens</italic>’ (see <xref rid="sup1" ref-type="supplementary-material">Supplementary methods</xref> for the detailed keyword lists). Then, we manually picked those that met the inclusion criteria described below. For the eligible source datasets, we downloaded raw-formatted microarray gene expression data directly from the GEO/ArrayExpress website and downloaded RNA-seq SRA files from NCBI using the ‘prefetch’ function in the sra-tools (version: 2.11.0) (<ext-link xlink:href="https://github.com/ncbi/sra-tools" ext-link-type="uri">https://github.com/ncbi/sra-tools</ext-link>), and then extracted FASTQ files from the SRA files with the ‘fastq-dump’ function. In CDS-DB, the raw SRA files cannot be obtained for only two RNA-seq source datasets (GSE136114 and GSE191127), and their count data were directly downloaded from GEO. Metadata were manually curated from the corresponding source references, including sample identifier (ID), patient ID, therapeutic regimen and administration dosage, the most fine-grained cancer subtype, drug response status and the response status definition given by the original authors (if available), sampling time and location, pediatric tumor or not, data production platform, source dataset and source publication. Intrinsic drug response status information was available for 45% of patients in CDS-DB. Based on the drug response status, we further classified patients into response and non-response groups (see <xref rid="sup1" ref-type="supplementary-material">Supplementary methods</xref> for the detailed response grouping criteria).</p>
      <p>Source dataset inclusion/exclusion criteria include the following: (i) paired (i.e. from the same patient) pre- and post-treatment patient samples were required; (ii) for microarray data, only datasets from Affymetrix, Agilent and Illumina platforms were collected; (iii) bulk transcriptomes were collected; (iv) datasets, in which drug therapy is combined with other physical therapies, were excluded (to ensure that the perturbation is induced only by drug therapy).</p>
    </sec>
    <sec id="SEC2-2">
      <title>Unified transcriptomic data processing</title>
      <sec id="SEC2-2-1">
        <title>Microarray data processing pipeline</title>
        <p>We only collected microarray datasets from Affymetrix, Illumina and Agilent platforms. Raw CEL files from Affymetrix chips were processed using the ‘rma’ function of the ‘affy’ R package (version: 1.70.0) (<xref rid="B20" ref-type="bibr">20</xref>). Summary-level files from Illumina BeadArrays were processed using the ‘neqc’ and ‘normalizeBetweenArrays’ functions of the ‘limma’ R package (version: 3.48.3) (<xref rid="B21" ref-type="bibr">21</xref>), and probes with detection <italic toggle="yes">P</italic>-values &gt;0.05 in at least three samples were removed. Image analysis output files from Agilent one-color chips were processed using the ‘backgroundCorrect’ and ‘normalizeBetweenArrays’ functions of the ‘limma’ R package. After processing, the expression values were log<sub>2</sub> transformed. Then, according to the platform-specific probe annotation files, probes were converted into gene symbols. Further, based on the gene information file from NCBI Entrez Gene (version: 20230411) (<xref rid="B22" ref-type="bibr">22</xref>), the gene symbols were converted into gene IDs. The maximum expression value was used for ‘many to one’ mapping during the conversion process.</p>
      </sec>
      <sec id="SEC2-2-2">
        <title>RNA-seq data processing pipeline</title>
        <p>Starting from FASTQ files, Trim Galore (version: 0.6.7) was first used to filter adaptor sequences and low-quality bases and remove reads with sequence lengths shorter than 20 bp (<ext-link xlink:href="https://github.com/FelixKrueger/TrimGalore" ext-link-type="uri">https://github.com/FelixKrueger/TrimGalore</ext-link>). Next, STAR (version: 2.7.10a) (2-pass mode) was used to map reads to the <italic toggle="yes">Homo sapiens</italic> genome (assembly hg38 and annotation v22) (<xref rid="B23" ref-type="bibr">23</xref>). HTSeq (version: 2.0.2) was used to count the reads mapped to each gene (<xref rid="B24" ref-type="bibr">24</xref>). Finally, Ensembl gene IDs were converted to the Entrez Gene IDs and gene symbols based on the gene information file from the NCBI Entrez Gene (version: 20230411), and the maximum count value was used for ‘many to one’ mapping. For the source dataset ‘GSE168204’, because its data were produced by two RNA-seq platforms, batch effect removal was also performed using the ‘ComBat_seq’ function of the ‘sva’ R package (<xref rid="B25" ref-type="bibr">25</xref>). The FPKM (Fragments Per Kilobase of transcript per million mapped reads) method was used to normalize read counts.</p>
      </sec>
    </sec>
    <sec id="SEC2-3">
      <title>Terminology standardization</title>
      <p>Drugs were standardized with DrugBank IDs and names (if they can be mapped to DrugBank drugs) (version: 5.1.9) (<xref rid="B26" ref-type="bibr">26</xref>), cancer subtypes with Disease Ontology (DO) IDs and names (version: August 2022) (<xref rid="B27" ref-type="bibr">27</xref>), and genes with Entrez Gene IDs (<xref rid="B22" ref-type="bibr">22</xref>) and HGNC gene symbols (<xref rid="B28" ref-type="bibr">28</xref>).</p>
    </sec>
    <sec id="SEC2-4">
      <title>External annotation integration</title>
      <p>We also integrated drug, cancer and gene annotations from external databases in CDS-DB. For drugs, target annotations were from DrugBank (version: 5.1.10) (<xref rid="B26" ref-type="bibr">26</xref>), MOA annotations were from Drug Repurposing Hub (version: 20200324) (<xref rid="B29" ref-type="bibr">29</xref>), and drug type (chemotherapy, targeted therapy, hormone therapy or immunotherapy) and FDA approval annotations were obtained by manual curation. For cancers, the annotations and classification were from the DO database (version: March 2023) (<xref rid="B27" ref-type="bibr">27</xref>). For genes, their protein − protein interaction (PPI) partners were parsed from BioGRID (version: 4.4.219) (<xref rid="B30" ref-type="bibr">30</xref>); gene sets (a gene belongs to) were from the Molecular Signatures Database (MSigDB, v7.4) (<xref rid="B31" ref-type="bibr">31</xref>), including Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway (<xref rid="B32" ref-type="bibr">32</xref>), Reactome pathway (<xref rid="B33" ref-type="bibr">33</xref>), WikiPathways (<xref rid="B34" ref-type="bibr">34</xref>), hallmark gene set, microRNA target and transcription factor target; immune checkpoint-related information was from CKTTD (version: 2020-September) (<xref rid="B35" ref-type="bibr">35</xref>), mainly including whether a gene is a known immune checkpoint together with its confidence score and the primary reference, and its corresponding drug (if it has) together with the primary reference; cancer type-specific fitness genes together with corresponding cancer types were from Behan <italic toggle="yes">et al.</italic>’s study (<xref rid="B36" ref-type="bibr">36</xref>), and are defined as those required for cancer cell growth or viability.</p>
    </sec>
    <sec id="SEC2-5">
      <title>CDS-DB dataset definition</title>
      <p>A source dataset (from GEO/ArrayExpress) was further divided into ‘CDS-DB datasets’. A CDS-DB dataset was composed of paired pre- and post-treatment patient samples with the same therapeutic regimen and administration dosage, with the same cancer subtype of the finest particle size, with similar post-treatment sampling time and the same sampling location category (tissue, blood, bone marrow or ascites), with the same drug response grouping (response or non-response) if available, from the same source dataset. The CDS-DB dataset partitioning principle, especially the involved several factors such as administration dosage, sampling time and sampling location, is mainly based on original references.</p>
    </sec>
    <sec id="SEC2-6">
      <title>CDS-DB dataset- and patient-level signature definitions</title>
      <p>A gene perturbation signature was composed of all genes in the transcriptome with log<sub>2</sub> fold changes (logFCs). The logFCs were derived from differential gene expression analysis between paired post- and pre-treatment transcriptomes, assuming the pre-treatment samples as the control group (see more in ‘Differential gene expression analysis’). A dataset-level gene perturbation signature was obtained based on paired patient samples in a CDS-DB dataset, while a patient-level gene signature based on a pair of post- and pre-treatment samples of a patient.</p>
      <p>Analogous to the gene perturbation signature, a cell perturbation signature was composed of all cell populations in TME with logFCs. The logFCs were obtained by differential analysis of abundances of TME cell populations between paired post- and pre-treatment samples (see more in ‘Tumor microenvironment analysis’). In the later text of this paper, a ‘CDS-DB signature’ is usually equivalent to a gene perturbation signature unless the signature is specially described as a cell perturbation signature (mainly used in the signature connectivity analysis-related paragraphs).</p>
      <p>A CDS-DB dataset-level signature must correspond to a CDS-DB dataset, but a CDS-DB dataset does not necessarily correspond to a CDS-DB dataset-level signature. Only the CDS-DB datasets with ≥2 patients (i.e. 4 samples) have corresponding dataset-level signatures. Because for those datasets only having 1 patient (i.e. 2 samples), statistical test for differential gene expression analysis (see more in ‘Differential gene expression analysis’) cannot be performed, they don’t have dataset-level signatures.</p>
    </sec>
    <sec id="SEC2-7">
      <title>Differential gene expression analysis</title>
      <p>To obtain a CDS-DB dataset-level gene perturbation signature, the ‘limma’ (version: 3.48.3) (<xref rid="B21" ref-type="bibr">21</xref>) and ‘DESeq2’ (version: 1.32.0) (<xref rid="B37" ref-type="bibr">37</xref>) R packages were used to obtain the logFC together with <italic toggle="yes">P</italic>-value and adjusted <italic toggle="yes">P</italic>-value separately for microarray and RNA-seq data. To obtain a CDS-DB patient-level gene signature, the logFC of each gene was computed based on the log<sub>2</sub> expression value for microarray data and the FPKM for RNA-seq data.</p>
    </sec>
    <sec id="SEC2-8">
      <title>Tumor microenvironment analysis</title>
      <p>The abundances of various cell populations in TME were first predicted based on the bulk gene expression profile of a patient sample. Differential analysis of cell abundances between paired post- and pre-treatment samples was then performed to obtain a dataset- or patient-level cell perturbation signature. For a CDS-DB dataset-level signature, differential analysis for a TME cell type was implemented using the two-sided Student's <italic toggle="yes">t</italic>-test, the adjusted <italic toggle="yes">P</italic>-value was computed by Benjamini-Hochberg (BH) multiple testing correction (<xref rid="B38" ref-type="bibr">38</xref>), and the logFC was computed based on the mean value of abundances of the cell type in post-/pre-treatment samples. For a CDS-DB patient-level signature, this was done by directly computing the logFC. Here, we used two methods, MCP-counter and xCell, to predict cell type abundances, implemented by their respective R packages (version 1.2.0 for the former and version 1.1.0 for the latter) (<xref rid="B39" ref-type="bibr">39</xref>,<xref rid="B40" ref-type="bibr">40</xref>). These two methods support 10 (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>) and 64 cell types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>), respectively. Therefore, a cell perturbation signature from MCP-counter consists of 10 cell types, while a signature from xCell 64 cell types.</p>
    </sec>
    <sec id="SEC2-9">
      <title>Functional enrichment analysis</title>
      <sec id="SEC2-9-1">
        <title>Functional enrichment analysis for the single signature analysis workflow</title>
        <p>Over-representation analysis (ORA) and gene set enrichment analysis (GSEA) (<xref rid="B41" ref-type="bibr">41</xref>) two methods are supported. ORA was conducted based on significantly differentially expressed genes (DEGs) (satisfying the |logFC| and adjusted <italic toggle="yes">P</italic>-value cutoffs), and GSEA based on all genes ranked by descending logFCs. Both ORA and GSEA were implemented using the ‘clusterProfiler’ R package (version: 4.0.5) (<xref rid="B42" ref-type="bibr">42</xref>), where <italic toggle="yes">P</italic>-values were adjusted by BH method. In ORA, the enrichment ratio (ER) was used to measure the enrichment degree of a functional gene set, calculated as the ratio of the proportion of gene set member genes among significant DEGs to that among the whole genome. In GSEA, the normalized enrichment score (NES) was computed to measure the degree to which a gene set is over-represented at the top (NES &gt;0) or bottom (NES &lt;0) of the ranked genes, i.e. the degree to which a gene set is up- or down-regulated.</p>
      </sec>
      <sec id="SEC2-9-2">
        <title>Cancer subtype and therapeutic regimen enrichment analyses for the search workflow</title>
        <p>For a given item (gene, cell type or pathway), CDS-DB signatures were first ranked in descending order of the item's logFCs or NESs in these signatures. ‘GSEA’ was then conducted, where CDS-DB signatures with a certain cancer subtype/therapeutic regimen constituted a ‘signature set’ (equivalent to a ‘gene set’ in the standard GSEA).</p>
      </sec>
      <sec id="SEC2-9-3">
        <title>Drug target and MOA enrichment analyses for the signature connectivity analysis workflow</title>
        <p>‘GSEA’ was performed based on signatures ranked in descending order of connectivity score, where signatures with a certain target or MOA constituted a ‘signature set’ (equivalent to a ‘gene set’ in the standard GSEA).</p>
      </sec>
    </sec>
    <sec id="SEC2-10">
      <title>Correlation analysis</title>
      <p>For a pair of items (gene, gene set or cell type), the correlation was measured by Spearman's rank correlation coefficient between their perturbation extents across all patients in a CDS-DB dataset using the ‘cor.test’ function of the ‘stats’ R package (version: 4.1.1). The perturbation extent of an item in a patient was measured by logFC for a gene/cell type and by NES for a pathway, which was from the analysis results of the patient-level signature.</p>
    </sec>
    <sec id="SEC2-11">
      <title>Meta-analysis</title>
      <p>The variable coefficient for an item (gene, cell type or pathway) was computed as the standard deviation divided by the mean of its perturbation extents across different CDS-DB signatures, where the perturbation extent was measured by logFC for a gene/cell type and NES for a pathway. For the comparison of multiple CDS-DB dataset-level signatures, a meta-<italic toggle="yes">P</italic>-value was further computed by integrating the <italic toggle="yes">P</italic>-values of individual signatures using the sumz method in the ‘metap’ R package (version: 1.8) (<ext-link xlink:href="https://CRAN.R-project.org/package=metap" ext-link-type="uri">https://CRAN.R-project.org/package=metap</ext-link>), and the adjusted meta-<italic toggle="yes">P</italic>-value was obtained using the BH method.</p>
    </sec>
    <sec id="SEC2-12">
      <title>Signature connectivity analysis</title>
      <p>When a gene signature with logFCs is submitted, its connectivity score with a CDS-DB gene perturbation signature is computed as the cosine similarity of the two logFC vectors. When up- and down-regulated gene sets or cell type sets are submitted, we use the Connectivity Map (CMAP) score (<xref rid="B11" ref-type="bibr">11</xref>) (see Supplementary methods).</p>
    </sec>
    <sec id="SEC2-13">
      <title>Database implementation</title>
      <p>Node.js (<ext-link xlink:href="https://nodejs.org/" ext-link-type="uri">https://nodejs.org/</ext-link>) and Vue.js (<ext-link xlink:href="https://vuejs.org/" ext-link-type="uri">https://vuejs.org/</ext-link>) were used as back- and front-end frameworks, respectively. Nginx was used as a reverse proxy (<ext-link xlink:href="https://www.nginx.com/" ext-link-type="uri">https://www.nginx.com/</ext-link>). Back-end data were stored and managed using MongoDB (<ext-link xlink:href="https://docs.mongodb.com/" ext-link-type="uri">https://docs.mongodb.com/</ext-link>). The data analysis workflows were written in R, where the volcano plot, barplot and slope plot were implemented using the ‘ggplot2’ R package (version: 3.4.2) (<xref rid="B43" ref-type="bibr">43</xref>). The interactive heatmap on the analysis result page of ‘Analyze’ was implemented using D3.js (<ext-link xlink:href="https://d3js.org/" ext-link-type="uri">https://d3js.org/</ext-link>) and other heatmaps using the ‘ComplexHeatmap’ R package (version: 2.10.0) (<xref rid="B44" ref-type="bibr">44</xref>). The interactive doughnut chart on the homepage was drawn using Apache ECharts (<ext-link xlink:href="https://echarts.apache.org/en/index.html" ext-link-type="uri">https://echarts.apache.org/en/index.html</ext-link>).</p>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>Results</title>
    <sec id="SEC3-1">
      <title>Overview</title>
      <p>CDS-DB is designed to be a comprehensive data resource for basic and clinical researchers to access, integrate and (re-)use patient-derived drug-induced gene expression signatures obtained from paired pre- and post-treatment clinical transcriptomic data derived from patients with cancer (Figure <xref rid="F1" ref-type="fig">1</xref>).</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Overview of the CDS-DB.</p>
        </caption>
        <graphic xlink:href="gkad888fig1" position="float"/>
      </fig>
      <p>The patient-derived paired pre- and post-treatment transcriptomes were manually collected from GEO and ArrayExpress under strict inclusion criteria. The related clinical annotations were manually curated from the corresponding source references, and terminologies were standardized. All transcriptomic data were reprocessed using the uniform data preprocessing pipeline. The processed and standardized source datasets were partitioned into CDS-DB datasets, and further, CDS-DB dataset- and patient-level gene perturbation signatures were obtained (see Methods). Cancer/drug/ gene-related annotations from external databases were also integrated (Figure <xref rid="F1" ref-type="fig">1</xref>).</p>
      <p>To facilitate the access, integration and (re-)use of the CDS-DB data, besides basic data browsing, retrieval and download using the ‘Browse’ function of the website, CDS-DB also supports multiple data analysis workflows (Figure <xref rid="F1" ref-type="fig">1</xref>). The single signature analysis workflow, including perturbation signature analysis, tumor microenvironment analysis and correlation analysis, is used to analyze a CDS-DB dataset- or patient-level signature, and the pre-analysis results are presented on the detailed annotation page of a CDS-DB dataset- or patient-level signature. The signature comparative analysis workflow (accessed using the ‘Compare’ function) supports comparison of the single signature analysis results of multiple user-selected signatures for meta-analysis. The ‘Search’ workflow allows users to check the perturbed extents of the gene, pathway or TME cell type of interest across different CDS-DB signatures and to further analyze the cancer subtype or drug preference of the perturbations. Finally, the signature connectivity analysis workflow (‘Analyze’) is designed to search CDS-DB signatures that mimic or reverse the user-uploaded signature and further analyze enriched targets or MOAs of the returned signatures. All website functions ‘interact with’ each other. Analysis results are returned as heatmaps, volcano plots, slope plots, bar graphs and various result tables (Figure <xref rid="F1" ref-type="fig">1</xref>), and all results can be downloaded.</p>
    </sec>
    <sec id="SEC3-2">
      <title>Data statistics</title>
      <p>The current version of the CDS-DB houses 2012 CDS-DB patient-level gene perturbation signatures and 181 CDS-DB dataset-level gene perturbation signatures obtained from 3628 patient samples of 219 CDS-DB datasets. These CDS-DB datasets were obtained by dividing 78 patient-derived paired pre- and post-treatment transcriptomic source datasets. These signatures involve 39 cancer subtypes of the finest particle size belonging to 19 cancer histological types, with breast cancer, kidney cancer, leukemia, melanoma and ovarian cancer having the most dataset-/patient-level signatures (Figure <xref rid="F2" ref-type="fig">2A</xref> and <xref rid="F2" ref-type="fig">B</xref>). There are 85 therapeutic regimens (Figure <xref rid="F2" ref-type="fig">2C</xref>), 71 drugs covering targeted therapy, chemotherapy, immunotherapy and hormone therapy (ordered from high to low) (Figure <xref rid="F2" ref-type="fig">2D</xref>). The post-treatment sampling time of 94% of dataset-level signatures is within 3 months, 78% within 2 months, 66% within 4 weeks and 36% within 2 weeks (Figure <xref rid="F2" ref-type="fig">2E</xref>). The proportions are 82%, 64%, 53% and 31% for patient-level signatures, respectively (Figure <xref rid="F2" ref-type="fig">2F</xref>). Sampling locations include tissue, blood, bone marrow and ascites (Figure <xref rid="F2" ref-type="fig">2A</xref> and <xref rid="F2" ref-type="fig">B</xref>). 70% of the CDS-DB datasets have samples not smaller than 6, and 56% not smaller than 10 (Figure <xref rid="F2" ref-type="fig">2G</xref>). Intrinsic drug response information is available for 57% of the CDS-DB dataset-level signatures.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Data statistics of the CDS-DB. (<bold>A, B</bold>) CDS-DB dataset-level (A) and patient-level (B) signature distributions across data types, therapeutic regimen types, sampling location categories and cancer histological types (from the inner to the outer ring). (<bold>C</bold>) Therapeutic regimen type distribution. (<bold>D</bold>) Drug type distribution. (<bold>E, F</bold>) Post-treatment sampling time distributions of CDS-DB dataset-level (E) and patient-level (F) signatures. Only 146 dataset-level signatures and 1799 patient-level signatures with specific and single sampling times were included in the analyses. (<bold>G</bold>) Patient sample number distribution of CDS-DB datasets. (<bold>H, I</bold>) Dataset-level (H) and patient-level (I) signature number distributions of therapeutic regimens. (<bold>J</bold>) Cancer subtype number distribution of the therapeutic regimens in CDS-DB. (<bold>K</bold>) Therapeutic regimen number distribution of cancer subtypes in CDS-DB. (<bold>L</bold>) Numbers of therapeutic regimens/drugs with different cancer types in CDS-DB. (<bold>M</bold>) Publication year distribution of CDS-DB source datasets (from 2006 to July 2022).</p>
        </caption>
        <graphic xlink:href="gkad888fig2" position="float"/>
      </fig>
      <p>The medians of CDS-DB dataset- and patient-level perturbation signatures that a therapeutic regimen has are 2 and 9, respectively. 91% and 74% of therapeutic regimens have dataset-level signatures not larger than 3 and patient-level signatures not larger than 20, respectively (Figure <xref rid="F2" ref-type="fig">2H</xref> and <xref rid="F2" ref-type="fig">I</xref>). Nivolumab and Letrozole have received the most attention and have the most perturbation signatures. In CDS-DB data, in most cases, a therapeutic regimen is only used for the treatment of a cancer subtype, indicating the cancer specificity of treatment (Figure <xref rid="F2" ref-type="fig">2J</xref>). Also, most cancer subtypes have ≤2 therapeutic regimens (Figure <xref rid="F2" ref-type="fig">2K</xref>). In CDS-DB, the cancer types with the most therapeutic regimens are breast cancer, leukemia, melanoma and ovarian cancer (Figure <xref rid="F2" ref-type="fig">2L</xref>). Finally, publication years for source datasets collected by CDS-DB show increasing attention to patient-derived paired pre- and post-treatment transcriptomic data, as 34% of the collected source datasets (spanning the 17 years from 2006 to July 2022) are from the last 3 years and 47% from the last 5 years (Figure <xref rid="F2" ref-type="fig">2M</xref>).</p>
    </sec>
    <sec id="SEC3-3">
      <title>Browse and download</title>
      <p>Using ‘Browse’ function of the website, CDS-DB dataset-level signatures, patient-level signatures, drugs and cancers can be browsed and retrieved, and signature-related data can be downloaded.</p>
      <p>On the ‘Dataset’/‘Patient’ tab (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1A</xref>), CDS-DB dataset-/patient-level signatures and their corresponding key clinical annotations are listed. These signatures can be filtered/retrieved by drug type (chemotherapy, immunotherapy, hormone therapy and targeted therapy), drug name, cancer (sub-)type, sampling location category (ascites, bone marrow, blood and tumor tissue), sample size, data type (RNA-seq and Microarray), response grouping (non-response and response), pediatric oncology, source dataset (GEO or ArrayExpress dataset ID) and CDS-DB signature ID. Gene expression matrix, sample clinical information, and gene perturbation signature files of user-selected or all signatures can also be downloaded here. Clicking on the CDS-DB signature ID in the data browsing table leads to a detailed annotation page, where the more detailed annotations of the signature and the interactive single signature analysis results are displayed.</p>
      <p>On the ‘Drug’ tab, all drugs related to CDS-DB signatures are listed in four categories (chemotherapy, immunotherapy, hormone therapy and targeted therapy) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1B</xref>). On the ‘Cancer’ tab, cancer subtypes and their parent cancer types can be browsed as a six-level hierarchy (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1C</xref>). The search box enables search of a drug or cancer (sub-)type by name. Once a drug or cancer (sub-)type is selected, the right side of the page shows its detailed annotations. ‘CDS-DB dataset signature number’ gives the number of CDS-DB dataset-level signatures related to the selected drug/cancer (sub-)type, and ‘CDS-DB patient signature number’ gives the number of the related CDS-DB patient-level signatures. Clicking on the number leads to the corresponding signature browsing page.</p>
      <p>In addition, CDS-DB dataset- or patient-level signatures can also be browsed using the doughnut of data statistics on the homepage (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1D and E</xref>). Clicking on a sector (data type, sampling location category, drug type or cancer type) on the doughnut leads to the browsing page for the sector-related signatures.</p>
    </sec>
    <sec id="SEC3-4">
      <title>Single signature analysis</title>
      <p>Each CDS-DB dataset- or patient-level signature has been pre-analyzed using the single signature analysis workflow, which includes perturbation signature analysis and tumor microenvironment analysis. Interactive correlation analysis is also supported for a dataset-level signature. This workflow is designed to reveal the drug MOAs in patients with cancer. The pre-analysis results and the correlation analysis function are presented on the detailed annotation page of the CDS-DB signature.</p>
      <sec id="SEC3-4-1">
        <title>Perturbation signature analysis</title>
        <p>The results of this function include three tabs: DEG, ORA and GSEA, aiming at revealing molecular and functional changes induced by the cancer treatment and understanding the molecular mechanisms of drug response/non-response for signatures with drug response grouping information.</p>
        <p>The DEG tab gives the differential gene expression analysis results between paired post- and pre-treatment patient samples of the signature (i.e. gene perturbation signature itself) (Figure <xref rid="F3" ref-type="fig">3A</xref>). For a dataset-level signature, significant DEGs (with the absolute values of logFCs larger than a certain cutoff and the adjusted <italic toggle="yes">P</italic>-values smaller than a certain cutoff) are potentially important molecules related to drug MOAs in patients. The ‘Significant DEGs’ mode of the result table, the volcano plot and the heatmap emphasize these significant DEGs. To further help users focus on drug MOA-related key genes, in the result table, for each gene, we also provide the following fields: whether the gene is the known target of the therapeutic regimen of the signature or the target's interactors (‘Target or target's interactor’ field), whether an ‘Immune checkpoint’ or a ‘Cancer type-specific fitness gene’ (required for cancer cell growth or viability) together with the cancer types. The table headers support gene filtering and re-ranking. For patient-level signatures, the DEG tab only gives the result table presenting the differential analysis results of all genes (i.e. patient-level gene perturbation signature itself), without the heatmap and volcano plot.</p>
        <fig position="float" id="F3">
          <label>Figure 3.</label>
          <caption>
            <p>Result pages of the single signature analysis. Here the dataset-level signature CDS_dataset_Microarray_81 is used as an example. (<bold>A</bold>) The perturbation signature analysis result page and the DEG tab page. Users can change logFC and adjusted <italic toggle="yes">P</italic>-value cutoffs to redefine significant DEGs and update the DEG and ORA results. DEG tab displays the differential gene expression analysis results of the dataset-level signature, including a volcano plot, a heatmap and a detailed result table. Clicking on the gene symbol in the result table leads to the ‘Search’ result page for the gene. Clicking on the ‘&gt;’ front of the gene symbol will lead to a slope plot presenting the gene's expression changes in the paired pre- and post-treatment samples in the dataset (shown in the embedded figure). (<bold>B</bold>) The ORA tab. Here presents the ORA results of KEGG pathways. Clicking on the pathway name in the result table leads to the ‘Search’ result page for the pathway. (<bold>C</bold>) The GSEA tab. Here shows the GSEA results of KEGG pathways. Clicking on the pathway name in the result table leads to the ‘Search’ result page for the pathway. (<bold>D</bold>) Tumor microenvironment analysis result page. Here shows the results obtained based on MCP-counter. Clicking on the ‘&gt;’ front of the cell type leads to a slope plot displaying the cell type's abundance changes in the paired pre- and post-treatment samples in the dataset (shown in the embedded figure). Clicking on the name itself leads to the ‘Search’ result page for the cell type. (<bold>E</bold>) Correlation analysis result page.</p>
          </caption>
          <graphic xlink:href="gkad888fig3" position="float"/>
        </fig>
        <p>The ORA tab gives the functional gene sets significantly perturbed by the treatment (Figure <xref rid="F3" ref-type="fig">3B</xref>), and the GSEA tab displays the gene sets significantly up-/down-regulated by the treatment (Figure <xref rid="F3" ref-type="fig">3C</xref>). Six types of gene sets are supported, including hallmark gene sets, KEGG pathways, Reactome pathways, WikiPathways, target gene sets of transcriptional factors and target gene sets of microRNAs. For a patient-level signature, there is no ORA tab.</p>
        <p>Users can change logFC and adjusted <italic toggle="yes">P</italic>-value cutoffs to redefine significant DEGs and update results in the DEG and ORA tabs (GSEA results are unaffected by parameter changes) (Figure <xref rid="F3" ref-type="fig">3A</xref>). Parameter change is not supported for a patient-level signature.</p>
      </sec>
      <sec id="SEC3-4-2">
        <title>Tumor microenvironment analysis</title>
        <p>Tumors contain a complex mixture of noncancerous cell types and matrix components, referred to as the tumor microenvironment (TME) (<xref rid="B45" ref-type="bibr">45</xref>). Compared with pre-clinical models such as cell lines, one advantage of patient samples is that they can reflect TME responses to treatment. In addition to immunotherapy targeting TME, accumulating evidence has shown that chemotherapy, targeted therapy and even hormone therapy also influence immune and non-immune components in the TME, which plays an important role in activity and efficacy of treatments (<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B47" ref-type="bibr">47</xref>). This function is designed to reveal drug-induced TME changes, providing more clues for understanding drug MOAs in patients and optimizing the combination of immunotherapy and other types of therapy. The TME analysis page gives differential analysis results of the predicted cell population abundances in TME between paired post- and pre-treatment samples (Figure <xref rid="F3" ref-type="fig">3D</xref>). We used two methods (MCP-counter and xCell) to predict cell type abundances (see Methods), and analysis results are given, respectively.</p>
      </sec>
      <sec id="SEC3-4-3">
        <title>Correlation analysis</title>
        <p>If a pair of items has consistent or opposite changes after treatment in all patients in a CDS-DB dataset, they are likely to be functionally related. This analysis is designed to reveal such functional relevance based on the correlation analysis of two items’ respective drug-induced changes across all patients in a CDS-DB dataset, in order to provide more clues for uncovering drug MOAs in patients. This analysis is only suitable for CDS-DB dataset-level signatures with patients not smaller than three. Three classes of items are supported, including genes, gene sets and TME cell types. The result table and heatmap (visually) give the correlation analysis results between items (Figure <xref rid="F3" ref-type="fig">3E</xref>).</p>
      </sec>
    </sec>
    <sec id="SEC3-5">
      <title>Signature comparative analysis</title>
      <p>This workflow can be accessed using the ‘Compare’ function, to implement the comparison of pre-analysis results (including DEG, GSEA and TME) of the user-selected multiple CDS-DB dataset- or patient-level signatures and their meta-analysis. This workflow is designed to explore the heterogeneity and homogeneity of treatment-induced gene, pathway and TME cell population perturbations across different patients or patient cohorts (e.g. those using the same drug, but with different cancer subtypes, administration dosages, post-treatment sampling times, sampling locations or treatment response states), and discover interesting shared/inconsistent drug MOA-related molecules, pathways or TME cell types. The signature filtering function on the left side of the submission page facilitates the signature selection. In particular, comparing a pair of CDS-DB dataset-level signatures with the same key metadata but with opposite drug response groupings (i.e. they are from the same source dataset, and were divided into two different CDS-DB datasets only because they have opposite response groupings) can help reveal intrinsic drug resistance mechanisms and discover predictive biomarkers of drug response from the perspective of drug perturbation. On the detailed annotation page of a CDS-DB dataset-level signature, the signature with drug response grouping opposite to it is given if available. In total, there are 43 pairs of such CDS-DB dataset-level signatures having opposite response groupings.</p>
      <p>The analysis results include seven tabs: DEG, TME-MCP-counter, TME-xCell, Hallmark gene set GSEA, KEGG pathway GSEA, Reactome pathway GSEA and WikiPathways GSEA. Each tab contains two heatmaps (except TME-MCP-counter) and a result table (Figure <xref rid="F4" ref-type="fig">4</xref>). The result table gives the meta-analysis results, where a large/small absolute value of variable coefficient indicates inconsistent/consistent perturbations of an item (gene, cell type or pathway) across different CDS-DB signatures. For the dataset-level signature comparison, meta-<italic toggle="yes">P</italic>-value is also computed, and a small meta-<italic toggle="yes">P</italic>-value means that the item has strong relevance with drug perturbations across multiple signatures. The heatmaps present the perturbations of the most consistent and inconsistent items across signatures.</p>
      <fig position="float" id="F4">
        <label>Figure 4.</label>
        <caption>
          <p>The signature comparative analysis result page. Here we use the comparison of 5 Imatinib-induced dataset-level signatures as the example and present the comparative analysis results for KEGG pathways. For dataset-level signature comparison, the heatmaps show the top 10 significantly inconsistent/consistent items across different CDS-DB signatures, where the statistical significance is measured by the adjusted meta-<italic toggle="yes">P</italic>-value. Users can change the adjusted meta-<italic toggle="yes">P</italic>-value cutoff to re-define statistical significance and update the heatmaps. Clicking on the item name in the table leads to its ‘Search’ result page.</p>
        </caption>
        <graphic xlink:href="gkad888fig4" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-6">
      <title>Search</title>
      <p>This workflow can be accessed using ‘Search’ function of the website. It supports the search for a gene, biological pathway or TME cell type. The result page includes two sections: ‘Basic information’ and ‘Analysis results’. The ‘Basic information’ gives the item-related detailed annotations. The ‘Analysis results’ gives the item's perturbed extents across all CDS-DB dataset- or patient-level perturbation signatures (Figure <xref rid="F5" ref-type="fig">5A</xref>) and drug and cancer subtype enrichment analysis results (see Methods), in order to explore by which drugs or in which cancer subtypes the item is significantly up-/down-regulated (Figure <xref rid="F5" ref-type="fig">5B</xref> and <xref rid="F5" ref-type="fig">C</xref>). The primary objective of this workflow is to elucidate the functions of the gene/biological pathway/cell type of interest and contribute to new target and drug discovery.</p>
      <fig position="float" id="F5">
        <label>Figure 5.</label>
        <caption>
          <p>The search result page. Here we use <italic toggle="yes">SKP2</italic> gene as the example and show the results for dataset-level signatures. (<bold>A</bold>) The results presenting the perturbation extents of the gene across CDS-DB dataset-level signatures. The two bar plots display the top and down 10 signatures, according to the perturbation extent. (<bold>B</bold>) Cancer subtype enrichment analysis result table. (<bold>C</bold>) Drug enrichment analysis result table.</p>
        </caption>
        <graphic xlink:href="gkad888fig5" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-7">
      <title>Signature connectivity analysis</title>
      <p>The signature connectivity analysis workflow can be accessed using ‘Analyze’ function of the website. This workflow is used to prioritize CDS-DB dataset-/patient-level signatures mimicking (‘mimic’ mode) or reversing (‘reverse’ mode) a user-uploaded signature and to further analyze MOA and target preference of the returned ranked signatures. Depending on the user's submission, this workflow can be used in many biomedical settings. For example, when a (patient-derived) disease signature is submitted, potential drugs and targets/MOAs for the disease can be recommended by searching CDS-DB signatures reversing the input (i.e. drug discovery/repositioning or target/MOA discovery); when a (patient-derived) drug resistance signature is submitted, the analysis results can suggest a combinational drug B that may be able to overcome resistance to drug A via the ‘reverse’ mode. This workflow aims at providing clues for such biomedical settings from a new dimension (i.e. patient-derived perturbation signature).</p>
      <p>Three input types are supported (Figure <xref rid="F6" ref-type="fig">6A</xref>): (i) ‘Gene set’, up- and down-regulated gene lists are required; (ii) ‘Signature’, a gene list with logFCs is required; (iii) ‘Cell type’, up- and down-regulated cell type lists are required. For the first two input types, the input signature is connected with CDS-DB gene perturbation signatures, while for the last one, with the cell perturbation signature (see Methods). We used MCP-counter and xCell two methods to obtain the cell perturbation signatures, and thus here, users need to select the method. MCP-counter supports 10 cell types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>), and xCell supports 64 cell types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>). Users can only use the supported cell types as the input. In addition, users can also select a patient-derived drug intrinsic resistance signature from CTR-DB as the input of the ‘Signature’ type by clicking the ‘CTR-DB patient-derived intrinsic drug resistance signatures’ button. CTR-DB, previously developed by our group, is a database designed to comprehensively collect patient-derived baseline transcriptomes with intrinsic cancer drug response (<xref rid="B48" ref-type="bibr">48</xref>), where an intrinsic drug resistance signature was obtained from differential gene expression analysis of baseline (i.e. pre-treatment) transcriptomes between non-responsive and responsive patients. In signature connectivity analysis, the optional parameters include signature level (CDS-DB dataset- or patient-level signature) and direction (mimic or reverse).</p>
      <fig position="float" id="F6">
        <label>Figure 6.</label>
        <caption>
          <p>User submission page (A) and result pages (B, C, D and E) of the signature connectivity analysis workflow. An acute lymphoblastic leukemia (ALL) disease signature is used as the input example (see Supplementary methods), and ‘dataset-level signature’ and ‘reverse’ mode are selected. (<bold>A</bold>) User submission page. (<bold>B</bold>) The interactive heatmap which presents top 20 returned CDS-DB dataset-level signatures. Users can modify the logFC cutoff to recolor the heatmap and also switch the column label name of the heatmap among cancer subtype, therapeutic regimen and signature ID. (<bold>C</bold>) The detailed result table presents the returned ranked CDS-DB signatures. Users can select ≥2 CDS-DB signatures in the table, and check their signature comparative analysis results by clicking the ‘Compare’ button under the table. Users can also select signatures of interest in the table and use the ‘Refresh’ button to repeat the MOA and target enrichment analyses based on the selected signatures. (<bold>D</bold>) The MOA enrichment analysis result table. (<bold>E</bold>) The target enrichment analysis result table.</p>
        </caption>
        <graphic xlink:href="gkad888fig6" position="float"/>
      </fig>
      <p>The analysis results include an interactive heatmap (Figure <xref rid="F6" ref-type="fig">6B</xref>) and three result tables (Figure <xref rid="F6" ref-type="fig">6C</xref>–<xref rid="F6" ref-type="fig">E</xref>). The heatmap visualizes the perturbation extents (logFCs) of the input genes/cell types in the top 20 returned CDS-DB gene/cell signatures, emphasizing the reversal or simulation of the CDS-DB signatures to the input signature (Figure <xref rid="F6" ref-type="fig">6B</xref>). Below the heatmap is the detailed result table of the returned CDS-DB signatures, ranked according to descending/ascending connectivity scores for the ‘mimic’/‘reverse’ mode (see Methods) (Figure <xref rid="F6" ref-type="fig">6C</xref>). In order to help users better check consistent or inconsistent parts of the returned signatures, users can select ≥2 CDS-DB signatures in the table and click the ‘Compare’ button under the table (Figure <xref rid="F6" ref-type="fig">6C</xref>) to obtain the comparative analysis results of the selected signatures. The last two tables give targets and MOAs significantly enriched at the top of the returned ranked signature list in the first table (Figure <xref rid="F6" ref-type="fig">6D</xref> and <xref rid="F6" ref-type="fig">E</xref>). Users can filter the returned signatures based on various data fields in the first table, and then click ‘Refresh’ button under the first table to update the target and MOA enrichment analysis results (Figure <xref rid="F6" ref-type="fig">6C</xref>). For example, users can require that the length of the intersection between the input and the CDS-DB signature (‘Overlap_num’) is not smaller than a certain cutoff, the sampling location category is tumor tissue, the response grouping is ‘response’, and childhood cancer is excluded.</p>
    </sec>
    <sec id="SEC3-8">
      <title>Use cases</title>
      <p>Here, we use several examples to demonstrate the use and potential of key CDS-DB workflows used to reveal drug MOAs (including TME-related MOAs) and their homogeneity/heterogeneity in patients and for drug (combination) discovery.</p>
      <sec id="SEC3-8-1">
        <title>Single signature analysis</title>
        <p>We used the dataset-level signature CDS_dataset_Microarray_81 as an example. In this dataset, nine patients with chronic myeloid leukemia (CML) received Imatinib, and paired bone marrow samples were obtained before and four weeks after treatment. The original reference did not report the drug response status information. It has been known that CML is caused mainly by the fusion oncogene BCR-ABL1, whose protein product has constitutive tyrosine kinase activity, and Imatinib, a BCR-ABL1 tyrosine kinase inhibitor, is the standard therapy for CML (<xref rid="B49" ref-type="bibr">49</xref>).</p>
        <p>The ‘Perturbation signature analysis’ results show that after four weeks of treatment, the most significantly down-regulated hallmark gene set is E2F targets (NES = −2.35, <italic toggle="yes">P</italic>-value = 1.00E−10) and DNA replication is also significantly down-regulated in KEGG GSEA analysis (NES = −2.09, <italic toggle="yes">P</italic>-value = 3.11E−08). Upstream, we find that the transcriptional factor E2F1 is significantly down-regulated (logFC = −0.22, <italic toggle="yes">P</italic>-value = 4.32E−02), several cyclin-dependent kinases (CDKs) such as CDK4 (logFC = −0.87, <italic toggle="yes">P</italic>-value = 3.56E−02) and CDK2 (logFC = −0.48, <italic toggle="yes">P</italic>-value = 7.27E−02) are down-regulated, as is SKP2 (logFC = −0.94, <italic toggle="yes">P</italic>-value = 3.82E−05). SKP2 is a ubiquitin ligase subunit that specifically recognizes the CDK inhibitor CDKN1B (i.e. P27) and promotes its degradation (<xref rid="B50" ref-type="bibr">50</xref>). Indeed, in our analysis results we find that, consistent with the down-regulation of SKP2, ‘REACTOME_SCF_SKP2_MEDIATED_DEGRADATION_OF_ P27_P21’ is significantly down-regulated (NES = −1.65, <italic toggle="yes">P</italic>-value = 2.44E−03). Further, CDKs are known to promote the release of E2F transcriptional factors, drive cell-cycle progression from G1 to S, and launch DNA replication (<xref rid="B51" ref-type="bibr">51</xref>). Integrating the prior knowledge and our results, we speculate that in these patients with CML, Imatinib caused cell cycle arrest at G1-S transition via the upstream SKP2-P27-CDK-E2F axis (Figure <xref rid="F7" ref-type="fig">7</xref>). This finding is consistent with previous cell line level studies that BCR-ABL up-regulates SKP2 expression via PI3K pathway, and Imatinib can induce cell cycle arrest by reducing SKP2 expression and accumulating P27 in BCR-ABL-positive cells (<xref rid="B52" ref-type="bibr">52</xref>).</p>
        <fig position="float" id="F7">
          <label>Figure 7.</label>
          <caption>
            <p>Schematic diagram of Imatinib MOAs in the treatment of chronic myeloid leukemia. The MOAs are speculated based on the single signature analysis results of CDS_dataset_Microarray_81, presented in the figure. The results suggest that on the one hand, Imatinib down-regulates SKP2 and further reduces ubiquitination-mediated degradation of P27 protein, then accumulating P27 inhibits the activities of CDKs and downstream E2F1, and eventually Imatinib induces cell cycle arrest. On the other hand, Imatinib exerts anti-tumor effects also by CD8+ T cell- and NK-cell-mediated cytotoxicity. These findings are consistent with previous studies (<xref rid="B52" ref-type="bibr">52</xref>,<xref rid="B53" ref-type="bibr">53</xref>). The red crosses in the figure represent the action of Imatinib, and the red arrows show its regulatory direction (up- or down-regulation).</p>
          </caption>
          <graphic xlink:href="gkad888fig7" position="float"/>
        </fig>
        <p>Further, from the ‘Tumor microenvironment analysis’ results of MCP-counter, we find that after treatment, the abundances of CD8+ T cells (logFC = 0.16, <italic toggle="yes">P</italic>-value = 7.08E−04) and NK cells (logFC = 0.16, <italic toggle="yes">P</italic>-value = 2.85E−03) are significantly up-regulated. Meanwhile, the related ‘T cell receptor signature pathway’ (NES = 2.11, <italic toggle="yes">P</italic>-value = 2.32E−07), ‘antigen processing and presentation’ (NES = 2.00, <italic toggle="yes">P</italic>-value = 5.91E−06), and ‘natural killer cell mediated cytotoxicity’ (NES = 2.48, <italic toggle="yes">P</italic>-value = 1.00E−10) KEGG pathways are also significantly up-regulated. These results suggest that in these patients, in addition to stopping the cell cycle, Imatinib exerted therapeutic effects via CD8+ T cell- and NK cell-mediated cell cytotoxicity (Figure <xref rid="F7" ref-type="fig">7</xref>). These findings are consistent with previous studies (<xref rid="B53" ref-type="bibr">53</xref>).</p>
      </sec>
      <sec id="SEC3-8-2">
        <title>Signature comparative analysis</title>
        <p>In addition to CDS_dataset_Microarray_81, CDS-DB contains four other dataset-level signatures induced by Imatinib, including CDS_dataset_Microarray_91 and CDS_dataset_Microarray_92 for CML, CDS_dataset_Microarray_71 for gastrointestinal stromal tumor and CDS_dataset_RNAseq_41 for colorectal cancer. None have drug response information, and CDS_dataset_Microarray_91 and CDS_dataset_Microarray_92 are derived from the same source dataset with different administration dosages (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S3</xref>). According to the comparative analysis results across different dataset-level signatures of CML, we find that Imatinib MOAs (both cell cycle arrest induced by SKP2-CDK-E2F axis and CD8+ T cell- and NK cell-mediated cell cytotoxicity) identified in the single signature analysis above are further validated in the other two dataset-level signatures (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref>), showing the homogeneity of Imatinib MOAs in CML. The comparative results also suggest strong heterogeneity in treating different cancer types. For example, in colorectal cancer (CDS_dataset_RNAseq_41), the perturbation of the SKP2-CDK-E2F axis has almost the exact opposite trend with CML (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref>), and Imatinib hardly induces significant changes on SKP2-CDK-E2F axis, CD8+ T cells, and NK cells in gastrointestinal stromal tumor (CDS_dataset_Microarray_71) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref>). Indeed, previous studies have indicated that instead of targeting BCR-ABL fusion oncoprotein in CML, the therapeutic effects of Imatinib depend on inhibiting the tyrosine kinase activities of c-kit and PDGF in gastrointestinal stromal tumor (<xref rid="B54" ref-type="bibr">54</xref>) and perhaps c-kit and PDGF in colorectal cancer (<xref rid="B55" ref-type="bibr">55</xref>,<xref rid="B56" ref-type="bibr">56</xref>).</p>
      </sec>
      <sec id="SEC3-8-3">
        <title>Signature connectivity analysis</title>
        <p>Using the patient-derived acute lymphoblastic leukemia (ALL) disease signature (see <xref rid="sup1" ref-type="supplementary-material">Supplementary methods</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S5</xref>) as the input, we searched CDS-DB signatures reversing it. We find that, in both dataset- and patient-level signature connectivity analyses, the most significantly enriched MOA at the top of the returned signatures is ‘glucocorticoid receptor agonist’ such as prednisone, prednisolone and dexamethasone (NES = −1.74, <italic toggle="yes">P</italic>-value = 1.85E−03 for dataset-level; NES = −2.14, <italic toggle="yes">P</italic>-value = 2.65E−10 for patient-level), and the target in the first place is NR3C1 (i.e. glucocorticoid receptor) (NES = −1.73, <italic toggle="yes">P</italic>-value = 1.61E−03 for dataset-level; NES = −2.11, <italic toggle="yes">P</italic>-value = 3.69E−10 for patient-level) (Figure <xref rid="F6" ref-type="fig">6D</xref> and <xref rid="F6" ref-type="fig">E</xref>). It is known that in clinical ALL treatment glucocorticoids are essential chemotherapy components (<xref rid="B57" ref-type="bibr">57</xref>), demonstrating this workflow's potential in cancer drug discovery.</p>
        <p>To further demonstrate the workflow's potential in drug combination discovery, using the ‘CTR-DB patient-derived intrinsic drug resistance signatures’ function, we selected the patient-derived intrinsic drug resistance signature ‘CTR_RNAseq_342″ from the CTR-DB database as the input. CTR_RNAseq_342 has 38 patients with oligodendroglioma receiving Temozolomide, of which 10 are responders, and 28 are resistant. The resistance signature was obtained by differential gene expression analysis between non-responders and responders. Using ‘Analyze’, we looked for combinational drug B able to overcome the Temozolomide resistance by searching CDS-DB signatures that reverse the intrinsic resistance signature. We find that, at the dataset-level, three of the top 10 returned signatures are Letrozole-related, and one is Tamoxifen-related. In the patient-level results, these two drugs are also ranked near the top. We know that Letrozole is an aromatase inhibitor, where aromatase is also called estrogen synthetase. Tamoxifen is an estrogen receptor antagonist. The results suggest that estrogen and estrogen receptor may be important targets combined with Temozolomide. Recent preclinical studies indeed found that Letrozole (<xref rid="B58" ref-type="bibr">58</xref>) and Tamoxifen (<xref rid="B59" ref-type="bibr">59</xref>) may have an important role in the treatment of gliomas, and Letrozole/Tamoxifen and Temozolomide have synergistic effects in glioblastoma cell lines (<xref rid="B60" ref-type="bibr">60</xref>,<xref rid="B61" ref-type="bibr">61</xref>). A Phase I clinical trial has been conducted to test the combination of Tamoxifen and Temozolomide in gliomas (<xref rid="B62" ref-type="bibr">62</xref>), and Cristofori <italic toggle="yes">et al.</italic> suggested that Tamoxifen potentially increases the efficacy of Temozolomide in patients with recurrent glioblastoma (<xref rid="B63" ref-type="bibr">63</xref>).</p>
      </sec>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>Discussion</title>
    <p>Patient-derived gene expression signatures induced by cancer treatment, obtained from paired pre- and post-treatment clinical transcriptomes, can help understand molecular changes in patients in response to treatment and reveal the molecular response mechanisms resulting in tumor sensitivity or resistance. Moreover, their integration and reuse may provide new insights. In the era of precision medicine, increasing amounts of paired pre- and post-treatment clinical transcriptomic data are being generated. However, to date, there is no database comprehensively collecting these data and facilitating their integration and (re-)use. Therefore, we developed CDS-DB.</p>
    <p>In current CDS-DB, we have used two methods (MCP-counter and xCell) to predict abundances of cell populations in TME. As many other scholars have argued, each method has strengths and weaknesses, and it is advisable to compare results of several methods (e.g. (<xref rid="B64" ref-type="bibr">64</xref>)). Actually there are several other options. For example, the advantage of ImmuCellAI is comprehensive T-cell subset abundance prediction (<xref rid="B65" ref-type="bibr">65</xref>). In the future version, we plan to support more methods, facilitating users to compare results from different methods and gain more comprehensive and robust results.</p>
    <p>As the first database of patient-derived cancer drug-induced gene expression signatures, CDS-DB can help answer questions that existing related resources cannot answer. To be specific, CDS-DB will have irreplaceable advantages for (i) validating drug MOA knowledge obtained from laboratory settings in patients, (ii) filling the knowledge gap (especially TME-related) on drug MOAs in patients, (iii) exploring molecular response mechanism heterogeneity of patients to treatment and (iv) understanding drug sensitivity/resistance mechanisms in patients from the perspective of drug perturbation. (v) Furthermore, when used for drug discovery, drug repositioning, etc., connectivity analysis based on CDS-DB signatures can provide clues from a new dimension (i.e. the patient level). These clues can validate and complement analyses based on currently commonly used cell line-level drug perturbation signatures (e.g. CMAP(11) or LINCS L1000 (<xref rid="B12" ref-type="bibr">12</xref>)). Moreover, when users input a patient-derived signature, analysis based on CDS-DB drug perturbation signatures also from patient samples may have potentially better performance. (vi) Finally, because the CDS-DB data come from clinical patients, there are many perturbation signatures induced by drug combination regimens in clinical use (e.g. chemotherapy regimens or combined chemotherapy and immunotherapy) as well as antibody drugs such as Trastuzumab, Rituximab, Cetuximab, Figitumumab, Pidilizumab, etc., which generally are not covered by existing resources. Understanding the molecular response of patients to them will contribute to the understanding of their MOAs, leading to more precise clinical use, as well as the exact combination with other drugs.</p>
    <p>In summary, CDS-DB, with unique patient-derived treatment-induced transcriptomic signatures, and abundant and useful data analysis functions, can benefit numerous basic and clinical researchers focusing on (cancer) drug development and clinical precise use of cancer drugs.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkad888_Supplemental_Files</label>
      <media xlink:href="gkad888_supplemental_files.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>We would like to thank Qiaosheng Xie from China-Japan Friendship Hospital (Beijing, China) for the fruitful discussion, Pengfei Gao, Honglei Li, Xiaohua Luo, Xun Wang, Zhonghua Yan, Jiachen Guo and He Chen for the technical support.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>CDS-DB can be accessed at <ext-link xlink:href="http://cdsdb.ncpsb.org.cn/" ext-link-type="uri">http://cdsdb.ncpsb.org.cn/</ext-link>.</p>
  </sec>
  <sec id="SEC6">
    <title>Supplementary data</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkad888#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC7">
    <title>Funding</title>
    <p>National Natural Science Foundation of China [32088101]; National Key Research and Development Program of China [2021YFA1301603, 2020YFE0202200]. Funding for open access charge: National Natural Science Foundation of China [32088101].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. The human body image in the graphical abstract and Figure <xref rid="F1" ref-type="fig">1</xref> is from Figdraw and Figure <xref rid="F7" ref-type="fig">7</xref> was created with BioRender.com.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname><given-names>J.</given-names></string-name>, <string-name><surname>Fong</surname><given-names>S.H.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Bakkenist</surname><given-names>C.J.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Mourragui</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wessels</surname><given-names>L.F.A.</given-names></string-name>, <string-name><surname>Hafner</surname><given-names>M.</given-names></string-name>, <string-name><surname>Sharan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Peng</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients</article-title>. <source>Nat. Cancer</source>. <year>2021</year>; <volume>2</volume>:<fpage>233</fpage>–<lpage>244</lpage>.<pub-id pub-id-type="pmid">34223192</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Engel</surname><given-names>R.H.</given-names></string-name>, <string-name><surname>Brown</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Von Roenn</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>O’Regan</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Bergan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Badve</surname><given-names>S.</given-names></string-name>, <string-name><surname>Rademaker</surname><given-names>A.</given-names></string-name>, <string-name><surname>Gradishar</surname><given-names>W.J.</given-names></string-name></person-group><article-title>A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience</article-title>. <source>Cancer Invest.</source><year>2007</year>; <volume>25</volume>:<fpage>733</fpage>–<lpage>737</lpage>.<pub-id pub-id-type="pmid">17952740</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schwaederle</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>M.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Eggermont</surname><given-names>A.M.</given-names></string-name>, <string-name><surname>Schilsky</surname><given-names>R.L.</given-names></string-name>, <string-name><surname>Mendelsohn</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lazar</surname><given-names>V.</given-names></string-name>, <string-name><surname>Kurzrock</surname><given-names>R.</given-names></string-name></person-group><article-title>Impact of Precision Medicine in Diverse Cancers: a Meta-Analysis of Phase II Clinical Trials</article-title>. <source>J. Clin. Oncol.</source><year>2015</year>; <volume>33</volume>:<fpage>3817</fpage>–<lpage>3825</lpage>.<pub-id pub-id-type="pmid">26304871</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X.</given-names></string-name></person-group><article-title>Drug resistance and combating drug resistance in cancer</article-title>. <source>Cancer Drug Resist.</source><year>2019</year>; <volume>2</volume>:<fpage>141</fpage>–<lpage>160</lpage>.<pub-id pub-id-type="pmid">34322663</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meng</surname><given-names>F.</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>C.M.</given-names></string-name>, <string-name><surname>Joung</surname><given-names>D.</given-names></string-name>, <string-name><surname>Vallera</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>McAlpine</surname><given-names>M.C.</given-names></string-name>, <string-name><surname>Panoskaltsis-Mortari</surname><given-names>A.</given-names></string-name></person-group><article-title>3D Bioprinted In Vitro Metastatic Models via Reconstruction of Tumor Microenvironments</article-title>. <source>Adv. Mater.</source><year>2019</year>; <volume>31</volume>:<fpage>e1806899</fpage>.<pub-id pub-id-type="pmid">30663123</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Palmer</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Sorger</surname><given-names>P.K.</given-names></string-name></person-group><article-title>Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy</article-title>. <source>Cell</source>. <year>2017</year>; <volume>171</volume>:<fpage>1678</fpage>–<lpage>1691</lpage>.<pub-id pub-id-type="pmid">29245013</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schmidt</surname><given-names>S.</given-names></string-name>, <string-name><surname>Rainer</surname><given-names>J.</given-names></string-name>, <string-name><surname>Riml</surname><given-names>S.</given-names></string-name>, <string-name><surname>Ploner</surname><given-names>C.</given-names></string-name>, <string-name><surname>Jesacher</surname><given-names>S.</given-names></string-name>, <string-name><surname>Achmüller</surname><given-names>C.</given-names></string-name>, <string-name><surname>Presul</surname><given-names>E.</given-names></string-name>, <string-name><surname>Skvortsov</surname><given-names>S.</given-names></string-name>, <string-name><surname>Crazzolara</surname><given-names>R.</given-names></string-name>, <string-name><surname>Fiegl</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia</article-title>. <source>Blood</source>. <year>2006</year>; <volume>107</volume>:<fpage>2061</fpage>–<lpage>2069</lpage>.<pub-id pub-id-type="pmid">16293608</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ward</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Pettaway</surname><given-names>C.A.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>L.Z.</given-names></string-name>, <string-name><surname>Subudhi</surname><given-names>S.K.</given-names></string-name>, <string-name><surname>Vence</surname><given-names>L.M.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>H.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>H.</given-names></string-name>, <string-name><surname>Efstathiou</surname><given-names>E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer</article-title>. <source>Nat. Med.</source><year>2017</year>; <volume>23</volume>:<fpage>551</fpage>–<lpage>555</lpage>.<pub-id pub-id-type="pmid">28346412</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Triulzi</surname><given-names>T.</given-names></string-name>, <string-name><surname>Regondi</surname><given-names>V.</given-names></string-name>, <string-name><surname>De Cecco</surname><given-names>L.</given-names></string-name>, <string-name><surname>Cappelletti</surname><given-names>M.R.</given-names></string-name>, <string-name><surname>Di Modica</surname><given-names>M.</given-names></string-name>, <string-name><surname>Paolini</surname><given-names>B.</given-names></string-name>, <string-name><surname>Lollini</surname><given-names>P.L.</given-names></string-name>, <string-name><surname>Di Cosimo</surname><given-names>S.</given-names></string-name>, <string-name><surname>Sfondrini</surname><given-names>L.</given-names></string-name>, <string-name><surname>Generali</surname><given-names>D.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit</article-title>. <source>Br. J. Cancer</source>. <year>2018</year>; <volume>119</volume>:<fpage>1487</fpage>–<lpage>1494</lpage>.<pub-id pub-id-type="pmid">30478407</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Odunsi</surname><given-names>K.</given-names></string-name>, <string-name><surname>Qian</surname><given-names>F.</given-names></string-name>, <string-name><surname>Lugade</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Geller</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Fling</surname><given-names>S.P.</given-names></string-name>, <string-name><surname>Kaiser</surname><given-names>J.C.</given-names></string-name>, <string-name><surname>Lacroix</surname><given-names>A.M.</given-names></string-name>, <string-name><surname>D’Amico</surname><given-names>L.</given-names></string-name>, <string-name><surname>Ramchurren</surname><given-names>N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses</article-title>. <source>Sci. Transl. Med.</source><year>2022</year>; <volume>14</volume>:<fpage>eabg8402</fpage>.<pub-id pub-id-type="pmid">35294258</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lamb</surname><given-names>J.</given-names></string-name>, <string-name><surname>Crawford</surname><given-names>E.D.</given-names></string-name>, <string-name><surname>Peck</surname><given-names>D.</given-names></string-name>, <string-name><surname>Modell</surname><given-names>J.W.</given-names></string-name>, <string-name><surname>Blat</surname><given-names>I.C.</given-names></string-name>, <string-name><surname>Wrobel</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Lerner</surname><given-names>J.</given-names></string-name>, <string-name><surname>Brunet</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ross</surname><given-names>K.N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease</article-title>. <source>Science</source>. <year>2006</year>; <volume>313</volume>:<fpage>1929</fpage>–<lpage>1935</lpage>.<pub-id pub-id-type="pmid">17008526</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Narayan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Corsello</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Peck</surname><given-names>D.D.</given-names></string-name>, <string-name><surname>Natoli</surname><given-names>T.E.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Gould</surname><given-names>J.</given-names></string-name>, <string-name><surname>Davis</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Tubelli</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Asiedu</surname><given-names>J.K.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A next generation connectivity map: L1000 platform and the first 1,000,000 profiles</article-title>. <source>Cell</source>. <year>2017</year>; <volume>171</volume>:<fpage>1437</fpage>–<lpage>1452</lpage>.<pub-id pub-id-type="pmid">29195078</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keenan</surname><given-names>A.B.</given-names></string-name>, <string-name><surname>Wojciechowicz</surname><given-names>M.L.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Jagodnik</surname><given-names>K.M.</given-names></string-name>, <string-name><surname>Jenkins</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Lachmann</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ma’ayan</surname><given-names>A.</given-names></string-name></person-group><article-title>Connectivity mapping: methods and applications</article-title>. <source>Annu. Rev. Biomed. Data Sci.</source><year>2019</year>; <volume>2</volume>:<fpage>69</fpage>–<lpage>92</lpage>.</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>W.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>M.M.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ju</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Nesser</surname><given-names>N.K.</given-names></string-name>, <string-name><surname>Johnson-Camacho</surname><given-names>K.</given-names></string-name>, <string-name><surname>Boniface</surname><given-names>C.T.</given-names></string-name>, <string-name><surname>Lawrence</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Pande</surname><given-names>N.T.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Large-scale characterization of drug responses of clinically relevant proteins in cancer cell lines</article-title>. <source>Cancer Cell</source>. <year>2020</year>; <volume>38</volume>:<fpage>829</fpage>–<lpage>843</lpage>.<pub-id pub-id-type="pmid">33157050</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mitchell</surname><given-names>D.C.</given-names></string-name>, <string-name><surname>Kuljanin</surname><given-names>M.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Van Vranken</surname><given-names>J.G.</given-names></string-name>, <string-name><surname>Bulloch</surname><given-names>N.</given-names></string-name>, <string-name><surname>Schweppe</surname><given-names>D.K.</given-names></string-name>, <string-name><surname>Huttlin</surname><given-names>E.L.</given-names></string-name>, <string-name><surname>Gygi</surname><given-names>S.P.</given-names></string-name></person-group><article-title>A proteome-wide atlas of drug mechanism of action</article-title>. <source>Nat. Biotechnol.</source><year>2023</year>; <volume>41</volume>:<fpage>845</fpage>–<lpage>857</lpage>.<pub-id pub-id-type="pmid">36593396</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tian</surname><given-names>S.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Lv</surname><given-names>C.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Fang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>L.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zu</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Exploring pharmacological active ingredients of traditional Chinese medicine by pharmacotranscriptomic map in ITCM</article-title>. <source>Brief. Bioinform.</source><year>2023</year>; <volume>24</volume>:<fpage>bbad027</fpage>.<pub-id pub-id-type="pmid">36719094</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>M.</given-names></string-name>, <string-name><surname>Miao</surname><given-names>Y.R.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>G.Y.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Kwok</surname><given-names>H.F.</given-names></string-name>, <string-name><surname>Feng</surname><given-names>J.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.Y.</given-names></string-name></person-group><article-title>ICBatlas: a comprehensive resource for depicting immune checkpoint blockade therapy characteristics from transcriptome profiles</article-title>. <source>Cancer Immunol. Res.</source><year>2022</year>; <volume>10</volume>:<fpage>1398</fpage>–<lpage>1406</lpage>.<pub-id pub-id-type="pmid">36095221</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clough</surname><given-names>E.</given-names></string-name>, <string-name><surname>Barrett</surname><given-names>T.</given-names></string-name></person-group><article-title>The Gene Expression Omnibus Database</article-title>. <source>Methods Mol. Biol.</source><year>2016</year>; <volume>1418</volume>:<fpage>93</fpage>–<lpage>110</lpage>.<pub-id pub-id-type="pmid">27008011</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sarkans</surname><given-names>U.</given-names></string-name>, <string-name><surname>Füllgrabe</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ali</surname><given-names>A.</given-names></string-name>, <string-name><surname>Athar</surname><given-names>A.</given-names></string-name>, <string-name><surname>Behrangi</surname><given-names>E.</given-names></string-name>, <string-name><surname>Diaz</surname><given-names>N.</given-names></string-name>, <string-name><surname>Fexova</surname><given-names>S.</given-names></string-name>, <string-name><surname>George</surname><given-names>N.</given-names></string-name>, <string-name><surname>Iqbal</surname><given-names>H.</given-names></string-name>, <string-name><surname>Kurri</surname><given-names>S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>From ArrayExpress to BioStudies</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D1502</fpage>–<lpage>D1506</lpage>.<pub-id pub-id-type="pmid">33211879</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gautier</surname><given-names>L.</given-names></string-name>, <string-name><surname>Cope</surname><given-names>L.</given-names></string-name>, <string-name><surname>Bolstad</surname><given-names>B.M.</given-names></string-name>, <string-name><surname>Irizarry</surname><given-names>R.A.</given-names></string-name></person-group><article-title>affy–analysis of Affymetrix GeneChip data at the probe level</article-title>. <source>Bioinformatics</source>. <year>2004</year>; <volume>20</volume>:<fpage>307</fpage>–<lpage>315</lpage>.<pub-id pub-id-type="pmid">14960456</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ritchie</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Phipson</surname><given-names>B.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>D.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Law</surname><given-names>C.W.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>W.</given-names></string-name>, <string-name><surname>Smyth</surname><given-names>G.K.</given-names></string-name></person-group><article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>. <source>Nucleic Acids Res.</source><year>2015</year>; <volume>43</volume>:<fpage>e47</fpage>.<pub-id pub-id-type="pmid">25605792</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maglott</surname><given-names>D.</given-names></string-name>, <string-name><surname>Ostell</surname><given-names>J.</given-names></string-name>, <string-name><surname>Pruitt</surname><given-names>K.D.</given-names></string-name>, <string-name><surname>Tatusova</surname><given-names>T.</given-names></string-name></person-group><article-title>Entrez Gene: gene-centered information at NCBI</article-title>. <source>Nucleic Acids Res.</source><year>2011</year>; <volume>39</volume>:<fpage>D52</fpage>–<lpage>D57</lpage>.<pub-id pub-id-type="pmid">21115458</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dobin</surname><given-names>A.</given-names></string-name>, <string-name><surname>Davis</surname><given-names>C.A.</given-names></string-name>, <string-name><surname>Schlesinger</surname><given-names>F.</given-names></string-name>, <string-name><surname>Drenkow</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zaleski</surname><given-names>C.</given-names></string-name>, <string-name><surname>Jha</surname><given-names>S.</given-names></string-name>, <string-name><surname>Batut</surname><given-names>P.</given-names></string-name>, <string-name><surname>Chaisson</surname><given-names>M.</given-names></string-name>, <string-name><surname>Gingeras</surname><given-names>T.R.</given-names></string-name></person-group><article-title>STAR: ultrafast universal RNA-seq aligner</article-title>. <source>Bioinformatics</source>. <year>2013</year>; <volume>29</volume>:<fpage>15</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">23104886</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anders</surname><given-names>S.</given-names></string-name>, <string-name><surname>Pyl</surname><given-names>P.T.</given-names></string-name>, <string-name><surname>Huber</surname><given-names>W.</given-names></string-name></person-group><article-title>HTSeq–a Python framework to work with high-throughput sequencing data</article-title>. <source>Bioinformatics</source>. <year>2015</year>; <volume>31</volume>:<fpage>166</fpage>–<lpage>169</lpage>.<pub-id pub-id-type="pmid">25260700</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leek</surname><given-names>J.T.</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>W.E.</given-names></string-name>, <string-name><surname>Parker</surname><given-names>H.S.</given-names></string-name>, <string-name><surname>Jaffe</surname><given-names>A.E.</given-names></string-name>, <string-name><surname>Storey</surname><given-names>J.D.</given-names></string-name></person-group><article-title>The sva package for removing batch effects and other unwanted variation in high-throughput experiments</article-title>. <source>Bioinformatics</source>. <year>2012</year>; <volume>28</volume>:<fpage>882</fpage>–<lpage>883</lpage>.<pub-id pub-id-type="pmid">22257669</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Feunang</surname><given-names>Y.D.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Lo</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Marcu</surname><given-names>A.</given-names></string-name>, <string-name><surname>Grant</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Sajed</surname><given-names>T.</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>D.</given-names></string-name>, <string-name><surname>Li</surname><given-names>C.</given-names></string-name>, <string-name><surname>Sayeeda</surname><given-names>Z.</given-names></string-name><etal>et al</etal>.</person-group><article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schriml</surname><given-names>L.M.</given-names></string-name>, <string-name><surname>Munro</surname><given-names>J.B.</given-names></string-name>, <string-name><surname>Schor</surname><given-names>M.</given-names></string-name>, <string-name><surname>Olley</surname><given-names>D.</given-names></string-name>, <string-name><surname>McCracken</surname><given-names>C.</given-names></string-name>, <string-name><surname>Felix</surname><given-names>V.</given-names></string-name>, <string-name><surname>Baron</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>R.</given-names></string-name>, <string-name><surname>Bello</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Bearer</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The Human Disease Ontology 2022 update</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D1255</fpage>–<lpage>D1261</lpage>.<pub-id pub-id-type="pmid">34755882</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seal</surname><given-names>R.L.</given-names></string-name>, <string-name><surname>Braschi</surname><given-names>B.</given-names></string-name>, <string-name><surname>Gray</surname><given-names>K.</given-names></string-name>, <string-name><surname>Jones</surname><given-names>T.E.M.</given-names></string-name>, <string-name><surname>Tweedie</surname><given-names>S.</given-names></string-name>, <string-name><surname>Haim-Vilmovsky</surname><given-names>L.</given-names></string-name>, <string-name><surname>Bruford</surname><given-names>E.A.</given-names></string-name></person-group><article-title>Genenames.org: the HGNC resources in 2023</article-title>. <source>Nucleic Acids Res.</source><year>2023</year>; <volume>51</volume>:<fpage>D1003</fpage>–<lpage>D1009</lpage>.<pub-id pub-id-type="pmid">36243972</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Corsello</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Bittker</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Gould</surname><given-names>J.</given-names></string-name>, <string-name><surname>McCarren</surname><given-names>P.</given-names></string-name>, <string-name><surname>Hirschman</surname><given-names>J.E.</given-names></string-name>, <string-name><surname>Johnston</surname><given-names>S.E.</given-names></string-name>, <string-name><surname>Vrcic</surname><given-names>A.</given-names></string-name>, <string-name><surname>Wong</surname><given-names>B.</given-names></string-name>, <string-name><surname>Khan</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The Drug Repurposing Hub: a next-generation drug library and information resource</article-title>. <source>Nat. Med.</source><year>2017</year>; <volume>23</volume>:<fpage>405</fpage>–<lpage>408</lpage>.<pub-id pub-id-type="pmid">28388612</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Oughtred</surname><given-names>R.</given-names></string-name>, <string-name><surname>Rust</surname><given-names>J.</given-names></string-name>, <string-name><surname>Chang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Breitkreutz</surname><given-names>B.J.</given-names></string-name>, <string-name><surname>Stark</surname><given-names>C.</given-names></string-name>, <string-name><surname>Willems</surname><given-names>A.</given-names></string-name>, <string-name><surname>Boucher</surname><given-names>L.</given-names></string-name>, <string-name><surname>Leung</surname><given-names>G.</given-names></string-name>, <string-name><surname>Kolas</surname><given-names>N.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The BioGRID database: a comprehensive biomedical resource of curated protein, genetic, and chemical interactions</article-title>. <source>Protein Sci.</source><year>2021</year>; <volume>30</volume>:<fpage>187</fpage>–<lpage>200</lpage>.<pub-id pub-id-type="pmid">33070389</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liberzon</surname><given-names>A.</given-names></string-name>, <string-name><surname>Birger</surname><given-names>C.</given-names></string-name>, <string-name><surname>Thorvaldsdóttir</surname><given-names>H.</given-names></string-name>, <string-name><surname>Ghandi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Mesirov</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Tamayo</surname><given-names>P.</given-names></string-name></person-group><article-title>The Molecular Signatures Database (MSigDB) hallmark gene set collection</article-title>. <source>Cell Syst.</source><year>2015</year>; <volume>1</volume>:<fpage>417</fpage>–<lpage>425</lpage>.<pub-id pub-id-type="pmid">26771021</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kanehisa</surname><given-names>M.</given-names></string-name>, <string-name><surname>Furumichi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Sato</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Kawashima</surname><given-names>M.</given-names></string-name>, <string-name><surname>Ishiguro-Watanabe</surname><given-names>M.</given-names></string-name></person-group><article-title>KEGG for taxonomy-based analysis of pathways and genomes</article-title>. <source>Nucleic Acids Res.</source><year>2023</year>; <volume>51</volume>:<fpage>D587</fpage>–<lpage>D592</lpage>.<pub-id pub-id-type="pmid">36300620</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gillespie</surname><given-names>M.</given-names></string-name>, <string-name><surname>Jassal</surname><given-names>B.</given-names></string-name>, <string-name><surname>Stephan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Milacic</surname><given-names>M.</given-names></string-name>, <string-name><surname>Rothfels</surname><given-names>K.</given-names></string-name>, <string-name><surname>Senff-Ribeiro</surname><given-names>A.</given-names></string-name>, <string-name><surname>Griss</surname><given-names>J.</given-names></string-name>, <string-name><surname>Sevilla</surname><given-names>C.</given-names></string-name>, <string-name><surname>Matthews</surname><given-names>L.</given-names></string-name>, <string-name><surname>Gong</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The reactome pathway knowledgebase 2022</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D687</fpage>–<lpage>D692</lpage>.<pub-id pub-id-type="pmid">34788843</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Martens</surname><given-names>M.</given-names></string-name>, <string-name><surname>Ammar</surname><given-names>A.</given-names></string-name>, <string-name><surname>Riutta</surname><given-names>A.</given-names></string-name>, <string-name><surname>Waagmeester</surname><given-names>A.</given-names></string-name>, <string-name><surname>Slenter</surname><given-names>D.N.</given-names></string-name>, <string-name><surname>Hanspers</surname><given-names>K.</given-names></string-name>, <string-name><surname>Miller</surname><given-names>R.A.</given-names></string-name>, <string-name><surname>Digles</surname><given-names>D.</given-names></string-name>, <string-name><surname>Lopes</surname><given-names>E.N.</given-names></string-name>, <string-name><surname>Ehrhart</surname><given-names>F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>WikiPathways: connecting communities</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D613</fpage>–<lpage>D621</lpage>.<pub-id pub-id-type="pmid">33211851</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Yao</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>P.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Tian</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy</article-title>. <source>J. Immunother. Cancer</source>. <year>2020</year>; <volume>8</volume>:<fpage>e001247</fpage>.<pub-id pub-id-type="pmid">33109630</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Behan</surname><given-names>F.M.</given-names></string-name>, <string-name><surname>Iorio</surname><given-names>F.</given-names></string-name>, <string-name><surname>Picco</surname><given-names>G.</given-names></string-name>, <string-name><surname>Gonçalves</surname><given-names>E.</given-names></string-name>, <string-name><surname>Beaver</surname><given-names>C.M.</given-names></string-name>, <string-name><surname>Migliardi</surname><given-names>G.</given-names></string-name>, <string-name><surname>Santos</surname><given-names>R.</given-names></string-name>, <string-name><surname>Rao</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Sassi</surname><given-names>F.</given-names></string-name>, <string-name><surname>Pinnelli</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens</article-title>. <source>Nature</source>. <year>2019</year>; <volume>568</volume>:<fpage>511</fpage>–<lpage>516</lpage>.<pub-id pub-id-type="pmid">30971826</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Love</surname><given-names>M.I.</given-names></string-name>, <string-name><surname>Huber</surname><given-names>W.</given-names></string-name>, <string-name><surname>Anders</surname><given-names>S.</given-names></string-name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biol.</source><year>2014</year>; <volume>15</volume>:<fpage>550</fpage>.<pub-id pub-id-type="pmid">25516281</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Benjamini</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hochberg</surname><given-names>Y.</given-names></string-name></person-group><article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source>J. R. Stat. Soc.</source><year>1995</year>; <volume>57</volume>:<fpage>289</fpage>–<lpage>300</lpage>.</mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Becht</surname><given-names>E.</given-names></string-name>, <string-name><surname>Giraldo</surname><given-names>N.A.</given-names></string-name>, <string-name><surname>Lacroix</surname><given-names>L.</given-names></string-name>, <string-name><surname>Buttard</surname><given-names>B.</given-names></string-name>, <string-name><surname>Elarouci</surname><given-names>N.</given-names></string-name>, <string-name><surname>Petitprez</surname><given-names>F.</given-names></string-name>, <string-name><surname>Selves</surname><given-names>J.</given-names></string-name>, <string-name><surname>Laurent-Puig</surname><given-names>P.</given-names></string-name>, <string-name><surname>Sautès-Fridman</surname><given-names>C.</given-names></string-name>, <string-name><surname>Fridman</surname><given-names>W.H.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression</article-title>. <source>Genome Biol.</source><year>2016</year>; <volume>17</volume>:<fpage>218</fpage>.<pub-id pub-id-type="pmid">27765066</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aran</surname><given-names>D.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Butte</surname><given-names>A.J.</given-names></string-name></person-group><article-title>xCell: digitally portraying the tissue cellular heterogeneity landscape</article-title>. <source>Genome Biol.</source><year>2017</year>; <volume>18</volume>:<fpage>220</fpage>.<pub-id pub-id-type="pmid">29141660</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Tamayo</surname><given-names>P.</given-names></string-name>, <string-name><surname>Mootha</surname><given-names>V.K.</given-names></string-name>, <string-name><surname>Mukherjee</surname><given-names>S.</given-names></string-name>, <string-name><surname>Ebert</surname><given-names>B.L.</given-names></string-name>, <string-name><surname>Gillette</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Paulovich</surname><given-names>A.</given-names></string-name>, <string-name><surname>Pomeroy</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Golub</surname><given-names>T.R.</given-names></string-name>, <string-name><surname>Lander</surname><given-names>E.S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2005</year>; <volume>102</volume>:<fpage>15545</fpage>–<lpage>15550</lpage>.<pub-id pub-id-type="pmid">16199517</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>T.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>E.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>M.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>P.</given-names></string-name>, <string-name><surname>Dai</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Feng</surname><given-names>T.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>L.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Zhan</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>clusterProfiler 4.0: a universal enrichment tool for interpreting omics data</article-title>. <source>Innovation</source>. <year>2021</year>; <volume>2</volume>:<fpage>100141</fpage>.<pub-id pub-id-type="pmid">34557778</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Wickham</surname><given-names>H.</given-names></string-name></person-group><source>ggplot<italic toggle="yes">2: Elegant Graphics for Data Analysis</italic></source>. <year>2016</year>; <publisher-loc>NY</publisher-loc><publisher-name>Springer-Verlag</publisher-name>.</mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Eils</surname><given-names>R.</given-names></string-name>, <string-name><surname>Schlesner</surname><given-names>M.</given-names></string-name></person-group><article-title>Complex heatmaps reveal patterns and correlations in multidimensional genomic data</article-title>. <source>Bioinformatics</source>. <year>2016</year>; <volume>32</volume>:<fpage>2847</fpage>–<lpage>2849</lpage>.<pub-id pub-id-type="pmid">27207943</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hirata</surname><given-names>E.</given-names></string-name>, <string-name><surname>Sahai</surname><given-names>E.</given-names></string-name></person-group><article-title>Tumor microenvironment and differential responses to therapy</article-title>. <source>Cold Spring Harb. Perspect. Med.</source><year>2017</year>; <volume>7</volume>:<fpage>a026781</fpage>.<pub-id pub-id-type="pmid">28213438</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>J.Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.P.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.Q.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>N.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>J.</given-names></string-name></person-group><article-title>Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades</article-title>. <source>Mol. Cancer</source>. <year>2021</year>; <volume>20</volume>:<fpage>27</fpage>.<pub-id pub-id-type="pmid">33541368</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Li</surname><given-names>N.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>J.</given-names></string-name>, <string-name><surname>Pan</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>B.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>B.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>G.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>B.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer</article-title>. <source>Cancer Cell</source>. <year>2023</year>; <volume>41</volume>:<fpage>1345</fpage>–<lpage>1362</lpage>.<pub-id pub-id-type="pmid">37352863</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Kong</surname><given-names>X.</given-names></string-name>, <string-name><surname>He</surname><given-names>M.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Deng</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>CTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D1184</fpage>–<lpage>D1199</lpage>.<pub-id pub-id-type="pmid">34570230</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mojtahedi</surname><given-names>H.</given-names></string-name>, <string-name><surname>Yazdanpanah</surname><given-names>N.</given-names></string-name>, <string-name><surname>Rezaei</surname><given-names>N.</given-names></string-name></person-group><article-title>Chronic myeloid leukemia stem cells: targeting therapeutic implications</article-title>. <source>Stem Cell Res. Ther.</source><year>2021</year>; <volume>12</volume>:<fpage>603</fpage>.<pub-id pub-id-type="pmid">34922630</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carrano</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Eytan</surname><given-names>E.</given-names></string-name>, <string-name><surname>Hershko</surname><given-names>A.</given-names></string-name>, <string-name><surname>Pagano</surname><given-names>M.</given-names></string-name></person-group><article-title>SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27</article-title>. <source>Nat. Cell Biol.</source><year>1999</year>; <volume>1</volume>:<fpage>193</fpage>–<lpage>199</lpage>.<pub-id pub-id-type="pmid">10559916</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Otto</surname><given-names>T.</given-names></string-name>, <string-name><surname>Sicinski</surname><given-names>P.</given-names></string-name></person-group><article-title>Cell cycle proteins as promising targets in cancer therapy</article-title>. <source>Nat. Rev. Cancer</source>. <year>2017</year>; <volume>17</volume>:<fpage>93</fpage>–<lpage>115</lpage>.<pub-id pub-id-type="pmid">28127048</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andreu</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Lledó</surname><given-names>E.</given-names></string-name>, <string-name><surname>Poch</surname><given-names>E.</given-names></string-name>, <string-name><surname>Ivorra</surname><given-names>C.</given-names></string-name>, <string-name><surname>Albero</surname><given-names>M.P.</given-names></string-name>, <string-name><surname>Martínez-Climent</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Montiel-Duarte</surname><given-names>C.</given-names></string-name>, <string-name><surname>Rifón</surname><given-names>J.</given-names></string-name>, <string-name><surname>Pérez-Calvo</surname><given-names>J.</given-names></string-name>, <string-name><surname>Arbona</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells</article-title>. <source>Cancer Res.</source><year>2005</year>; <volume>65</volume>:<fpage>3264</fpage>–<lpage>3272</lpage>.<pub-id pub-id-type="pmid">15833859</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zitvogel</surname><given-names>L.</given-names></string-name>, <string-name><surname>Rusakiewicz</surname><given-names>S.</given-names></string-name>, <string-name><surname>Routy</surname><given-names>B.</given-names></string-name>, <string-name><surname>Ayyoub</surname><given-names>M.</given-names></string-name>, <string-name><surname>Kroemer</surname><given-names>G.</given-names></string-name></person-group><article-title>Immunological off-target effects of imatinib</article-title>. <source>Nat. Rev. Clin. Oncol.</source><year>2016</year>; <volume>13</volume>:<fpage>431</fpage>–<lpage>446</lpage>.<pub-id pub-id-type="pmid">27030078</pub-id></mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Pang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>H.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Tu</surname><given-names>L.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Jia</surname><given-names>X.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J.C.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.</given-names></string-name></person-group><article-title>Integrated screens identify CDK1 as a therapeutic target in advanced gastrointestinal stromal tumors</article-title>. <source>Cancer Res.</source><year>2021</year>; <volume>81</volume>:<fpage>2481</fpage>–<lpage>2494</lpage>.<pub-id pub-id-type="pmid">33727226</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Attoub</surname><given-names>S.</given-names></string-name>, <string-name><surname>Rivat</surname><given-names>C.</given-names></string-name>, <string-name><surname>Rodrigues</surname><given-names>S.</given-names></string-name>, <string-name><surname>Van Bocxlaer</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bedin</surname><given-names>M.</given-names></string-name>, <string-name><surname>Bruyneel</surname><given-names>E.</given-names></string-name>, <string-name><surname>Louvet</surname><given-names>C.</given-names></string-name>, <string-name><surname>Kornprobst</surname><given-names>M.</given-names></string-name>, <string-name><surname>André</surname><given-names>T.</given-names></string-name>, <string-name><surname>Mareel</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy</article-title>. <source>Cancer Res.</source><year>2002</year>; <volume>62</volume>:<fpage>4879</fpage>–<lpage>4883</lpage>.<pub-id pub-id-type="pmid">12208734</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <label>56.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Olsen</surname><given-names>R.S.</given-names></string-name>, <string-name><surname>Dimberg</surname><given-names>J.</given-names></string-name>, <string-name><surname>Geffers</surname><given-names>R.</given-names></string-name>, <string-name><surname>Wågsäter</surname><given-names>D</given-names></string-name></person-group><article-title>Possible role and therapeutic target of PDGF-D signalling in colorectal cancer</article-title>. <source>Cancer Invest.</source><year>2019</year>; <volume>37</volume>:<fpage>99</fpage>–<lpage>112</lpage>.<pub-id pub-id-type="pmid">30836770</pub-id></mixed-citation>
    </ref>
    <ref id="B57">
      <label>57.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kośmider</surname><given-names>K.</given-names></string-name>, <string-name><surname>Karska</surname><given-names>K.</given-names></string-name>, <string-name><surname>Kozakiewicz</surname><given-names>A.</given-names></string-name>, <string-name><surname>Lejman</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zawitkowska</surname><given-names>J.</given-names></string-name></person-group><article-title>Overcoming steroid resistance in pediatric acute lymphoblastic leukemia - the state-of-the-art knowledge and future prospects</article-title>. <source>Int. J. Mol. Sci.</source><year>2022</year>; <volume>23</volume>:<fpage>3795</fpage>.<pub-id pub-id-type="pmid">35409154</pub-id></mixed-citation>
    </ref>
    <ref id="B58">
      <label>58.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arora</surname><given-names>P.</given-names></string-name>, <string-name><surname>Adams</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Gudelsky</surname><given-names>G.</given-names></string-name>, <string-name><surname>DasGupta</surname><given-names>B.</given-names></string-name>, <string-name><surname>Desai</surname><given-names>P.B.</given-names></string-name></person-group><article-title>Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats</article-title>. <source>Cancer Chemother. Pharmacol.</source><year>2019</year>; <volume>83</volume>:<fpage>81</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="pmid">30357450</pub-id></mixed-citation>
    </ref>
    <ref id="B59">
      <label>59.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>He</surname><given-names>W.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>R.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>S.H.</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>F.</given-names></string-name></person-group><article-title>Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas</article-title>. <source>Anticancer Drugs</source>. <year>2015</year>; <volume>26</volume>:<fpage>293</fpage>–<lpage>300</lpage>.<pub-id pub-id-type="pmid">25535979</pub-id></mixed-citation>
    </ref>
    <ref id="B60">
      <label>60.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Karve</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Desai</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Dave</surname><given-names>N.</given-names></string-name>, <string-name><surname>Wise-Draper</surname><given-names>T.M.</given-names></string-name>, <string-name><surname>Gudelsky</surname><given-names>G.A.</given-names></string-name>, <string-name><surname>Phoenix</surname><given-names>T.N.</given-names></string-name>, <string-name><surname>DasGupta</surname><given-names>B.</given-names></string-name>, <string-name><surname>Sengupta</surname><given-names>S.</given-names></string-name>, <string-name><surname>Plas</surname><given-names>D.R.</given-names></string-name>, <string-name><surname>Desai</surname><given-names>P.B.</given-names></string-name></person-group><article-title>Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole</article-title>. <source>Cancer Chemother. Pharmacol.</source><year>2022</year>; <volume>90</volume>:<fpage>345</fpage>–<lpage>356</lpage>.<pub-id pub-id-type="pmid">36050497</pub-id></mixed-citation>
    </ref>
    <ref id="B61">
      <label>61.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Balça-Silva</surname><given-names>J.</given-names></string-name>, <string-name><surname>Matias</surname><given-names>D.</given-names></string-name>, <string-name><surname>do Carmo</surname><given-names>A.</given-names></string-name>, <string-name><surname>Girão</surname><given-names>H.</given-names></string-name>, <string-name><surname>Moura-Neto</surname><given-names>V.</given-names></string-name>, <string-name><surname>Sarmento-Ribeiro</surname><given-names>A.B.</given-names></string-name>, <string-name><surname>Lopes</surname><given-names>M.C.</given-names></string-name></person-group><article-title>Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines</article-title>. <source>Biochim. Biophys. Acta.</source><year>2015</year>; <volume>1850</volume>:<fpage>722</fpage>–<lpage>732</lpage>.<pub-id pub-id-type="pmid">25554223</pub-id></mixed-citation>
    </ref>
    <ref id="B62">
      <label>62.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Patel</surname><given-names>S.</given-names></string-name>, <string-name><surname>DiBiase</surname><given-names>S.</given-names></string-name>, <string-name><surname>Meisenberg</surname><given-names>B.</given-names></string-name>, <string-name><surname>Flannery</surname><given-names>T.</given-names></string-name>, <string-name><surname>Patel</surname><given-names>A.</given-names></string-name>, <string-name><surname>Dhople</surname><given-names>A.</given-names></string-name>, <string-name><surname>Cheston</surname><given-names>S.</given-names></string-name>, <string-name><surname>Amin</surname><given-names>P.</given-names></string-name></person-group><article-title>Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma</article-title>. <source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2012</year>; <volume>82</volume>:<fpage>739</fpage>–<lpage>742</lpage>.<pub-id pub-id-type="pmid">21353747</pub-id></mixed-citation>
    </ref>
    <ref id="B63">
      <label>63.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DI Cristofori</surname><given-names>A.</given-names></string-name>, <string-name><surname>Carrabba</surname><given-names>G.</given-names></string-name>, <string-name><surname>Lanfranchi</surname><given-names>G.</given-names></string-name>, <string-name><surname>Menghetti</surname><given-names>C.</given-names></string-name>, <string-name><surname>Rampini</surname><given-names>P.</given-names></string-name>, <string-name><surname>Caroli</surname><given-names>M.</given-names></string-name></person-group><article-title>Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma</article-title>. <source>Anticancer Res.</source><year>2013</year>; <volume>33</volume>:<fpage>3383</fpage>–<lpage>3389</lpage>.<pub-id pub-id-type="pmid">23898108</pub-id></mixed-citation>
    </ref>
    <ref id="B64">
      <label>64.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>T.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>D.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Li</surname><given-names>B.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.S.</given-names></string-name></person-group><article-title>TIMER2.0 for analysis of tumor-infiltrating immune cells</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>W509</fpage>–<lpage>W514</lpage>.<pub-id pub-id-type="pmid">32442275</pub-id></mixed-citation>
    </ref>
    <ref id="B65">
      <label>65.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miao</surname><given-names>Y.R.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Lei</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>G.Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.Y.</given-names></string-name></person-group><article-title>ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy</article-title>. <source>Adv. Sci.</source><year>2020</year>; <volume>7</volume>:<fpage>1902880</fpage>.</mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10767794</article-id>
    <article-id pub-id-type="pmid">37889038</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkad888</article-id>
    <article-id pub-id-type="publisher-id">gkad888</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>CDS-DB, an omnibus for patient-derived gene expression signatures induced by cancer treatment</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3371-2392</contrib-id>
        <name>
          <surname>Liu</surname>
          <given-names>Zhongyang</given-names>
        </name>
        <!--liuzy1984@163.com-->
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>College of Chemistry and Materials Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis (Hebei University), Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>College of Life Sciences, Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Ruzhen</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Lele</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>College of Chemistry and Materials Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis (Hebei University), Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-1810-6260</contrib-id>
        <name>
          <surname>Jiang</surname>
          <given-names>Jianzhou</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>College of Life Sciences, Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ma</surname>
          <given-names>Shurui</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>School of Basic Medicine, Anhui Medical University</institution>, <addr-line>Hefei 230032</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Lanhui</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>He</surname>
          <given-names>Mengqi</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Mao</surname>
          <given-names>Yichao</given-names>
        </name>
        <aff><institution>College of Life Sciences, Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Guo</surname>
          <given-names>Congcong</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Kong</surname>
          <given-names>Xiangya</given-names>
        </name>
        <aff><institution>Beijing Cloudna Technology Company</institution>, Limited, <addr-line>Beijing 100029</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Xinlei</given-names>
        </name>
        <aff><institution>Beijing Cloudna Technology Company</institution>, Limited, <addr-line>Beijing 100029</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Qi</surname>
          <given-names>Yaning</given-names>
        </name>
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <aff><institution>College of Chemistry and Materials Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis (Hebei University), Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Fengsong</given-names>
        </name>
        <aff><institution>College of Life Sciences, Hebei University</institution>, <addr-line>Baoding 071002</addr-line>, <country country="CN">China</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>He</surname>
          <given-names>Fuchu</given-names>
        </name>
        <!--hefc@nic.bmi.ac.cn-->
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR3" ref-type="corresp"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8680-0468</contrib-id>
        <name>
          <surname>Li</surname>
          <given-names>Dong</given-names>
        </name>
        <!--lidong.bprc@foxmail.com-->
        <aff><institution>State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics</institution>, <addr-line>Beijing 102206</addr-line>, <country country="CN">China</country></aff>
        <xref rid="COR2" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +861061777056; Fax: +861061777004; Email: <email>liuzy1984@163.com</email></corresp>
      <corresp id="COR2">Correspondence may also be addressed to Dong Li. Tel: +861061777057; Fax: +861061777004; Email: <email>lidong.bprc@foxmail.com</email></corresp>
      <corresp id="COR3">Correspondence may also be addressed to Fuchu He. Tel: +861061771001; Fax: +861061777004; Email: <email>hefc@nic.bmi.ac.cn</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first four authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-10-27">
      <day>27</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>27</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <volume>52</volume>
    <issue>D1</issue>
    <fpage>D1163</fpage>
    <lpage>D1179</lpage>
    <history>
      <date date-type="accepted">
        <day>05</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>25</day>
        <month>9</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>15</day>
        <month>8</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkad888.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Patient-derived gene expression signatures induced by cancer treatment, obtained from paired pre- and post-treatment clinical transcriptomes, can help reveal drug mechanisms of action (MOAs) in cancer patients and understand the molecular response mechanism of tumor sensitivity or resistance. Their integration and reuse may bring new insights. Paired pre- and post-treatment clinical transcriptomic data are rapidly accumulating. However, a lack of systematic collection makes data access, integration, and reuse challenging. We therefore present the Cancer Drug-induced gene expression Signature DataBase (CDS-DB). CDS-DB has collected 78 patient-derived, paired pre- and post-treatment transcriptomic source datasets with uniformly reprocessed expression profiles and manually curated metadata such as drug administration dosage, sampling time and location, and intrinsic drug response status. From these source datasets, 2012 patient-level gene perturbation signatures were obtained, covering 85 therapeutic regimens, 39 cancer subtypes and 3628 patient samples. Besides data browsing, download and search, CDS-DB also supports single signature analysis (including differential gene expression, functional enrichment, tumor microenvironment and correlation analyses), signature comparative analysis and signature connectivity analysis. This provides insights into drug MOA and its heterogeneity in patients, drug resistance mechanisms, drug repositioning and drug (combination) discovery, etc. CDS-DB is available at <ext-link xlink:href="http://cdsdb.ncpsb.org.cn/" ext-link-type="uri">http://cdsdb.ncpsb.org.cn/</ext-link>.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="gkad888figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Natural Science Foundation of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100001809</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>32088101</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Key Research and Development Program of China</institution>
            <institution-id institution-id-type="DOI">10.13039/501100012166</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>2021YFA1301603</award-id>
        <award-id>2020YFE0202200</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="17"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p>In cancer drug development, it is well known that drugs which demonstrate efficacy in preclinical models do not always achieve the expected curative effects in patients (<xref rid="B1" ref-type="bibr">1</xref>), where many such examples have been reported (e.g. (<xref rid="B2" ref-type="bibr">2</xref>)). Meanwhile, both for cancer chemotherapy and targeted therapy, the response rate of a so-called clinically effective drug is often far below 100% (i.e. intrinsic drug resistance) (<xref rid="B3" ref-type="bibr">3</xref>), and even for responders, a significant proportion of them progress after an initial treatment response (i.e. acquired drug resistance) (<xref rid="B4" ref-type="bibr">4</xref>). These problems are mainly due to the inevitable difference between preclinical models and patients (such as the lack of a native tumor microenvironment (TME) in preclinical models) (<xref rid="B5" ref-type="bibr">5</xref>) and the nature of tumor heterogeneity in patients (<xref rid="B6" ref-type="bibr">6</xref>). The key to addressing these problems is understanding the molecular changes (including TME dynamics) in patients in response to clinical treatment.</p>
    <p>Patient-derived gene perturbation signatures induced by cancer treatment, obtained from paired (i.e. from the same patient) pre- and post-treatment clinical transcriptomes, can help solve the above problems. Numerous studies have indicated that patient-derived treatment-induced gene perturbation signatures can help fill the knowledge gap on drug mechanisms of action (MOAs) (especially TME-related MOAs) in patients and reveal the molecular response mechanism that results in treatment sensitivity (<xref rid="B7" ref-type="bibr">7</xref>) or resistance (<xref rid="B8" ref-type="bibr">8</xref>), and even discover predictive biomarkers of treatment response (<xref rid="B9" ref-type="bibr">9</xref>) and potential combinational drug B to overcome resistance to drug A (<xref rid="B10" ref-type="bibr">10</xref>). More importantly, the integration and reuse of these data may provide unprecedented new insights, such as exploring the heterogeneity of molecular response of patients to treatment and drug repositioning by connectivity analysis with disease signatures.</p>
    <p>In the era of precision medicine, paired pre- and post-treatment clinical transcriptomic data derived from patients with cancer are rapidly accumulated. However, these data are scattered and often mixed with various other types of data, and often have inconsistent data formats, use non-uniform data processing pipelines and have poor machine-readable metadata, which brings challenges to data access, integration and reuse.</p>
    <p>Many great resources related to drug-induced molecular perturbation signatures have been developed. The most famous are the Connectivity Map (CMAP) (<xref rid="B11" ref-type="bibr">11</xref>) and its extended version LINCS L1000 (<xref rid="B12" ref-type="bibr">12</xref>), together with their numerous derivative resources/tools designed to search, visualize or reuse the CMAP/LINCS L1000 data as reviewed by Keenan <italic toggle="yes">et al.</italic> (<xref rid="B13" ref-type="bibr">13</xref>). Currently, CMAP and LINCS L1000 contain approximately one million gene perturbation signatures at the cell line level, induced by tens of thousands of small molecules (<ext-link xlink:href="https://clue.io/" ext-link-type="uri">https://clue.io/</ext-link>), which are highly valuable for drug discovery and drug repurposing. At the cell line level, there are also several other drug-induced molecular perturbation signature resources. For example, Zhao <italic toggle="yes">et al.</italic>’s study generated perturbed expression profiles of hundreds of clinically relevant proteins in response to ∼170 drug compounds (<xref rid="B14" ref-type="bibr">14</xref>), Mitchell <italic toggle="yes">et al.</italic> characterized proteome-wide perturbation signatures of 875 compounds (<xref rid="B15" ref-type="bibr">15</xref>), and Tian <italic toggle="yes">et al.</italic> developed the largest-to-date data repository of gene perturbation signatures for active ingredients of traditional Chinese medicine (including 496 active ingredients) (<xref rid="B16" ref-type="bibr">16</xref>). In addition, in ICBatlas (a comprehensive resource for collecting and reusing transcriptomic data from patients receiving immune checkpoint blockade therapy), besides the dominant pre-treatment samples, 7 of the 25 source datasets collected by them also contain post-treatment patient samples (154 post-treatment samples in total) (<xref rid="B17" ref-type="bibr">17</xref>). All of these resources have greatly contributed to (cancer) drug development and use. However, to the best of our knowledge, there is still no data resource focusing on patient-derived gene expression signatures induced by cancer treatment (obtained from a comprehensive collection of patient-derived paired pre- and post-treatment transcriptomic data).</p>
    <p>Here, we present the Cancer Drug-induced gene expression Signature DataBase (CDS-DB) (<ext-link xlink:href="http://cdsdb.ncpsb.org.cn/" ext-link-type="uri">http://cdsdb.ncpsb.org.cn/</ext-link>), a comprehensive database, designed to specifically collect patient-derived paired pre- and post-treatment clinical transcriptomic data in cancer and provide abundant analysis functions facilitating data integration and reuse.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <sec id="SEC2-1">
      <title>Data collection and curation</title>
      <p>Paired pre- and post-treatment transcriptomes derived from patients with cancer were manually mined from GEO (<xref rid="B18" ref-type="bibr">18</xref>) and ArrayExpress (<xref rid="B19" ref-type="bibr">19</xref>) (until July 2022). First, we obtained potentially related datasets by retrieving GEO/ArrayExpress with ‘cancer-related keywords AND drug-related keywords AND patient-related keywords AND <italic toggle="yes">Homo sapiens</italic>’ (see <xref rid="sup1" ref-type="supplementary-material">Supplementary methods</xref> for the detailed keyword lists). Then, we manually picked those that met the inclusion criteria described below. For the eligible source datasets, we downloaded raw-formatted microarray gene expression data directly from the GEO/ArrayExpress website and downloaded RNA-seq SRA files from NCBI using the ‘prefetch’ function in the sra-tools (version: 2.11.0) (<ext-link xlink:href="https://github.com/ncbi/sra-tools" ext-link-type="uri">https://github.com/ncbi/sra-tools</ext-link>), and then extracted FASTQ files from the SRA files with the ‘fastq-dump’ function. In CDS-DB, the raw SRA files cannot be obtained for only two RNA-seq source datasets (GSE136114 and GSE191127), and their count data were directly downloaded from GEO. Metadata were manually curated from the corresponding source references, including sample identifier (ID), patient ID, therapeutic regimen and administration dosage, the most fine-grained cancer subtype, drug response status and the response status definition given by the original authors (if available), sampling time and location, pediatric tumor or not, data production platform, source dataset and source publication. Intrinsic drug response status information was available for 45% of patients in CDS-DB. Based on the drug response status, we further classified patients into response and non-response groups (see <xref rid="sup1" ref-type="supplementary-material">Supplementary methods</xref> for the detailed response grouping criteria).</p>
      <p>Source dataset inclusion/exclusion criteria include the following: (i) paired (i.e. from the same patient) pre- and post-treatment patient samples were required; (ii) for microarray data, only datasets from Affymetrix, Agilent and Illumina platforms were collected; (iii) bulk transcriptomes were collected; (iv) datasets, in which drug therapy is combined with other physical therapies, were excluded (to ensure that the perturbation is induced only by drug therapy).</p>
    </sec>
    <sec id="SEC2-2">
      <title>Unified transcriptomic data processing</title>
      <sec id="SEC2-2-1">
        <title>Microarray data processing pipeline</title>
        <p>We only collected microarray datasets from Affymetrix, Illumina and Agilent platforms. Raw CEL files from Affymetrix chips were processed using the ‘rma’ function of the ‘affy’ R package (version: 1.70.0) (<xref rid="B20" ref-type="bibr">20</xref>). Summary-level files from Illumina BeadArrays were processed using the ‘neqc’ and ‘normalizeBetweenArrays’ functions of the ‘limma’ R package (version: 3.48.3) (<xref rid="B21" ref-type="bibr">21</xref>), and probes with detection <italic toggle="yes">P</italic>-values &gt;0.05 in at least three samples were removed. Image analysis output files from Agilent one-color chips were processed using the ‘backgroundCorrect’ and ‘normalizeBetweenArrays’ functions of the ‘limma’ R package. After processing, the expression values were log<sub>2</sub> transformed. Then, according to the platform-specific probe annotation files, probes were converted into gene symbols. Further, based on the gene information file from NCBI Entrez Gene (version: 20230411) (<xref rid="B22" ref-type="bibr">22</xref>), the gene symbols were converted into gene IDs. The maximum expression value was used for ‘many to one’ mapping during the conversion process.</p>
      </sec>
      <sec id="SEC2-2-2">
        <title>RNA-seq data processing pipeline</title>
        <p>Starting from FASTQ files, Trim Galore (version: 0.6.7) was first used to filter adaptor sequences and low-quality bases and remove reads with sequence lengths shorter than 20 bp (<ext-link xlink:href="https://github.com/FelixKrueger/TrimGalore" ext-link-type="uri">https://github.com/FelixKrueger/TrimGalore</ext-link>). Next, STAR (version: 2.7.10a) (2-pass mode) was used to map reads to the <italic toggle="yes">Homo sapiens</italic> genome (assembly hg38 and annotation v22) (<xref rid="B23" ref-type="bibr">23</xref>). HTSeq (version: 2.0.2) was used to count the reads mapped to each gene (<xref rid="B24" ref-type="bibr">24</xref>). Finally, Ensembl gene IDs were converted to the Entrez Gene IDs and gene symbols based on the gene information file from the NCBI Entrez Gene (version: 20230411), and the maximum count value was used for ‘many to one’ mapping. For the source dataset ‘GSE168204’, because its data were produced by two RNA-seq platforms, batch effect removal was also performed using the ‘ComBat_seq’ function of the ‘sva’ R package (<xref rid="B25" ref-type="bibr">25</xref>). The FPKM (Fragments Per Kilobase of transcript per million mapped reads) method was used to normalize read counts.</p>
      </sec>
    </sec>
    <sec id="SEC2-3">
      <title>Terminology standardization</title>
      <p>Drugs were standardized with DrugBank IDs and names (if they can be mapped to DrugBank drugs) (version: 5.1.9) (<xref rid="B26" ref-type="bibr">26</xref>), cancer subtypes with Disease Ontology (DO) IDs and names (version: August 2022) (<xref rid="B27" ref-type="bibr">27</xref>), and genes with Entrez Gene IDs (<xref rid="B22" ref-type="bibr">22</xref>) and HGNC gene symbols (<xref rid="B28" ref-type="bibr">28</xref>).</p>
    </sec>
    <sec id="SEC2-4">
      <title>External annotation integration</title>
      <p>We also integrated drug, cancer and gene annotations from external databases in CDS-DB. For drugs, target annotations were from DrugBank (version: 5.1.10) (<xref rid="B26" ref-type="bibr">26</xref>), MOA annotations were from Drug Repurposing Hub (version: 20200324) (<xref rid="B29" ref-type="bibr">29</xref>), and drug type (chemotherapy, targeted therapy, hormone therapy or immunotherapy) and FDA approval annotations were obtained by manual curation. For cancers, the annotations and classification were from the DO database (version: March 2023) (<xref rid="B27" ref-type="bibr">27</xref>). For genes, their protein − protein interaction (PPI) partners were parsed from BioGRID (version: 4.4.219) (<xref rid="B30" ref-type="bibr">30</xref>); gene sets (a gene belongs to) were from the Molecular Signatures Database (MSigDB, v7.4) (<xref rid="B31" ref-type="bibr">31</xref>), including Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway (<xref rid="B32" ref-type="bibr">32</xref>), Reactome pathway (<xref rid="B33" ref-type="bibr">33</xref>), WikiPathways (<xref rid="B34" ref-type="bibr">34</xref>), hallmark gene set, microRNA target and transcription factor target; immune checkpoint-related information was from CKTTD (version: 2020-September) (<xref rid="B35" ref-type="bibr">35</xref>), mainly including whether a gene is a known immune checkpoint together with its confidence score and the primary reference, and its corresponding drug (if it has) together with the primary reference; cancer type-specific fitness genes together with corresponding cancer types were from Behan <italic toggle="yes">et al.</italic>’s study (<xref rid="B36" ref-type="bibr">36</xref>), and are defined as those required for cancer cell growth or viability.</p>
    </sec>
    <sec id="SEC2-5">
      <title>CDS-DB dataset definition</title>
      <p>A source dataset (from GEO/ArrayExpress) was further divided into ‘CDS-DB datasets’. A CDS-DB dataset was composed of paired pre- and post-treatment patient samples with the same therapeutic regimen and administration dosage, with the same cancer subtype of the finest particle size, with similar post-treatment sampling time and the same sampling location category (tissue, blood, bone marrow or ascites), with the same drug response grouping (response or non-response) if available, from the same source dataset. The CDS-DB dataset partitioning principle, especially the involved several factors such as administration dosage, sampling time and sampling location, is mainly based on original references.</p>
    </sec>
    <sec id="SEC2-6">
      <title>CDS-DB dataset- and patient-level signature definitions</title>
      <p>A gene perturbation signature was composed of all genes in the transcriptome with log<sub>2</sub> fold changes (logFCs). The logFCs were derived from differential gene expression analysis between paired post- and pre-treatment transcriptomes, assuming the pre-treatment samples as the control group (see more in ‘Differential gene expression analysis’). A dataset-level gene perturbation signature was obtained based on paired patient samples in a CDS-DB dataset, while a patient-level gene signature based on a pair of post- and pre-treatment samples of a patient.</p>
      <p>Analogous to the gene perturbation signature, a cell perturbation signature was composed of all cell populations in TME with logFCs. The logFCs were obtained by differential analysis of abundances of TME cell populations between paired post- and pre-treatment samples (see more in ‘Tumor microenvironment analysis’). In the later text of this paper, a ‘CDS-DB signature’ is usually equivalent to a gene perturbation signature unless the signature is specially described as a cell perturbation signature (mainly used in the signature connectivity analysis-related paragraphs).</p>
      <p>A CDS-DB dataset-level signature must correspond to a CDS-DB dataset, but a CDS-DB dataset does not necessarily correspond to a CDS-DB dataset-level signature. Only the CDS-DB datasets with ≥2 patients (i.e. 4 samples) have corresponding dataset-level signatures. Because for those datasets only having 1 patient (i.e. 2 samples), statistical test for differential gene expression analysis (see more in ‘Differential gene expression analysis’) cannot be performed, they don’t have dataset-level signatures.</p>
    </sec>
    <sec id="SEC2-7">
      <title>Differential gene expression analysis</title>
      <p>To obtain a CDS-DB dataset-level gene perturbation signature, the ‘limma’ (version: 3.48.3) (<xref rid="B21" ref-type="bibr">21</xref>) and ‘DESeq2’ (version: 1.32.0) (<xref rid="B37" ref-type="bibr">37</xref>) R packages were used to obtain the logFC together with <italic toggle="yes">P</italic>-value and adjusted <italic toggle="yes">P</italic>-value separately for microarray and RNA-seq data. To obtain a CDS-DB patient-level gene signature, the logFC of each gene was computed based on the log<sub>2</sub> expression value for microarray data and the FPKM for RNA-seq data.</p>
    </sec>
    <sec id="SEC2-8">
      <title>Tumor microenvironment analysis</title>
      <p>The abundances of various cell populations in TME were first predicted based on the bulk gene expression profile of a patient sample. Differential analysis of cell abundances between paired post- and pre-treatment samples was then performed to obtain a dataset- or patient-level cell perturbation signature. For a CDS-DB dataset-level signature, differential analysis for a TME cell type was implemented using the two-sided Student's <italic toggle="yes">t</italic>-test, the adjusted <italic toggle="yes">P</italic>-value was computed by Benjamini-Hochberg (BH) multiple testing correction (<xref rid="B38" ref-type="bibr">38</xref>), and the logFC was computed based on the mean value of abundances of the cell type in post-/pre-treatment samples. For a CDS-DB patient-level signature, this was done by directly computing the logFC. Here, we used two methods, MCP-counter and xCell, to predict cell type abundances, implemented by their respective R packages (version 1.2.0 for the former and version 1.1.0 for the latter) (<xref rid="B39" ref-type="bibr">39</xref>,<xref rid="B40" ref-type="bibr">40</xref>). These two methods support 10 (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>) and 64 cell types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>), respectively. Therefore, a cell perturbation signature from MCP-counter consists of 10 cell types, while a signature from xCell 64 cell types.</p>
    </sec>
    <sec id="SEC2-9">
      <title>Functional enrichment analysis</title>
      <sec id="SEC2-9-1">
        <title>Functional enrichment analysis for the single signature analysis workflow</title>
        <p>Over-representation analysis (ORA) and gene set enrichment analysis (GSEA) (<xref rid="B41" ref-type="bibr">41</xref>) two methods are supported. ORA was conducted based on significantly differentially expressed genes (DEGs) (satisfying the |logFC| and adjusted <italic toggle="yes">P</italic>-value cutoffs), and GSEA based on all genes ranked by descending logFCs. Both ORA and GSEA were implemented using the ‘clusterProfiler’ R package (version: 4.0.5) (<xref rid="B42" ref-type="bibr">42</xref>), where <italic toggle="yes">P</italic>-values were adjusted by BH method. In ORA, the enrichment ratio (ER) was used to measure the enrichment degree of a functional gene set, calculated as the ratio of the proportion of gene set member genes among significant DEGs to that among the whole genome. In GSEA, the normalized enrichment score (NES) was computed to measure the degree to which a gene set is over-represented at the top (NES &gt;0) or bottom (NES &lt;0) of the ranked genes, i.e. the degree to which a gene set is up- or down-regulated.</p>
      </sec>
      <sec id="SEC2-9-2">
        <title>Cancer subtype and therapeutic regimen enrichment analyses for the search workflow</title>
        <p>For a given item (gene, cell type or pathway), CDS-DB signatures were first ranked in descending order of the item's logFCs or NESs in these signatures. ‘GSEA’ was then conducted, where CDS-DB signatures with a certain cancer subtype/therapeutic regimen constituted a ‘signature set’ (equivalent to a ‘gene set’ in the standard GSEA).</p>
      </sec>
      <sec id="SEC2-9-3">
        <title>Drug target and MOA enrichment analyses for the signature connectivity analysis workflow</title>
        <p>‘GSEA’ was performed based on signatures ranked in descending order of connectivity score, where signatures with a certain target or MOA constituted a ‘signature set’ (equivalent to a ‘gene set’ in the standard GSEA).</p>
      </sec>
    </sec>
    <sec id="SEC2-10">
      <title>Correlation analysis</title>
      <p>For a pair of items (gene, gene set or cell type), the correlation was measured by Spearman's rank correlation coefficient between their perturbation extents across all patients in a CDS-DB dataset using the ‘cor.test’ function of the ‘stats’ R package (version: 4.1.1). The perturbation extent of an item in a patient was measured by logFC for a gene/cell type and by NES for a pathway, which was from the analysis results of the patient-level signature.</p>
    </sec>
    <sec id="SEC2-11">
      <title>Meta-analysis</title>
      <p>The variable coefficient for an item (gene, cell type or pathway) was computed as the standard deviation divided by the mean of its perturbation extents across different CDS-DB signatures, where the perturbation extent was measured by logFC for a gene/cell type and NES for a pathway. For the comparison of multiple CDS-DB dataset-level signatures, a meta-<italic toggle="yes">P</italic>-value was further computed by integrating the <italic toggle="yes">P</italic>-values of individual signatures using the sumz method in the ‘metap’ R package (version: 1.8) (<ext-link xlink:href="https://CRAN.R-project.org/package=metap" ext-link-type="uri">https://CRAN.R-project.org/package=metap</ext-link>), and the adjusted meta-<italic toggle="yes">P</italic>-value was obtained using the BH method.</p>
    </sec>
    <sec id="SEC2-12">
      <title>Signature connectivity analysis</title>
      <p>When a gene signature with logFCs is submitted, its connectivity score with a CDS-DB gene perturbation signature is computed as the cosine similarity of the two logFC vectors. When up- and down-regulated gene sets or cell type sets are submitted, we use the Connectivity Map (CMAP) score (<xref rid="B11" ref-type="bibr">11</xref>) (see Supplementary methods).</p>
    </sec>
    <sec id="SEC2-13">
      <title>Database implementation</title>
      <p>Node.js (<ext-link xlink:href="https://nodejs.org/" ext-link-type="uri">https://nodejs.org/</ext-link>) and Vue.js (<ext-link xlink:href="https://vuejs.org/" ext-link-type="uri">https://vuejs.org/</ext-link>) were used as back- and front-end frameworks, respectively. Nginx was used as a reverse proxy (<ext-link xlink:href="https://www.nginx.com/" ext-link-type="uri">https://www.nginx.com/</ext-link>). Back-end data were stored and managed using MongoDB (<ext-link xlink:href="https://docs.mongodb.com/" ext-link-type="uri">https://docs.mongodb.com/</ext-link>). The data analysis workflows were written in R, where the volcano plot, barplot and slope plot were implemented using the ‘ggplot2’ R package (version: 3.4.2) (<xref rid="B43" ref-type="bibr">43</xref>). The interactive heatmap on the analysis result page of ‘Analyze’ was implemented using D3.js (<ext-link xlink:href="https://d3js.org/" ext-link-type="uri">https://d3js.org/</ext-link>) and other heatmaps using the ‘ComplexHeatmap’ R package (version: 2.10.0) (<xref rid="B44" ref-type="bibr">44</xref>). The interactive doughnut chart on the homepage was drawn using Apache ECharts (<ext-link xlink:href="https://echarts.apache.org/en/index.html" ext-link-type="uri">https://echarts.apache.org/en/index.html</ext-link>).</p>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>Results</title>
    <sec id="SEC3-1">
      <title>Overview</title>
      <p>CDS-DB is designed to be a comprehensive data resource for basic and clinical researchers to access, integrate and (re-)use patient-derived drug-induced gene expression signatures obtained from paired pre- and post-treatment clinical transcriptomic data derived from patients with cancer (Figure <xref rid="F1" ref-type="fig">1</xref>).</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Overview of the CDS-DB.</p>
        </caption>
        <graphic xlink:href="gkad888fig1" position="float"/>
      </fig>
      <p>The patient-derived paired pre- and post-treatment transcriptomes were manually collected from GEO and ArrayExpress under strict inclusion criteria. The related clinical annotations were manually curated from the corresponding source references, and terminologies were standardized. All transcriptomic data were reprocessed using the uniform data preprocessing pipeline. The processed and standardized source datasets were partitioned into CDS-DB datasets, and further, CDS-DB dataset- and patient-level gene perturbation signatures were obtained (see Methods). Cancer/drug/ gene-related annotations from external databases were also integrated (Figure <xref rid="F1" ref-type="fig">1</xref>).</p>
      <p>To facilitate the access, integration and (re-)use of the CDS-DB data, besides basic data browsing, retrieval and download using the ‘Browse’ function of the website, CDS-DB also supports multiple data analysis workflows (Figure <xref rid="F1" ref-type="fig">1</xref>). The single signature analysis workflow, including perturbation signature analysis, tumor microenvironment analysis and correlation analysis, is used to analyze a CDS-DB dataset- or patient-level signature, and the pre-analysis results are presented on the detailed annotation page of a CDS-DB dataset- or patient-level signature. The signature comparative analysis workflow (accessed using the ‘Compare’ function) supports comparison of the single signature analysis results of multiple user-selected signatures for meta-analysis. The ‘Search’ workflow allows users to check the perturbed extents of the gene, pathway or TME cell type of interest across different CDS-DB signatures and to further analyze the cancer subtype or drug preference of the perturbations. Finally, the signature connectivity analysis workflow (‘Analyze’) is designed to search CDS-DB signatures that mimic or reverse the user-uploaded signature and further analyze enriched targets or MOAs of the returned signatures. All website functions ‘interact with’ each other. Analysis results are returned as heatmaps, volcano plots, slope plots, bar graphs and various result tables (Figure <xref rid="F1" ref-type="fig">1</xref>), and all results can be downloaded.</p>
    </sec>
    <sec id="SEC3-2">
      <title>Data statistics</title>
      <p>The current version of the CDS-DB houses 2012 CDS-DB patient-level gene perturbation signatures and 181 CDS-DB dataset-level gene perturbation signatures obtained from 3628 patient samples of 219 CDS-DB datasets. These CDS-DB datasets were obtained by dividing 78 patient-derived paired pre- and post-treatment transcriptomic source datasets. These signatures involve 39 cancer subtypes of the finest particle size belonging to 19 cancer histological types, with breast cancer, kidney cancer, leukemia, melanoma and ovarian cancer having the most dataset-/patient-level signatures (Figure <xref rid="F2" ref-type="fig">2A</xref> and <xref rid="F2" ref-type="fig">B</xref>). There are 85 therapeutic regimens (Figure <xref rid="F2" ref-type="fig">2C</xref>), 71 drugs covering targeted therapy, chemotherapy, immunotherapy and hormone therapy (ordered from high to low) (Figure <xref rid="F2" ref-type="fig">2D</xref>). The post-treatment sampling time of 94% of dataset-level signatures is within 3 months, 78% within 2 months, 66% within 4 weeks and 36% within 2 weeks (Figure <xref rid="F2" ref-type="fig">2E</xref>). The proportions are 82%, 64%, 53% and 31% for patient-level signatures, respectively (Figure <xref rid="F2" ref-type="fig">2F</xref>). Sampling locations include tissue, blood, bone marrow and ascites (Figure <xref rid="F2" ref-type="fig">2A</xref> and <xref rid="F2" ref-type="fig">B</xref>). 70% of the CDS-DB datasets have samples not smaller than 6, and 56% not smaller than 10 (Figure <xref rid="F2" ref-type="fig">2G</xref>). Intrinsic drug response information is available for 57% of the CDS-DB dataset-level signatures.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Data statistics of the CDS-DB. (<bold>A, B</bold>) CDS-DB dataset-level (A) and patient-level (B) signature distributions across data types, therapeutic regimen types, sampling location categories and cancer histological types (from the inner to the outer ring). (<bold>C</bold>) Therapeutic regimen type distribution. (<bold>D</bold>) Drug type distribution. (<bold>E, F</bold>) Post-treatment sampling time distributions of CDS-DB dataset-level (E) and patient-level (F) signatures. Only 146 dataset-level signatures and 1799 patient-level signatures with specific and single sampling times were included in the analyses. (<bold>G</bold>) Patient sample number distribution of CDS-DB datasets. (<bold>H, I</bold>) Dataset-level (H) and patient-level (I) signature number distributions of therapeutic regimens. (<bold>J</bold>) Cancer subtype number distribution of the therapeutic regimens in CDS-DB. (<bold>K</bold>) Therapeutic regimen number distribution of cancer subtypes in CDS-DB. (<bold>L</bold>) Numbers of therapeutic regimens/drugs with different cancer types in CDS-DB. (<bold>M</bold>) Publication year distribution of CDS-DB source datasets (from 2006 to July 2022).</p>
        </caption>
        <graphic xlink:href="gkad888fig2" position="float"/>
      </fig>
      <p>The medians of CDS-DB dataset- and patient-level perturbation signatures that a therapeutic regimen has are 2 and 9, respectively. 91% and 74% of therapeutic regimens have dataset-level signatures not larger than 3 and patient-level signatures not larger than 20, respectively (Figure <xref rid="F2" ref-type="fig">2H</xref> and <xref rid="F2" ref-type="fig">I</xref>). Nivolumab and Letrozole have received the most attention and have the most perturbation signatures. In CDS-DB data, in most cases, a therapeutic regimen is only used for the treatment of a cancer subtype, indicating the cancer specificity of treatment (Figure <xref rid="F2" ref-type="fig">2J</xref>). Also, most cancer subtypes have ≤2 therapeutic regimens (Figure <xref rid="F2" ref-type="fig">2K</xref>). In CDS-DB, the cancer types with the most therapeutic regimens are breast cancer, leukemia, melanoma and ovarian cancer (Figure <xref rid="F2" ref-type="fig">2L</xref>). Finally, publication years for source datasets collected by CDS-DB show increasing attention to patient-derived paired pre- and post-treatment transcriptomic data, as 34% of the collected source datasets (spanning the 17 years from 2006 to July 2022) are from the last 3 years and 47% from the last 5 years (Figure <xref rid="F2" ref-type="fig">2M</xref>).</p>
    </sec>
    <sec id="SEC3-3">
      <title>Browse and download</title>
      <p>Using ‘Browse’ function of the website, CDS-DB dataset-level signatures, patient-level signatures, drugs and cancers can be browsed and retrieved, and signature-related data can be downloaded.</p>
      <p>On the ‘Dataset’/‘Patient’ tab (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1A</xref>), CDS-DB dataset-/patient-level signatures and their corresponding key clinical annotations are listed. These signatures can be filtered/retrieved by drug type (chemotherapy, immunotherapy, hormone therapy and targeted therapy), drug name, cancer (sub-)type, sampling location category (ascites, bone marrow, blood and tumor tissue), sample size, data type (RNA-seq and Microarray), response grouping (non-response and response), pediatric oncology, source dataset (GEO or ArrayExpress dataset ID) and CDS-DB signature ID. Gene expression matrix, sample clinical information, and gene perturbation signature files of user-selected or all signatures can also be downloaded here. Clicking on the CDS-DB signature ID in the data browsing table leads to a detailed annotation page, where the more detailed annotations of the signature and the interactive single signature analysis results are displayed.</p>
      <p>On the ‘Drug’ tab, all drugs related to CDS-DB signatures are listed in four categories (chemotherapy, immunotherapy, hormone therapy and targeted therapy) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1B</xref>). On the ‘Cancer’ tab, cancer subtypes and their parent cancer types can be browsed as a six-level hierarchy (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1C</xref>). The search box enables search of a drug or cancer (sub-)type by name. Once a drug or cancer (sub-)type is selected, the right side of the page shows its detailed annotations. ‘CDS-DB dataset signature number’ gives the number of CDS-DB dataset-level signatures related to the selected drug/cancer (sub-)type, and ‘CDS-DB patient signature number’ gives the number of the related CDS-DB patient-level signatures. Clicking on the number leads to the corresponding signature browsing page.</p>
      <p>In addition, CDS-DB dataset- or patient-level signatures can also be browsed using the doughnut of data statistics on the homepage (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1D and E</xref>). Clicking on a sector (data type, sampling location category, drug type or cancer type) on the doughnut leads to the browsing page for the sector-related signatures.</p>
    </sec>
    <sec id="SEC3-4">
      <title>Single signature analysis</title>
      <p>Each CDS-DB dataset- or patient-level signature has been pre-analyzed using the single signature analysis workflow, which includes perturbation signature analysis and tumor microenvironment analysis. Interactive correlation analysis is also supported for a dataset-level signature. This workflow is designed to reveal the drug MOAs in patients with cancer. The pre-analysis results and the correlation analysis function are presented on the detailed annotation page of the CDS-DB signature.</p>
      <sec id="SEC3-4-1">
        <title>Perturbation signature analysis</title>
        <p>The results of this function include three tabs: DEG, ORA and GSEA, aiming at revealing molecular and functional changes induced by the cancer treatment and understanding the molecular mechanisms of drug response/non-response for signatures with drug response grouping information.</p>
        <p>The DEG tab gives the differential gene expression analysis results between paired post- and pre-treatment patient samples of the signature (i.e. gene perturbation signature itself) (Figure <xref rid="F3" ref-type="fig">3A</xref>). For a dataset-level signature, significant DEGs (with the absolute values of logFCs larger than a certain cutoff and the adjusted <italic toggle="yes">P</italic>-values smaller than a certain cutoff) are potentially important molecules related to drug MOAs in patients. The ‘Significant DEGs’ mode of the result table, the volcano plot and the heatmap emphasize these significant DEGs. To further help users focus on drug MOA-related key genes, in the result table, for each gene, we also provide the following fields: whether the gene is the known target of the therapeutic regimen of the signature or the target's interactors (‘Target or target's interactor’ field), whether an ‘Immune checkpoint’ or a ‘Cancer type-specific fitness gene’ (required for cancer cell growth or viability) together with the cancer types. The table headers support gene filtering and re-ranking. For patient-level signatures, the DEG tab only gives the result table presenting the differential analysis results of all genes (i.e. patient-level gene perturbation signature itself), without the heatmap and volcano plot.</p>
        <fig position="float" id="F3">
          <label>Figure 3.</label>
          <caption>
            <p>Result pages of the single signature analysis. Here the dataset-level signature CDS_dataset_Microarray_81 is used as an example. (<bold>A</bold>) The perturbation signature analysis result page and the DEG tab page. Users can change logFC and adjusted <italic toggle="yes">P</italic>-value cutoffs to redefine significant DEGs and update the DEG and ORA results. DEG tab displays the differential gene expression analysis results of the dataset-level signature, including a volcano plot, a heatmap and a detailed result table. Clicking on the gene symbol in the result table leads to the ‘Search’ result page for the gene. Clicking on the ‘&gt;’ front of the gene symbol will lead to a slope plot presenting the gene's expression changes in the paired pre- and post-treatment samples in the dataset (shown in the embedded figure). (<bold>B</bold>) The ORA tab. Here presents the ORA results of KEGG pathways. Clicking on the pathway name in the result table leads to the ‘Search’ result page for the pathway. (<bold>C</bold>) The GSEA tab. Here shows the GSEA results of KEGG pathways. Clicking on the pathway name in the result table leads to the ‘Search’ result page for the pathway. (<bold>D</bold>) Tumor microenvironment analysis result page. Here shows the results obtained based on MCP-counter. Clicking on the ‘&gt;’ front of the cell type leads to a slope plot displaying the cell type's abundance changes in the paired pre- and post-treatment samples in the dataset (shown in the embedded figure). Clicking on the name itself leads to the ‘Search’ result page for the cell type. (<bold>E</bold>) Correlation analysis result page.</p>
          </caption>
          <graphic xlink:href="gkad888fig3" position="float"/>
        </fig>
        <p>The ORA tab gives the functional gene sets significantly perturbed by the treatment (Figure <xref rid="F3" ref-type="fig">3B</xref>), and the GSEA tab displays the gene sets significantly up-/down-regulated by the treatment (Figure <xref rid="F3" ref-type="fig">3C</xref>). Six types of gene sets are supported, including hallmark gene sets, KEGG pathways, Reactome pathways, WikiPathways, target gene sets of transcriptional factors and target gene sets of microRNAs. For a patient-level signature, there is no ORA tab.</p>
        <p>Users can change logFC and adjusted <italic toggle="yes">P</italic>-value cutoffs to redefine significant DEGs and update results in the DEG and ORA tabs (GSEA results are unaffected by parameter changes) (Figure <xref rid="F3" ref-type="fig">3A</xref>). Parameter change is not supported for a patient-level signature.</p>
      </sec>
      <sec id="SEC3-4-2">
        <title>Tumor microenvironment analysis</title>
        <p>Tumors contain a complex mixture of noncancerous cell types and matrix components, referred to as the tumor microenvironment (TME) (<xref rid="B45" ref-type="bibr">45</xref>). Compared with pre-clinical models such as cell lines, one advantage of patient samples is that they can reflect TME responses to treatment. In addition to immunotherapy targeting TME, accumulating evidence has shown that chemotherapy, targeted therapy and even hormone therapy also influence immune and non-immune components in the TME, which plays an important role in activity and efficacy of treatments (<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B47" ref-type="bibr">47</xref>). This function is designed to reveal drug-induced TME changes, providing more clues for understanding drug MOAs in patients and optimizing the combination of immunotherapy and other types of therapy. The TME analysis page gives differential analysis results of the predicted cell population abundances in TME between paired post- and pre-treatment samples (Figure <xref rid="F3" ref-type="fig">3D</xref>). We used two methods (MCP-counter and xCell) to predict cell type abundances (see Methods), and analysis results are given, respectively.</p>
      </sec>
      <sec id="SEC3-4-3">
        <title>Correlation analysis</title>
        <p>If a pair of items has consistent or opposite changes after treatment in all patients in a CDS-DB dataset, they are likely to be functionally related. This analysis is designed to reveal such functional relevance based on the correlation analysis of two items’ respective drug-induced changes across all patients in a CDS-DB dataset, in order to provide more clues for uncovering drug MOAs in patients. This analysis is only suitable for CDS-DB dataset-level signatures with patients not smaller than three. Three classes of items are supported, including genes, gene sets and TME cell types. The result table and heatmap (visually) give the correlation analysis results between items (Figure <xref rid="F3" ref-type="fig">3E</xref>).</p>
      </sec>
    </sec>
    <sec id="SEC3-5">
      <title>Signature comparative analysis</title>
      <p>This workflow can be accessed using the ‘Compare’ function, to implement the comparison of pre-analysis results (including DEG, GSEA and TME) of the user-selected multiple CDS-DB dataset- or patient-level signatures and their meta-analysis. This workflow is designed to explore the heterogeneity and homogeneity of treatment-induced gene, pathway and TME cell population perturbations across different patients or patient cohorts (e.g. those using the same drug, but with different cancer subtypes, administration dosages, post-treatment sampling times, sampling locations or treatment response states), and discover interesting shared/inconsistent drug MOA-related molecules, pathways or TME cell types. The signature filtering function on the left side of the submission page facilitates the signature selection. In particular, comparing a pair of CDS-DB dataset-level signatures with the same key metadata but with opposite drug response groupings (i.e. they are from the same source dataset, and were divided into two different CDS-DB datasets only because they have opposite response groupings) can help reveal intrinsic drug resistance mechanisms and discover predictive biomarkers of drug response from the perspective of drug perturbation. On the detailed annotation page of a CDS-DB dataset-level signature, the signature with drug response grouping opposite to it is given if available. In total, there are 43 pairs of such CDS-DB dataset-level signatures having opposite response groupings.</p>
      <p>The analysis results include seven tabs: DEG, TME-MCP-counter, TME-xCell, Hallmark gene set GSEA, KEGG pathway GSEA, Reactome pathway GSEA and WikiPathways GSEA. Each tab contains two heatmaps (except TME-MCP-counter) and a result table (Figure <xref rid="F4" ref-type="fig">4</xref>). The result table gives the meta-analysis results, where a large/small absolute value of variable coefficient indicates inconsistent/consistent perturbations of an item (gene, cell type or pathway) across different CDS-DB signatures. For the dataset-level signature comparison, meta-<italic toggle="yes">P</italic>-value is also computed, and a small meta-<italic toggle="yes">P</italic>-value means that the item has strong relevance with drug perturbations across multiple signatures. The heatmaps present the perturbations of the most consistent and inconsistent items across signatures.</p>
      <fig position="float" id="F4">
        <label>Figure 4.</label>
        <caption>
          <p>The signature comparative analysis result page. Here we use the comparison of 5 Imatinib-induced dataset-level signatures as the example and present the comparative analysis results for KEGG pathways. For dataset-level signature comparison, the heatmaps show the top 10 significantly inconsistent/consistent items across different CDS-DB signatures, where the statistical significance is measured by the adjusted meta-<italic toggle="yes">P</italic>-value. Users can change the adjusted meta-<italic toggle="yes">P</italic>-value cutoff to re-define statistical significance and update the heatmaps. Clicking on the item name in the table leads to its ‘Search’ result page.</p>
        </caption>
        <graphic xlink:href="gkad888fig4" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-6">
      <title>Search</title>
      <p>This workflow can be accessed using ‘Search’ function of the website. It supports the search for a gene, biological pathway or TME cell type. The result page includes two sections: ‘Basic information’ and ‘Analysis results’. The ‘Basic information’ gives the item-related detailed annotations. The ‘Analysis results’ gives the item's perturbed extents across all CDS-DB dataset- or patient-level perturbation signatures (Figure <xref rid="F5" ref-type="fig">5A</xref>) and drug and cancer subtype enrichment analysis results (see Methods), in order to explore by which drugs or in which cancer subtypes the item is significantly up-/down-regulated (Figure <xref rid="F5" ref-type="fig">5B</xref> and <xref rid="F5" ref-type="fig">C</xref>). The primary objective of this workflow is to elucidate the functions of the gene/biological pathway/cell type of interest and contribute to new target and drug discovery.</p>
      <fig position="float" id="F5">
        <label>Figure 5.</label>
        <caption>
          <p>The search result page. Here we use <italic toggle="yes">SKP2</italic> gene as the example and show the results for dataset-level signatures. (<bold>A</bold>) The results presenting the perturbation extents of the gene across CDS-DB dataset-level signatures. The two bar plots display the top and down 10 signatures, according to the perturbation extent. (<bold>B</bold>) Cancer subtype enrichment analysis result table. (<bold>C</bold>) Drug enrichment analysis result table.</p>
        </caption>
        <graphic xlink:href="gkad888fig5" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-7">
      <title>Signature connectivity analysis</title>
      <p>The signature connectivity analysis workflow can be accessed using ‘Analyze’ function of the website. This workflow is used to prioritize CDS-DB dataset-/patient-level signatures mimicking (‘mimic’ mode) or reversing (‘reverse’ mode) a user-uploaded signature and to further analyze MOA and target preference of the returned ranked signatures. Depending on the user's submission, this workflow can be used in many biomedical settings. For example, when a (patient-derived) disease signature is submitted, potential drugs and targets/MOAs for the disease can be recommended by searching CDS-DB signatures reversing the input (i.e. drug discovery/repositioning or target/MOA discovery); when a (patient-derived) drug resistance signature is submitted, the analysis results can suggest a combinational drug B that may be able to overcome resistance to drug A via the ‘reverse’ mode. This workflow aims at providing clues for such biomedical settings from a new dimension (i.e. patient-derived perturbation signature).</p>
      <p>Three input types are supported (Figure <xref rid="F6" ref-type="fig">6A</xref>): (i) ‘Gene set’, up- and down-regulated gene lists are required; (ii) ‘Signature’, a gene list with logFCs is required; (iii) ‘Cell type’, up- and down-regulated cell type lists are required. For the first two input types, the input signature is connected with CDS-DB gene perturbation signatures, while for the last one, with the cell perturbation signature (see Methods). We used MCP-counter and xCell two methods to obtain the cell perturbation signatures, and thus here, users need to select the method. MCP-counter supports 10 cell types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>), and xCell supports 64 cell types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>). Users can only use the supported cell types as the input. In addition, users can also select a patient-derived drug intrinsic resistance signature from CTR-DB as the input of the ‘Signature’ type by clicking the ‘CTR-DB patient-derived intrinsic drug resistance signatures’ button. CTR-DB, previously developed by our group, is a database designed to comprehensively collect patient-derived baseline transcriptomes with intrinsic cancer drug response (<xref rid="B48" ref-type="bibr">48</xref>), where an intrinsic drug resistance signature was obtained from differential gene expression analysis of baseline (i.e. pre-treatment) transcriptomes between non-responsive and responsive patients. In signature connectivity analysis, the optional parameters include signature level (CDS-DB dataset- or patient-level signature) and direction (mimic or reverse).</p>
      <fig position="float" id="F6">
        <label>Figure 6.</label>
        <caption>
          <p>User submission page (A) and result pages (B, C, D and E) of the signature connectivity analysis workflow. An acute lymphoblastic leukemia (ALL) disease signature is used as the input example (see Supplementary methods), and ‘dataset-level signature’ and ‘reverse’ mode are selected. (<bold>A</bold>) User submission page. (<bold>B</bold>) The interactive heatmap which presents top 20 returned CDS-DB dataset-level signatures. Users can modify the logFC cutoff to recolor the heatmap and also switch the column label name of the heatmap among cancer subtype, therapeutic regimen and signature ID. (<bold>C</bold>) The detailed result table presents the returned ranked CDS-DB signatures. Users can select ≥2 CDS-DB signatures in the table, and check their signature comparative analysis results by clicking the ‘Compare’ button under the table. Users can also select signatures of interest in the table and use the ‘Refresh’ button to repeat the MOA and target enrichment analyses based on the selected signatures. (<bold>D</bold>) The MOA enrichment analysis result table. (<bold>E</bold>) The target enrichment analysis result table.</p>
        </caption>
        <graphic xlink:href="gkad888fig6" position="float"/>
      </fig>
      <p>The analysis results include an interactive heatmap (Figure <xref rid="F6" ref-type="fig">6B</xref>) and three result tables (Figure <xref rid="F6" ref-type="fig">6C</xref>–<xref rid="F6" ref-type="fig">E</xref>). The heatmap visualizes the perturbation extents (logFCs) of the input genes/cell types in the top 20 returned CDS-DB gene/cell signatures, emphasizing the reversal or simulation of the CDS-DB signatures to the input signature (Figure <xref rid="F6" ref-type="fig">6B</xref>). Below the heatmap is the detailed result table of the returned CDS-DB signatures, ranked according to descending/ascending connectivity scores for the ‘mimic’/‘reverse’ mode (see Methods) (Figure <xref rid="F6" ref-type="fig">6C</xref>). In order to help users better check consistent or inconsistent parts of the returned signatures, users can select ≥2 CDS-DB signatures in the table and click the ‘Compare’ button under the table (Figure <xref rid="F6" ref-type="fig">6C</xref>) to obtain the comparative analysis results of the selected signatures. The last two tables give targets and MOAs significantly enriched at the top of the returned ranked signature list in the first table (Figure <xref rid="F6" ref-type="fig">6D</xref> and <xref rid="F6" ref-type="fig">E</xref>). Users can filter the returned signatures based on various data fields in the first table, and then click ‘Refresh’ button under the first table to update the target and MOA enrichment analysis results (Figure <xref rid="F6" ref-type="fig">6C</xref>). For example, users can require that the length of the intersection between the input and the CDS-DB signature (‘Overlap_num’) is not smaller than a certain cutoff, the sampling location category is tumor tissue, the response grouping is ‘response’, and childhood cancer is excluded.</p>
    </sec>
    <sec id="SEC3-8">
      <title>Use cases</title>
      <p>Here, we use several examples to demonstrate the use and potential of key CDS-DB workflows used to reveal drug MOAs (including TME-related MOAs) and their homogeneity/heterogeneity in patients and for drug (combination) discovery.</p>
      <sec id="SEC3-8-1">
        <title>Single signature analysis</title>
        <p>We used the dataset-level signature CDS_dataset_Microarray_81 as an example. In this dataset, nine patients with chronic myeloid leukemia (CML) received Imatinib, and paired bone marrow samples were obtained before and four weeks after treatment. The original reference did not report the drug response status information. It has been known that CML is caused mainly by the fusion oncogene BCR-ABL1, whose protein product has constitutive tyrosine kinase activity, and Imatinib, a BCR-ABL1 tyrosine kinase inhibitor, is the standard therapy for CML (<xref rid="B49" ref-type="bibr">49</xref>).</p>
        <p>The ‘Perturbation signature analysis’ results show that after four weeks of treatment, the most significantly down-regulated hallmark gene set is E2F targets (NES = −2.35, <italic toggle="yes">P</italic>-value = 1.00E−10) and DNA replication is also significantly down-regulated in KEGG GSEA analysis (NES = −2.09, <italic toggle="yes">P</italic>-value = 3.11E−08). Upstream, we find that the transcriptional factor E2F1 is significantly down-regulated (logFC = −0.22, <italic toggle="yes">P</italic>-value = 4.32E−02), several cyclin-dependent kinases (CDKs) such as CDK4 (logFC = −0.87, <italic toggle="yes">P</italic>-value = 3.56E−02) and CDK2 (logFC = −0.48, <italic toggle="yes">P</italic>-value = 7.27E−02) are down-regulated, as is SKP2 (logFC = −0.94, <italic toggle="yes">P</italic>-value = 3.82E−05). SKP2 is a ubiquitin ligase subunit that specifically recognizes the CDK inhibitor CDKN1B (i.e. P27) and promotes its degradation (<xref rid="B50" ref-type="bibr">50</xref>). Indeed, in our analysis results we find that, consistent with the down-regulation of SKP2, ‘REACTOME_SCF_SKP2_MEDIATED_DEGRADATION_OF_ P27_P21’ is significantly down-regulated (NES = −1.65, <italic toggle="yes">P</italic>-value = 2.44E−03). Further, CDKs are known to promote the release of E2F transcriptional factors, drive cell-cycle progression from G1 to S, and launch DNA replication (<xref rid="B51" ref-type="bibr">51</xref>). Integrating the prior knowledge and our results, we speculate that in these patients with CML, Imatinib caused cell cycle arrest at G1-S transition via the upstream SKP2-P27-CDK-E2F axis (Figure <xref rid="F7" ref-type="fig">7</xref>). This finding is consistent with previous cell line level studies that BCR-ABL up-regulates SKP2 expression via PI3K pathway, and Imatinib can induce cell cycle arrest by reducing SKP2 expression and accumulating P27 in BCR-ABL-positive cells (<xref rid="B52" ref-type="bibr">52</xref>).</p>
        <fig position="float" id="F7">
          <label>Figure 7.</label>
          <caption>
            <p>Schematic diagram of Imatinib MOAs in the treatment of chronic myeloid leukemia. The MOAs are speculated based on the single signature analysis results of CDS_dataset_Microarray_81, presented in the figure. The results suggest that on the one hand, Imatinib down-regulates SKP2 and further reduces ubiquitination-mediated degradation of P27 protein, then accumulating P27 inhibits the activities of CDKs and downstream E2F1, and eventually Imatinib induces cell cycle arrest. On the other hand, Imatinib exerts anti-tumor effects also by CD8+ T cell- and NK-cell-mediated cytotoxicity. These findings are consistent with previous studies (<xref rid="B52" ref-type="bibr">52</xref>,<xref rid="B53" ref-type="bibr">53</xref>). The red crosses in the figure represent the action of Imatinib, and the red arrows show its regulatory direction (up- or down-regulation).</p>
          </caption>
          <graphic xlink:href="gkad888fig7" position="float"/>
        </fig>
        <p>Further, from the ‘Tumor microenvironment analysis’ results of MCP-counter, we find that after treatment, the abundances of CD8+ T cells (logFC = 0.16, <italic toggle="yes">P</italic>-value = 7.08E−04) and NK cells (logFC = 0.16, <italic toggle="yes">P</italic>-value = 2.85E−03) are significantly up-regulated. Meanwhile, the related ‘T cell receptor signature pathway’ (NES = 2.11, <italic toggle="yes">P</italic>-value = 2.32E−07), ‘antigen processing and presentation’ (NES = 2.00, <italic toggle="yes">P</italic>-value = 5.91E−06), and ‘natural killer cell mediated cytotoxicity’ (NES = 2.48, <italic toggle="yes">P</italic>-value = 1.00E−10) KEGG pathways are also significantly up-regulated. These results suggest that in these patients, in addition to stopping the cell cycle, Imatinib exerted therapeutic effects via CD8+ T cell- and NK cell-mediated cell cytotoxicity (Figure <xref rid="F7" ref-type="fig">7</xref>). These findings are consistent with previous studies (<xref rid="B53" ref-type="bibr">53</xref>).</p>
      </sec>
      <sec id="SEC3-8-2">
        <title>Signature comparative analysis</title>
        <p>In addition to CDS_dataset_Microarray_81, CDS-DB contains four other dataset-level signatures induced by Imatinib, including CDS_dataset_Microarray_91 and CDS_dataset_Microarray_92 for CML, CDS_dataset_Microarray_71 for gastrointestinal stromal tumor and CDS_dataset_RNAseq_41 for colorectal cancer. None have drug response information, and CDS_dataset_Microarray_91 and CDS_dataset_Microarray_92 are derived from the same source dataset with different administration dosages (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S3</xref>). According to the comparative analysis results across different dataset-level signatures of CML, we find that Imatinib MOAs (both cell cycle arrest induced by SKP2-CDK-E2F axis and CD8+ T cell- and NK cell-mediated cell cytotoxicity) identified in the single signature analysis above are further validated in the other two dataset-level signatures (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref>), showing the homogeneity of Imatinib MOAs in CML. The comparative results also suggest strong heterogeneity in treating different cancer types. For example, in colorectal cancer (CDS_dataset_RNAseq_41), the perturbation of the SKP2-CDK-E2F axis has almost the exact opposite trend with CML (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref>), and Imatinib hardly induces significant changes on SKP2-CDK-E2F axis, CD8+ T cells, and NK cells in gastrointestinal stromal tumor (CDS_dataset_Microarray_71) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref>). Indeed, previous studies have indicated that instead of targeting BCR-ABL fusion oncoprotein in CML, the therapeutic effects of Imatinib depend on inhibiting the tyrosine kinase activities of c-kit and PDGF in gastrointestinal stromal tumor (<xref rid="B54" ref-type="bibr">54</xref>) and perhaps c-kit and PDGF in colorectal cancer (<xref rid="B55" ref-type="bibr">55</xref>,<xref rid="B56" ref-type="bibr">56</xref>).</p>
      </sec>
      <sec id="SEC3-8-3">
        <title>Signature connectivity analysis</title>
        <p>Using the patient-derived acute lymphoblastic leukemia (ALL) disease signature (see <xref rid="sup1" ref-type="supplementary-material">Supplementary methods</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S5</xref>) as the input, we searched CDS-DB signatures reversing it. We find that, in both dataset- and patient-level signature connectivity analyses, the most significantly enriched MOA at the top of the returned signatures is ‘glucocorticoid receptor agonist’ such as prednisone, prednisolone and dexamethasone (NES = −1.74, <italic toggle="yes">P</italic>-value = 1.85E−03 for dataset-level; NES = −2.14, <italic toggle="yes">P</italic>-value = 2.65E−10 for patient-level), and the target in the first place is NR3C1 (i.e. glucocorticoid receptor) (NES = −1.73, <italic toggle="yes">P</italic>-value = 1.61E−03 for dataset-level; NES = −2.11, <italic toggle="yes">P</italic>-value = 3.69E−10 for patient-level) (Figure <xref rid="F6" ref-type="fig">6D</xref> and <xref rid="F6" ref-type="fig">E</xref>). It is known that in clinical ALL treatment glucocorticoids are essential chemotherapy components (<xref rid="B57" ref-type="bibr">57</xref>), demonstrating this workflow's potential in cancer drug discovery.</p>
        <p>To further demonstrate the workflow's potential in drug combination discovery, using the ‘CTR-DB patient-derived intrinsic drug resistance signatures’ function, we selected the patient-derived intrinsic drug resistance signature ‘CTR_RNAseq_342″ from the CTR-DB database as the input. CTR_RNAseq_342 has 38 patients with oligodendroglioma receiving Temozolomide, of which 10 are responders, and 28 are resistant. The resistance signature was obtained by differential gene expression analysis between non-responders and responders. Using ‘Analyze’, we looked for combinational drug B able to overcome the Temozolomide resistance by searching CDS-DB signatures that reverse the intrinsic resistance signature. We find that, at the dataset-level, three of the top 10 returned signatures are Letrozole-related, and one is Tamoxifen-related. In the patient-level results, these two drugs are also ranked near the top. We know that Letrozole is an aromatase inhibitor, where aromatase is also called estrogen synthetase. Tamoxifen is an estrogen receptor antagonist. The results suggest that estrogen and estrogen receptor may be important targets combined with Temozolomide. Recent preclinical studies indeed found that Letrozole (<xref rid="B58" ref-type="bibr">58</xref>) and Tamoxifen (<xref rid="B59" ref-type="bibr">59</xref>) may have an important role in the treatment of gliomas, and Letrozole/Tamoxifen and Temozolomide have synergistic effects in glioblastoma cell lines (<xref rid="B60" ref-type="bibr">60</xref>,<xref rid="B61" ref-type="bibr">61</xref>). A Phase I clinical trial has been conducted to test the combination of Tamoxifen and Temozolomide in gliomas (<xref rid="B62" ref-type="bibr">62</xref>), and Cristofori <italic toggle="yes">et al.</italic> suggested that Tamoxifen potentially increases the efficacy of Temozolomide in patients with recurrent glioblastoma (<xref rid="B63" ref-type="bibr">63</xref>).</p>
      </sec>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>Discussion</title>
    <p>Patient-derived gene expression signatures induced by cancer treatment, obtained from paired pre- and post-treatment clinical transcriptomes, can help understand molecular changes in patients in response to treatment and reveal the molecular response mechanisms resulting in tumor sensitivity or resistance. Moreover, their integration and reuse may provide new insights. In the era of precision medicine, increasing amounts of paired pre- and post-treatment clinical transcriptomic data are being generated. However, to date, there is no database comprehensively collecting these data and facilitating their integration and (re-)use. Therefore, we developed CDS-DB.</p>
    <p>In current CDS-DB, we have used two methods (MCP-counter and xCell) to predict abundances of cell populations in TME. As many other scholars have argued, each method has strengths and weaknesses, and it is advisable to compare results of several methods (e.g. (<xref rid="B64" ref-type="bibr">64</xref>)). Actually there are several other options. For example, the advantage of ImmuCellAI is comprehensive T-cell subset abundance prediction (<xref rid="B65" ref-type="bibr">65</xref>). In the future version, we plan to support more methods, facilitating users to compare results from different methods and gain more comprehensive and robust results.</p>
    <p>As the first database of patient-derived cancer drug-induced gene expression signatures, CDS-DB can help answer questions that existing related resources cannot answer. To be specific, CDS-DB will have irreplaceable advantages for (i) validating drug MOA knowledge obtained from laboratory settings in patients, (ii) filling the knowledge gap (especially TME-related) on drug MOAs in patients, (iii) exploring molecular response mechanism heterogeneity of patients to treatment and (iv) understanding drug sensitivity/resistance mechanisms in patients from the perspective of drug perturbation. (v) Furthermore, when used for drug discovery, drug repositioning, etc., connectivity analysis based on CDS-DB signatures can provide clues from a new dimension (i.e. the patient level). These clues can validate and complement analyses based on currently commonly used cell line-level drug perturbation signatures (e.g. CMAP(11) or LINCS L1000 (<xref rid="B12" ref-type="bibr">12</xref>)). Moreover, when users input a patient-derived signature, analysis based on CDS-DB drug perturbation signatures also from patient samples may have potentially better performance. (vi) Finally, because the CDS-DB data come from clinical patients, there are many perturbation signatures induced by drug combination regimens in clinical use (e.g. chemotherapy regimens or combined chemotherapy and immunotherapy) as well as antibody drugs such as Trastuzumab, Rituximab, Cetuximab, Figitumumab, Pidilizumab, etc., which generally are not covered by existing resources. Understanding the molecular response of patients to them will contribute to the understanding of their MOAs, leading to more precise clinical use, as well as the exact combination with other drugs.</p>
    <p>In summary, CDS-DB, with unique patient-derived treatment-induced transcriptomic signatures, and abundant and useful data analysis functions, can benefit numerous basic and clinical researchers focusing on (cancer) drug development and clinical precise use of cancer drugs.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkad888_Supplemental_Files</label>
      <media xlink:href="gkad888_supplemental_files.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>We would like to thank Qiaosheng Xie from China-Japan Friendship Hospital (Beijing, China) for the fruitful discussion, Pengfei Gao, Honglei Li, Xiaohua Luo, Xun Wang, Zhonghua Yan, Jiachen Guo and He Chen for the technical support.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>CDS-DB can be accessed at <ext-link xlink:href="http://cdsdb.ncpsb.org.cn/" ext-link-type="uri">http://cdsdb.ncpsb.org.cn/</ext-link>.</p>
  </sec>
  <sec id="SEC6">
    <title>Supplementary data</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkad888#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC7">
    <title>Funding</title>
    <p>National Natural Science Foundation of China [32088101]; National Key Research and Development Program of China [2021YFA1301603, 2020YFE0202200]. Funding for open access charge: National Natural Science Foundation of China [32088101].</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. The human body image in the graphical abstract and Figure <xref rid="F1" ref-type="fig">1</xref> is from Figdraw and Figure <xref rid="F7" ref-type="fig">7</xref> was created with BioRender.com.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname><given-names>J.</given-names></string-name>, <string-name><surname>Fong</surname><given-names>S.H.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Bakkenist</surname><given-names>C.J.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Mourragui</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wessels</surname><given-names>L.F.A.</given-names></string-name>, <string-name><surname>Hafner</surname><given-names>M.</given-names></string-name>, <string-name><surname>Sharan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Peng</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients</article-title>. <source>Nat. Cancer</source>. <year>2021</year>; <volume>2</volume>:<fpage>233</fpage>–<lpage>244</lpage>.<pub-id pub-id-type="pmid">34223192</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Engel</surname><given-names>R.H.</given-names></string-name>, <string-name><surname>Brown</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Von Roenn</surname><given-names>J.H.</given-names></string-name>, <string-name><surname>O’Regan</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Bergan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Badve</surname><given-names>S.</given-names></string-name>, <string-name><surname>Rademaker</surname><given-names>A.</given-names></string-name>, <string-name><surname>Gradishar</surname><given-names>W.J.</given-names></string-name></person-group><article-title>A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience</article-title>. <source>Cancer Invest.</source><year>2007</year>; <volume>25</volume>:<fpage>733</fpage>–<lpage>737</lpage>.<pub-id pub-id-type="pmid">17952740</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schwaederle</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>M.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Eggermont</surname><given-names>A.M.</given-names></string-name>, <string-name><surname>Schilsky</surname><given-names>R.L.</given-names></string-name>, <string-name><surname>Mendelsohn</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lazar</surname><given-names>V.</given-names></string-name>, <string-name><surname>Kurzrock</surname><given-names>R.</given-names></string-name></person-group><article-title>Impact of Precision Medicine in Diverse Cancers: a Meta-Analysis of Phase II Clinical Trials</article-title>. <source>J. Clin. Oncol.</source><year>2015</year>; <volume>33</volume>:<fpage>3817</fpage>–<lpage>3825</lpage>.<pub-id pub-id-type="pmid">26304871</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X.</given-names></string-name></person-group><article-title>Drug resistance and combating drug resistance in cancer</article-title>. <source>Cancer Drug Resist.</source><year>2019</year>; <volume>2</volume>:<fpage>141</fpage>–<lpage>160</lpage>.<pub-id pub-id-type="pmid">34322663</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meng</surname><given-names>F.</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>C.M.</given-names></string-name>, <string-name><surname>Joung</surname><given-names>D.</given-names></string-name>, <string-name><surname>Vallera</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>McAlpine</surname><given-names>M.C.</given-names></string-name>, <string-name><surname>Panoskaltsis-Mortari</surname><given-names>A.</given-names></string-name></person-group><article-title>3D Bioprinted In Vitro Metastatic Models via Reconstruction of Tumor Microenvironments</article-title>. <source>Adv. Mater.</source><year>2019</year>; <volume>31</volume>:<fpage>e1806899</fpage>.<pub-id pub-id-type="pmid">30663123</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Palmer</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Sorger</surname><given-names>P.K.</given-names></string-name></person-group><article-title>Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy</article-title>. <source>Cell</source>. <year>2017</year>; <volume>171</volume>:<fpage>1678</fpage>–<lpage>1691</lpage>.<pub-id pub-id-type="pmid">29245013</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schmidt</surname><given-names>S.</given-names></string-name>, <string-name><surname>Rainer</surname><given-names>J.</given-names></string-name>, <string-name><surname>Riml</surname><given-names>S.</given-names></string-name>, <string-name><surname>Ploner</surname><given-names>C.</given-names></string-name>, <string-name><surname>Jesacher</surname><given-names>S.</given-names></string-name>, <string-name><surname>Achmüller</surname><given-names>C.</given-names></string-name>, <string-name><surname>Presul</surname><given-names>E.</given-names></string-name>, <string-name><surname>Skvortsov</surname><given-names>S.</given-names></string-name>, <string-name><surname>Crazzolara</surname><given-names>R.</given-names></string-name>, <string-name><surname>Fiegl</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemia</article-title>. <source>Blood</source>. <year>2006</year>; <volume>107</volume>:<fpage>2061</fpage>–<lpage>2069</lpage>.<pub-id pub-id-type="pmid">16293608</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ward</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Pettaway</surname><given-names>C.A.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>L.Z.</given-names></string-name>, <string-name><surname>Subudhi</surname><given-names>S.K.</given-names></string-name>, <string-name><surname>Vence</surname><given-names>L.M.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>H.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>H.</given-names></string-name>, <string-name><surname>Efstathiou</surname><given-names>E.</given-names></string-name><etal>et al</etal>.</person-group><article-title>VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer</article-title>. <source>Nat. Med.</source><year>2017</year>; <volume>23</volume>:<fpage>551</fpage>–<lpage>555</lpage>.<pub-id pub-id-type="pmid">28346412</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Triulzi</surname><given-names>T.</given-names></string-name>, <string-name><surname>Regondi</surname><given-names>V.</given-names></string-name>, <string-name><surname>De Cecco</surname><given-names>L.</given-names></string-name>, <string-name><surname>Cappelletti</surname><given-names>M.R.</given-names></string-name>, <string-name><surname>Di Modica</surname><given-names>M.</given-names></string-name>, <string-name><surname>Paolini</surname><given-names>B.</given-names></string-name>, <string-name><surname>Lollini</surname><given-names>P.L.</given-names></string-name>, <string-name><surname>Di Cosimo</surname><given-names>S.</given-names></string-name>, <string-name><surname>Sfondrini</surname><given-names>L.</given-names></string-name>, <string-name><surname>Generali</surname><given-names>D.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit</article-title>. <source>Br. J. Cancer</source>. <year>2018</year>; <volume>119</volume>:<fpage>1487</fpage>–<lpage>1494</lpage>.<pub-id pub-id-type="pmid">30478407</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Odunsi</surname><given-names>K.</given-names></string-name>, <string-name><surname>Qian</surname><given-names>F.</given-names></string-name>, <string-name><surname>Lugade</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Yu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Geller</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Fling</surname><given-names>S.P.</given-names></string-name>, <string-name><surname>Kaiser</surname><given-names>J.C.</given-names></string-name>, <string-name><surname>Lacroix</surname><given-names>A.M.</given-names></string-name>, <string-name><surname>D’Amico</surname><given-names>L.</given-names></string-name>, <string-name><surname>Ramchurren</surname><given-names>N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses</article-title>. <source>Sci. Transl. Med.</source><year>2022</year>; <volume>14</volume>:<fpage>eabg8402</fpage>.<pub-id pub-id-type="pmid">35294258</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lamb</surname><given-names>J.</given-names></string-name>, <string-name><surname>Crawford</surname><given-names>E.D.</given-names></string-name>, <string-name><surname>Peck</surname><given-names>D.</given-names></string-name>, <string-name><surname>Modell</surname><given-names>J.W.</given-names></string-name>, <string-name><surname>Blat</surname><given-names>I.C.</given-names></string-name>, <string-name><surname>Wrobel</surname><given-names>M.J.</given-names></string-name>, <string-name><surname>Lerner</surname><given-names>J.</given-names></string-name>, <string-name><surname>Brunet</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ross</surname><given-names>K.N.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease</article-title>. <source>Science</source>. <year>2006</year>; <volume>313</volume>:<fpage>1929</fpage>–<lpage>1935</lpage>.<pub-id pub-id-type="pmid">17008526</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Narayan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Corsello</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Peck</surname><given-names>D.D.</given-names></string-name>, <string-name><surname>Natoli</surname><given-names>T.E.</given-names></string-name>, <string-name><surname>Lu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Gould</surname><given-names>J.</given-names></string-name>, <string-name><surname>Davis</surname><given-names>J.F.</given-names></string-name>, <string-name><surname>Tubelli</surname><given-names>A.A.</given-names></string-name>, <string-name><surname>Asiedu</surname><given-names>J.K.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A next generation connectivity map: L1000 platform and the first 1,000,000 profiles</article-title>. <source>Cell</source>. <year>2017</year>; <volume>171</volume>:<fpage>1437</fpage>–<lpage>1452</lpage>.<pub-id pub-id-type="pmid">29195078</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keenan</surname><given-names>A.B.</given-names></string-name>, <string-name><surname>Wojciechowicz</surname><given-names>M.L.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Jagodnik</surname><given-names>K.M.</given-names></string-name>, <string-name><surname>Jenkins</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Lachmann</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ma’ayan</surname><given-names>A.</given-names></string-name></person-group><article-title>Connectivity mapping: methods and applications</article-title>. <source>Annu. Rev. Biomed. Data Sci.</source><year>2019</year>; <volume>2</volume>:<fpage>69</fpage>–<lpage>92</lpage>.</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>W.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>M.M.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ju</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Nesser</surname><given-names>N.K.</given-names></string-name>, <string-name><surname>Johnson-Camacho</surname><given-names>K.</given-names></string-name>, <string-name><surname>Boniface</surname><given-names>C.T.</given-names></string-name>, <string-name><surname>Lawrence</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Pande</surname><given-names>N.T.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Large-scale characterization of drug responses of clinically relevant proteins in cancer cell lines</article-title>. <source>Cancer Cell</source>. <year>2020</year>; <volume>38</volume>:<fpage>829</fpage>–<lpage>843</lpage>.<pub-id pub-id-type="pmid">33157050</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mitchell</surname><given-names>D.C.</given-names></string-name>, <string-name><surname>Kuljanin</surname><given-names>M.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Van Vranken</surname><given-names>J.G.</given-names></string-name>, <string-name><surname>Bulloch</surname><given-names>N.</given-names></string-name>, <string-name><surname>Schweppe</surname><given-names>D.K.</given-names></string-name>, <string-name><surname>Huttlin</surname><given-names>E.L.</given-names></string-name>, <string-name><surname>Gygi</surname><given-names>S.P.</given-names></string-name></person-group><article-title>A proteome-wide atlas of drug mechanism of action</article-title>. <source>Nat. Biotechnol.</source><year>2023</year>; <volume>41</volume>:<fpage>845</fpage>–<lpage>857</lpage>.<pub-id pub-id-type="pmid">36593396</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tian</surname><given-names>S.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Lv</surname><given-names>C.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Fang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>L.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zu</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Exploring pharmacological active ingredients of traditional Chinese medicine by pharmacotranscriptomic map in ITCM</article-title>. <source>Brief. Bioinform.</source><year>2023</year>; <volume>24</volume>:<fpage>bbad027</fpage>.<pub-id pub-id-type="pmid">36719094</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>M.</given-names></string-name>, <string-name><surname>Miao</surname><given-names>Y.R.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>G.Y.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Kwok</surname><given-names>H.F.</given-names></string-name>, <string-name><surname>Feng</surname><given-names>J.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.Y.</given-names></string-name></person-group><article-title>ICBatlas: a comprehensive resource for depicting immune checkpoint blockade therapy characteristics from transcriptome profiles</article-title>. <source>Cancer Immunol. Res.</source><year>2022</year>; <volume>10</volume>:<fpage>1398</fpage>–<lpage>1406</lpage>.<pub-id pub-id-type="pmid">36095221</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clough</surname><given-names>E.</given-names></string-name>, <string-name><surname>Barrett</surname><given-names>T.</given-names></string-name></person-group><article-title>The Gene Expression Omnibus Database</article-title>. <source>Methods Mol. Biol.</source><year>2016</year>; <volume>1418</volume>:<fpage>93</fpage>–<lpage>110</lpage>.<pub-id pub-id-type="pmid">27008011</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sarkans</surname><given-names>U.</given-names></string-name>, <string-name><surname>Füllgrabe</surname><given-names>A.</given-names></string-name>, <string-name><surname>Ali</surname><given-names>A.</given-names></string-name>, <string-name><surname>Athar</surname><given-names>A.</given-names></string-name>, <string-name><surname>Behrangi</surname><given-names>E.</given-names></string-name>, <string-name><surname>Diaz</surname><given-names>N.</given-names></string-name>, <string-name><surname>Fexova</surname><given-names>S.</given-names></string-name>, <string-name><surname>George</surname><given-names>N.</given-names></string-name>, <string-name><surname>Iqbal</surname><given-names>H.</given-names></string-name>, <string-name><surname>Kurri</surname><given-names>S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>From ArrayExpress to BioStudies</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D1502</fpage>–<lpage>D1506</lpage>.<pub-id pub-id-type="pmid">33211879</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gautier</surname><given-names>L.</given-names></string-name>, <string-name><surname>Cope</surname><given-names>L.</given-names></string-name>, <string-name><surname>Bolstad</surname><given-names>B.M.</given-names></string-name>, <string-name><surname>Irizarry</surname><given-names>R.A.</given-names></string-name></person-group><article-title>affy–analysis of Affymetrix GeneChip data at the probe level</article-title>. <source>Bioinformatics</source>. <year>2004</year>; <volume>20</volume>:<fpage>307</fpage>–<lpage>315</lpage>.<pub-id pub-id-type="pmid">14960456</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ritchie</surname><given-names>M.E.</given-names></string-name>, <string-name><surname>Phipson</surname><given-names>B.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>D.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Law</surname><given-names>C.W.</given-names></string-name>, <string-name><surname>Shi</surname><given-names>W.</given-names></string-name>, <string-name><surname>Smyth</surname><given-names>G.K.</given-names></string-name></person-group><article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>. <source>Nucleic Acids Res.</source><year>2015</year>; <volume>43</volume>:<fpage>e47</fpage>.<pub-id pub-id-type="pmid">25605792</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maglott</surname><given-names>D.</given-names></string-name>, <string-name><surname>Ostell</surname><given-names>J.</given-names></string-name>, <string-name><surname>Pruitt</surname><given-names>K.D.</given-names></string-name>, <string-name><surname>Tatusova</surname><given-names>T.</given-names></string-name></person-group><article-title>Entrez Gene: gene-centered information at NCBI</article-title>. <source>Nucleic Acids Res.</source><year>2011</year>; <volume>39</volume>:<fpage>D52</fpage>–<lpage>D57</lpage>.<pub-id pub-id-type="pmid">21115458</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dobin</surname><given-names>A.</given-names></string-name>, <string-name><surname>Davis</surname><given-names>C.A.</given-names></string-name>, <string-name><surname>Schlesinger</surname><given-names>F.</given-names></string-name>, <string-name><surname>Drenkow</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zaleski</surname><given-names>C.</given-names></string-name>, <string-name><surname>Jha</surname><given-names>S.</given-names></string-name>, <string-name><surname>Batut</surname><given-names>P.</given-names></string-name>, <string-name><surname>Chaisson</surname><given-names>M.</given-names></string-name>, <string-name><surname>Gingeras</surname><given-names>T.R.</given-names></string-name></person-group><article-title>STAR: ultrafast universal RNA-seq aligner</article-title>. <source>Bioinformatics</source>. <year>2013</year>; <volume>29</volume>:<fpage>15</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">23104886</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anders</surname><given-names>S.</given-names></string-name>, <string-name><surname>Pyl</surname><given-names>P.T.</given-names></string-name>, <string-name><surname>Huber</surname><given-names>W.</given-names></string-name></person-group><article-title>HTSeq–a Python framework to work with high-throughput sequencing data</article-title>. <source>Bioinformatics</source>. <year>2015</year>; <volume>31</volume>:<fpage>166</fpage>–<lpage>169</lpage>.<pub-id pub-id-type="pmid">25260700</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leek</surname><given-names>J.T.</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>W.E.</given-names></string-name>, <string-name><surname>Parker</surname><given-names>H.S.</given-names></string-name>, <string-name><surname>Jaffe</surname><given-names>A.E.</given-names></string-name>, <string-name><surname>Storey</surname><given-names>J.D.</given-names></string-name></person-group><article-title>The sva package for removing batch effects and other unwanted variation in high-throughput experiments</article-title>. <source>Bioinformatics</source>. <year>2012</year>; <volume>28</volume>:<fpage>882</fpage>–<lpage>883</lpage>.<pub-id pub-id-type="pmid">22257669</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wishart</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Feunang</surname><given-names>Y.D.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Lo</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Marcu</surname><given-names>A.</given-names></string-name>, <string-name><surname>Grant</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Sajed</surname><given-names>T.</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>D.</given-names></string-name>, <string-name><surname>Li</surname><given-names>C.</given-names></string-name>, <string-name><surname>Sayeeda</surname><given-names>Z.</given-names></string-name><etal>et al</etal>.</person-group><article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>; <volume>46</volume>:<fpage>D1074</fpage>–<lpage>D1082</lpage>.<pub-id pub-id-type="pmid">29126136</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schriml</surname><given-names>L.M.</given-names></string-name>, <string-name><surname>Munro</surname><given-names>J.B.</given-names></string-name>, <string-name><surname>Schor</surname><given-names>M.</given-names></string-name>, <string-name><surname>Olley</surname><given-names>D.</given-names></string-name>, <string-name><surname>McCracken</surname><given-names>C.</given-names></string-name>, <string-name><surname>Felix</surname><given-names>V.</given-names></string-name>, <string-name><surname>Baron</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>R.</given-names></string-name>, <string-name><surname>Bello</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Bearer</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The Human Disease Ontology 2022 update</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D1255</fpage>–<lpage>D1261</lpage>.<pub-id pub-id-type="pmid">34755882</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seal</surname><given-names>R.L.</given-names></string-name>, <string-name><surname>Braschi</surname><given-names>B.</given-names></string-name>, <string-name><surname>Gray</surname><given-names>K.</given-names></string-name>, <string-name><surname>Jones</surname><given-names>T.E.M.</given-names></string-name>, <string-name><surname>Tweedie</surname><given-names>S.</given-names></string-name>, <string-name><surname>Haim-Vilmovsky</surname><given-names>L.</given-names></string-name>, <string-name><surname>Bruford</surname><given-names>E.A.</given-names></string-name></person-group><article-title>Genenames.org: the HGNC resources in 2023</article-title>. <source>Nucleic Acids Res.</source><year>2023</year>; <volume>51</volume>:<fpage>D1003</fpage>–<lpage>D1009</lpage>.<pub-id pub-id-type="pmid">36243972</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Corsello</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Bittker</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Gould</surname><given-names>J.</given-names></string-name>, <string-name><surname>McCarren</surname><given-names>P.</given-names></string-name>, <string-name><surname>Hirschman</surname><given-names>J.E.</given-names></string-name>, <string-name><surname>Johnston</surname><given-names>S.E.</given-names></string-name>, <string-name><surname>Vrcic</surname><given-names>A.</given-names></string-name>, <string-name><surname>Wong</surname><given-names>B.</given-names></string-name>, <string-name><surname>Khan</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The Drug Repurposing Hub: a next-generation drug library and information resource</article-title>. <source>Nat. Med.</source><year>2017</year>; <volume>23</volume>:<fpage>405</fpage>–<lpage>408</lpage>.<pub-id pub-id-type="pmid">28388612</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Oughtred</surname><given-names>R.</given-names></string-name>, <string-name><surname>Rust</surname><given-names>J.</given-names></string-name>, <string-name><surname>Chang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Breitkreutz</surname><given-names>B.J.</given-names></string-name>, <string-name><surname>Stark</surname><given-names>C.</given-names></string-name>, <string-name><surname>Willems</surname><given-names>A.</given-names></string-name>, <string-name><surname>Boucher</surname><given-names>L.</given-names></string-name>, <string-name><surname>Leung</surname><given-names>G.</given-names></string-name>, <string-name><surname>Kolas</surname><given-names>N.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The BioGRID database: a comprehensive biomedical resource of curated protein, genetic, and chemical interactions</article-title>. <source>Protein Sci.</source><year>2021</year>; <volume>30</volume>:<fpage>187</fpage>–<lpage>200</lpage>.<pub-id pub-id-type="pmid">33070389</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liberzon</surname><given-names>A.</given-names></string-name>, <string-name><surname>Birger</surname><given-names>C.</given-names></string-name>, <string-name><surname>Thorvaldsdóttir</surname><given-names>H.</given-names></string-name>, <string-name><surname>Ghandi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Mesirov</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Tamayo</surname><given-names>P.</given-names></string-name></person-group><article-title>The Molecular Signatures Database (MSigDB) hallmark gene set collection</article-title>. <source>Cell Syst.</source><year>2015</year>; <volume>1</volume>:<fpage>417</fpage>–<lpage>425</lpage>.<pub-id pub-id-type="pmid">26771021</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kanehisa</surname><given-names>M.</given-names></string-name>, <string-name><surname>Furumichi</surname><given-names>M.</given-names></string-name>, <string-name><surname>Sato</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Kawashima</surname><given-names>M.</given-names></string-name>, <string-name><surname>Ishiguro-Watanabe</surname><given-names>M.</given-names></string-name></person-group><article-title>KEGG for taxonomy-based analysis of pathways and genomes</article-title>. <source>Nucleic Acids Res.</source><year>2023</year>; <volume>51</volume>:<fpage>D587</fpage>–<lpage>D592</lpage>.<pub-id pub-id-type="pmid">36300620</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gillespie</surname><given-names>M.</given-names></string-name>, <string-name><surname>Jassal</surname><given-names>B.</given-names></string-name>, <string-name><surname>Stephan</surname><given-names>R.</given-names></string-name>, <string-name><surname>Milacic</surname><given-names>M.</given-names></string-name>, <string-name><surname>Rothfels</surname><given-names>K.</given-names></string-name>, <string-name><surname>Senff-Ribeiro</surname><given-names>A.</given-names></string-name>, <string-name><surname>Griss</surname><given-names>J.</given-names></string-name>, <string-name><surname>Sevilla</surname><given-names>C.</given-names></string-name>, <string-name><surname>Matthews</surname><given-names>L.</given-names></string-name>, <string-name><surname>Gong</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The reactome pathway knowledgebase 2022</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D687</fpage>–<lpage>D692</lpage>.<pub-id pub-id-type="pmid">34788843</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Martens</surname><given-names>M.</given-names></string-name>, <string-name><surname>Ammar</surname><given-names>A.</given-names></string-name>, <string-name><surname>Riutta</surname><given-names>A.</given-names></string-name>, <string-name><surname>Waagmeester</surname><given-names>A.</given-names></string-name>, <string-name><surname>Slenter</surname><given-names>D.N.</given-names></string-name>, <string-name><surname>Hanspers</surname><given-names>K.</given-names></string-name>, <string-name><surname>Miller</surname><given-names>R.A.</given-names></string-name>, <string-name><surname>Digles</surname><given-names>D.</given-names></string-name>, <string-name><surname>Lopes</surname><given-names>E.N.</given-names></string-name>, <string-name><surname>Ehrhart</surname><given-names>F.</given-names></string-name><etal>et al</etal>.</person-group><article-title>WikiPathways: connecting communities</article-title>. <source>Nucleic Acids Res.</source><year>2021</year>; <volume>49</volume>:<fpage>D613</fpage>–<lpage>D621</lpage>.<pub-id pub-id-type="pmid">33211851</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Yao</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>P.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>H.</given-names></string-name>, <string-name><surname>Tian</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy</article-title>. <source>J. Immunother. Cancer</source>. <year>2020</year>; <volume>8</volume>:<fpage>e001247</fpage>.<pub-id pub-id-type="pmid">33109630</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Behan</surname><given-names>F.M.</given-names></string-name>, <string-name><surname>Iorio</surname><given-names>F.</given-names></string-name>, <string-name><surname>Picco</surname><given-names>G.</given-names></string-name>, <string-name><surname>Gonçalves</surname><given-names>E.</given-names></string-name>, <string-name><surname>Beaver</surname><given-names>C.M.</given-names></string-name>, <string-name><surname>Migliardi</surname><given-names>G.</given-names></string-name>, <string-name><surname>Santos</surname><given-names>R.</given-names></string-name>, <string-name><surname>Rao</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Sassi</surname><given-names>F.</given-names></string-name>, <string-name><surname>Pinnelli</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens</article-title>. <source>Nature</source>. <year>2019</year>; <volume>568</volume>:<fpage>511</fpage>–<lpage>516</lpage>.<pub-id pub-id-type="pmid">30971826</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Love</surname><given-names>M.I.</given-names></string-name>, <string-name><surname>Huber</surname><given-names>W.</given-names></string-name>, <string-name><surname>Anders</surname><given-names>S.</given-names></string-name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biol.</source><year>2014</year>; <volume>15</volume>:<fpage>550</fpage>.<pub-id pub-id-type="pmid">25516281</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Benjamini</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hochberg</surname><given-names>Y.</given-names></string-name></person-group><article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source>J. R. Stat. Soc.</source><year>1995</year>; <volume>57</volume>:<fpage>289</fpage>–<lpage>300</lpage>.</mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Becht</surname><given-names>E.</given-names></string-name>, <string-name><surname>Giraldo</surname><given-names>N.A.</given-names></string-name>, <string-name><surname>Lacroix</surname><given-names>L.</given-names></string-name>, <string-name><surname>Buttard</surname><given-names>B.</given-names></string-name>, <string-name><surname>Elarouci</surname><given-names>N.</given-names></string-name>, <string-name><surname>Petitprez</surname><given-names>F.</given-names></string-name>, <string-name><surname>Selves</surname><given-names>J.</given-names></string-name>, <string-name><surname>Laurent-Puig</surname><given-names>P.</given-names></string-name>, <string-name><surname>Sautès-Fridman</surname><given-names>C.</given-names></string-name>, <string-name><surname>Fridman</surname><given-names>W.H.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression</article-title>. <source>Genome Biol.</source><year>2016</year>; <volume>17</volume>:<fpage>218</fpage>.<pub-id pub-id-type="pmid">27765066</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aran</surname><given-names>D.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Butte</surname><given-names>A.J.</given-names></string-name></person-group><article-title>xCell: digitally portraying the tissue cellular heterogeneity landscape</article-title>. <source>Genome Biol.</source><year>2017</year>; <volume>18</volume>:<fpage>220</fpage>.<pub-id pub-id-type="pmid">29141660</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname><given-names>A.</given-names></string-name>, <string-name><surname>Tamayo</surname><given-names>P.</given-names></string-name>, <string-name><surname>Mootha</surname><given-names>V.K.</given-names></string-name>, <string-name><surname>Mukherjee</surname><given-names>S.</given-names></string-name>, <string-name><surname>Ebert</surname><given-names>B.L.</given-names></string-name>, <string-name><surname>Gillette</surname><given-names>M.A.</given-names></string-name>, <string-name><surname>Paulovich</surname><given-names>A.</given-names></string-name>, <string-name><surname>Pomeroy</surname><given-names>S.L.</given-names></string-name>, <string-name><surname>Golub</surname><given-names>T.R.</given-names></string-name>, <string-name><surname>Lander</surname><given-names>E.S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2005</year>; <volume>102</volume>:<fpage>15545</fpage>–<lpage>15550</lpage>.<pub-id pub-id-type="pmid">16199517</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>T.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>E.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>S.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>M.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>P.</given-names></string-name>, <string-name><surname>Dai</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Feng</surname><given-names>T.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>L.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Zhan</surname><given-names>L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>clusterProfiler 4.0: a universal enrichment tool for interpreting omics data</article-title>. <source>Innovation</source>. <year>2021</year>; <volume>2</volume>:<fpage>100141</fpage>.<pub-id pub-id-type="pmid">34557778</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Wickham</surname><given-names>H.</given-names></string-name></person-group><source>ggplot<italic toggle="yes">2: Elegant Graphics for Data Analysis</italic></source>. <year>2016</year>; <publisher-loc>NY</publisher-loc><publisher-name>Springer-Verlag</publisher-name>.</mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Eils</surname><given-names>R.</given-names></string-name>, <string-name><surname>Schlesner</surname><given-names>M.</given-names></string-name></person-group><article-title>Complex heatmaps reveal patterns and correlations in multidimensional genomic data</article-title>. <source>Bioinformatics</source>. <year>2016</year>; <volume>32</volume>:<fpage>2847</fpage>–<lpage>2849</lpage>.<pub-id pub-id-type="pmid">27207943</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hirata</surname><given-names>E.</given-names></string-name>, <string-name><surname>Sahai</surname><given-names>E.</given-names></string-name></person-group><article-title>Tumor microenvironment and differential responses to therapy</article-title>. <source>Cold Spring Harb. Perspect. Med.</source><year>2017</year>; <volume>7</volume>:<fpage>a026781</fpage>.<pub-id pub-id-type="pmid">28213438</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>J.Y.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.P.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.Q.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>N.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>J.</given-names></string-name></person-group><article-title>Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades</article-title>. <source>Mol. Cancer</source>. <year>2021</year>; <volume>20</volume>:<fpage>27</fpage>.<pub-id pub-id-type="pmid">33541368</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Li</surname><given-names>N.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>J.</given-names></string-name>, <string-name><surname>Pan</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>B.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>B.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>G.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>B.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer</article-title>. <source>Cancer Cell</source>. <year>2023</year>; <volume>41</volume>:<fpage>1345</fpage>–<lpage>1362</lpage>.<pub-id pub-id-type="pmid">37352863</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name>, <string-name><surname>Kong</surname><given-names>X.</given-names></string-name>, <string-name><surname>He</surname><given-names>M.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Deng</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>CTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response</article-title>. <source>Nucleic Acids Res.</source><year>2022</year>; <volume>50</volume>:<fpage>D1184</fpage>–<lpage>D1199</lpage>.<pub-id pub-id-type="pmid">34570230</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mojtahedi</surname><given-names>H.</given-names></string-name>, <string-name><surname>Yazdanpanah</surname><given-names>N.</given-names></string-name>, <string-name><surname>Rezaei</surname><given-names>N.</given-names></string-name></person-group><article-title>Chronic myeloid leukemia stem cells: targeting therapeutic implications</article-title>. <source>Stem Cell Res. Ther.</source><year>2021</year>; <volume>12</volume>:<fpage>603</fpage>.<pub-id pub-id-type="pmid">34922630</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carrano</surname><given-names>A.C.</given-names></string-name>, <string-name><surname>Eytan</surname><given-names>E.</given-names></string-name>, <string-name><surname>Hershko</surname><given-names>A.</given-names></string-name>, <string-name><surname>Pagano</surname><given-names>M.</given-names></string-name></person-group><article-title>SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27</article-title>. <source>Nat. Cell Biol.</source><year>1999</year>; <volume>1</volume>:<fpage>193</fpage>–<lpage>199</lpage>.<pub-id pub-id-type="pmid">10559916</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Otto</surname><given-names>T.</given-names></string-name>, <string-name><surname>Sicinski</surname><given-names>P.</given-names></string-name></person-group><article-title>Cell cycle proteins as promising targets in cancer therapy</article-title>. <source>Nat. Rev. Cancer</source>. <year>2017</year>; <volume>17</volume>:<fpage>93</fpage>–<lpage>115</lpage>.<pub-id pub-id-type="pmid">28127048</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andreu</surname><given-names>E.J.</given-names></string-name>, <string-name><surname>Lledó</surname><given-names>E.</given-names></string-name>, <string-name><surname>Poch</surname><given-names>E.</given-names></string-name>, <string-name><surname>Ivorra</surname><given-names>C.</given-names></string-name>, <string-name><surname>Albero</surname><given-names>M.P.</given-names></string-name>, <string-name><surname>Martínez-Climent</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>Montiel-Duarte</surname><given-names>C.</given-names></string-name>, <string-name><surname>Rifón</surname><given-names>J.</given-names></string-name>, <string-name><surname>Pérez-Calvo</surname><given-names>J.</given-names></string-name>, <string-name><surname>Arbona</surname><given-names>C.</given-names></string-name><etal>et al</etal>.</person-group><article-title>BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells</article-title>. <source>Cancer Res.</source><year>2005</year>; <volume>65</volume>:<fpage>3264</fpage>–<lpage>3272</lpage>.<pub-id pub-id-type="pmid">15833859</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zitvogel</surname><given-names>L.</given-names></string-name>, <string-name><surname>Rusakiewicz</surname><given-names>S.</given-names></string-name>, <string-name><surname>Routy</surname><given-names>B.</given-names></string-name>, <string-name><surname>Ayyoub</surname><given-names>M.</given-names></string-name>, <string-name><surname>Kroemer</surname><given-names>G.</given-names></string-name></person-group><article-title>Immunological off-target effects of imatinib</article-title>. <source>Nat. Rev. Clin. Oncol.</source><year>2016</year>; <volume>13</volume>:<fpage>431</fpage>–<lpage>446</lpage>.<pub-id pub-id-type="pmid">27030078</pub-id></mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Pang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>H.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Tu</surname><given-names>L.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Jia</surname><given-names>X.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J.C.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.</given-names></string-name></person-group><article-title>Integrated screens identify CDK1 as a therapeutic target in advanced gastrointestinal stromal tumors</article-title>. <source>Cancer Res.</source><year>2021</year>; <volume>81</volume>:<fpage>2481</fpage>–<lpage>2494</lpage>.<pub-id pub-id-type="pmid">33727226</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Attoub</surname><given-names>S.</given-names></string-name>, <string-name><surname>Rivat</surname><given-names>C.</given-names></string-name>, <string-name><surname>Rodrigues</surname><given-names>S.</given-names></string-name>, <string-name><surname>Van Bocxlaer</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bedin</surname><given-names>M.</given-names></string-name>, <string-name><surname>Bruyneel</surname><given-names>E.</given-names></string-name>, <string-name><surname>Louvet</surname><given-names>C.</given-names></string-name>, <string-name><surname>Kornprobst</surname><given-names>M.</given-names></string-name>, <string-name><surname>André</surname><given-names>T.</given-names></string-name>, <string-name><surname>Mareel</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy</article-title>. <source>Cancer Res.</source><year>2002</year>; <volume>62</volume>:<fpage>4879</fpage>–<lpage>4883</lpage>.<pub-id pub-id-type="pmid">12208734</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <label>56.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Olsen</surname><given-names>R.S.</given-names></string-name>, <string-name><surname>Dimberg</surname><given-names>J.</given-names></string-name>, <string-name><surname>Geffers</surname><given-names>R.</given-names></string-name>, <string-name><surname>Wågsäter</surname><given-names>D</given-names></string-name></person-group><article-title>Possible role and therapeutic target of PDGF-D signalling in colorectal cancer</article-title>. <source>Cancer Invest.</source><year>2019</year>; <volume>37</volume>:<fpage>99</fpage>–<lpage>112</lpage>.<pub-id pub-id-type="pmid">30836770</pub-id></mixed-citation>
    </ref>
    <ref id="B57">
      <label>57.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kośmider</surname><given-names>K.</given-names></string-name>, <string-name><surname>Karska</surname><given-names>K.</given-names></string-name>, <string-name><surname>Kozakiewicz</surname><given-names>A.</given-names></string-name>, <string-name><surname>Lejman</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zawitkowska</surname><given-names>J.</given-names></string-name></person-group><article-title>Overcoming steroid resistance in pediatric acute lymphoblastic leukemia - the state-of-the-art knowledge and future prospects</article-title>. <source>Int. J. Mol. Sci.</source><year>2022</year>; <volume>23</volume>:<fpage>3795</fpage>.<pub-id pub-id-type="pmid">35409154</pub-id></mixed-citation>
    </ref>
    <ref id="B58">
      <label>58.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arora</surname><given-names>P.</given-names></string-name>, <string-name><surname>Adams</surname><given-names>C.H.</given-names></string-name>, <string-name><surname>Gudelsky</surname><given-names>G.</given-names></string-name>, <string-name><surname>DasGupta</surname><given-names>B.</given-names></string-name>, <string-name><surname>Desai</surname><given-names>P.B.</given-names></string-name></person-group><article-title>Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats</article-title>. <source>Cancer Chemother. Pharmacol.</source><year>2019</year>; <volume>83</volume>:<fpage>81</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="pmid">30357450</pub-id></mixed-citation>
    </ref>
    <ref id="B59">
      <label>59.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>He</surname><given-names>W.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>R.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>S.H.</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>F.</given-names></string-name></person-group><article-title>Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas</article-title>. <source>Anticancer Drugs</source>. <year>2015</year>; <volume>26</volume>:<fpage>293</fpage>–<lpage>300</lpage>.<pub-id pub-id-type="pmid">25535979</pub-id></mixed-citation>
    </ref>
    <ref id="B60">
      <label>60.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Karve</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Desai</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Dave</surname><given-names>N.</given-names></string-name>, <string-name><surname>Wise-Draper</surname><given-names>T.M.</given-names></string-name>, <string-name><surname>Gudelsky</surname><given-names>G.A.</given-names></string-name>, <string-name><surname>Phoenix</surname><given-names>T.N.</given-names></string-name>, <string-name><surname>DasGupta</surname><given-names>B.</given-names></string-name>, <string-name><surname>Sengupta</surname><given-names>S.</given-names></string-name>, <string-name><surname>Plas</surname><given-names>D.R.</given-names></string-name>, <string-name><surname>Desai</surname><given-names>P.B.</given-names></string-name></person-group><article-title>Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole</article-title>. <source>Cancer Chemother. Pharmacol.</source><year>2022</year>; <volume>90</volume>:<fpage>345</fpage>–<lpage>356</lpage>.<pub-id pub-id-type="pmid">36050497</pub-id></mixed-citation>
    </ref>
    <ref id="B61">
      <label>61.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Balça-Silva</surname><given-names>J.</given-names></string-name>, <string-name><surname>Matias</surname><given-names>D.</given-names></string-name>, <string-name><surname>do Carmo</surname><given-names>A.</given-names></string-name>, <string-name><surname>Girão</surname><given-names>H.</given-names></string-name>, <string-name><surname>Moura-Neto</surname><given-names>V.</given-names></string-name>, <string-name><surname>Sarmento-Ribeiro</surname><given-names>A.B.</given-names></string-name>, <string-name><surname>Lopes</surname><given-names>M.C.</given-names></string-name></person-group><article-title>Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines</article-title>. <source>Biochim. Biophys. Acta.</source><year>2015</year>; <volume>1850</volume>:<fpage>722</fpage>–<lpage>732</lpage>.<pub-id pub-id-type="pmid">25554223</pub-id></mixed-citation>
    </ref>
    <ref id="B62">
      <label>62.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Patel</surname><given-names>S.</given-names></string-name>, <string-name><surname>DiBiase</surname><given-names>S.</given-names></string-name>, <string-name><surname>Meisenberg</surname><given-names>B.</given-names></string-name>, <string-name><surname>Flannery</surname><given-names>T.</given-names></string-name>, <string-name><surname>Patel</surname><given-names>A.</given-names></string-name>, <string-name><surname>Dhople</surname><given-names>A.</given-names></string-name>, <string-name><surname>Cheston</surname><given-names>S.</given-names></string-name>, <string-name><surname>Amin</surname><given-names>P.</given-names></string-name></person-group><article-title>Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma</article-title>. <source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2012</year>; <volume>82</volume>:<fpage>739</fpage>–<lpage>742</lpage>.<pub-id pub-id-type="pmid">21353747</pub-id></mixed-citation>
    </ref>
    <ref id="B63">
      <label>63.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DI Cristofori</surname><given-names>A.</given-names></string-name>, <string-name><surname>Carrabba</surname><given-names>G.</given-names></string-name>, <string-name><surname>Lanfranchi</surname><given-names>G.</given-names></string-name>, <string-name><surname>Menghetti</surname><given-names>C.</given-names></string-name>, <string-name><surname>Rampini</surname><given-names>P.</given-names></string-name>, <string-name><surname>Caroli</surname><given-names>M.</given-names></string-name></person-group><article-title>Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma</article-title>. <source>Anticancer Res.</source><year>2013</year>; <volume>33</volume>:<fpage>3383</fpage>–<lpage>3389</lpage>.<pub-id pub-id-type="pmid">23898108</pub-id></mixed-citation>
    </ref>
    <ref id="B64">
      <label>64.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>T.</given-names></string-name>, <string-name><surname>Fu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>D.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Li</surname><given-names>B.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.S.</given-names></string-name></person-group><article-title>TIMER2.0 for analysis of tumor-infiltrating immune cells</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>W509</fpage>–<lpage>W514</lpage>.<pub-id pub-id-type="pmid">32442275</pub-id></mixed-citation>
    </ref>
    <ref id="B65">
      <label>65.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miao</surname><given-names>Y.R.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Lei</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>M.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>G.Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H.</given-names></string-name>, <string-name><surname>Guo</surname><given-names>A.Y.</given-names></string-name></person-group><article-title>ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy</article-title>. <source>Adv. Sci.</source><year>2020</year>; <volume>7</volume>:<fpage>1902880</fpage>.</mixed-citation>
    </ref>
  </ref-list>
</back>
